Allaxys Communications --- Transponder V --- Allaxys Forum 1

Pages: [1]

Author Topic: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!  (Read 648 times)

Thymian

  • Jr. Member
  • *
  • Posts: 2139
Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« on: December 04, 2022, 12:29:47 PM »

Wir sagen es schon seit Anfang 2020: SarsCoV2 verursacht Hirnschäden.

Bei dem folgenden Zitat muß man den wichtigsten Punkt beachten: Die Bildgebung ist sehr grob und zeigt nur große Schäden. Die Schäden sind auch sehr viel feiner vorhanden, können aber nicht so gut oder zur Zeit noch gar nicht radiologisch erfaßt werden.

Mit anderen Worten: ALLE INFIZIERTEN haben Hirnschäden.  Die Situation ist weitaus dramatischer als bisher zugegeben wurde.


https://deutsch.medscape.com/artikelansicht/4911860#vp_3

[*quote*]
Radiologen finden Anomalien im Gehirn von COVID-19-Patienten

Das Ziel, schweres COVID-19 zu vermeiden, ist wichtiger denn je. Laut einer Studie, die nächste Woche auf der Jahrestagung der Radiological Society of North America vorgestellt wird, haben Forscher per MRT Gehirnveränderungen bei Patienten bis zu 6 Monate nach ihrer Genesung von COVID-19 entdeckt. 

Für diese Studie verwendeten Neurologen eine sensitivitätsgewichtete Bildgebung, um die Auswirkungen von COVID-19 auf das Gehirn zu analysieren. Sie analysierten Bildgebungsdaten von 46 genesenen Patienten und 30 gesunden Kontrollpersonen. Die Bildgebung wurde innerhalb von 6 Monaten nach der Genesung durchgeführt.

Patienten, die sich von COVID-19 erholt hatten, zeigten im Vergleich zu gesunden Kontrollpersonen signifikante Unterschiede im Frontallappen und im Hirnstamm. Teile des linken orbital-inferioren Frontalgyrus (einer Schlüsselregion für Sprache), des rechten orbital-inferioren Frontalgyrus (verbunden mit verschiedenen kognitiven Funktionen) und der angrenzenden Bereiche der weißen Substanz waren betroffen.

Die Forscher fanden auch signifikante Unterschiede in der rechten ventralen Zwischenhirnregion des Hirnstamms. Diese Region ist mit vielen entscheidenden Körperfunktionen verbunden, einschließlich der Koordination mit dem endokrinen System zur Freisetzung von Hormonen, der Weiterleitung sensorischer und motorischer Signale an die Großhirnrinde und der Regulierung des zirkadianen Rhythmus.

„Diese Studie weist auf schwerwiegende Langzeitkomplikationen hin, die durch das Coronavirus verursacht werden können, sogar Monate nach der Genesung von der Infektion“, sagte Sapna S. Mishra vom Indian Institute of Technology in Delhi. „Die vorliegenden Befunde stammen aus dem kleinen zeitlichen Fenster. Die Längsschnittzeitpunkte über ein paar Jahre hinweg werden jedoch Aufschluss darüber geben, ob es dauerhafte Veränderungen gibt.“
[*/quote*]


[Typo in Überschrift behoben, Pangwall]
« Last Edit: July 11, 2024, 08:25:17 PM by Pangwall »
Logged
.         Im Angesicht von Gewalt ist Höflichkeit gegenstandslos.
.         At face with violence politeness is pointless.

.         (User TNT in the former CDU forum)
--------------------------------------- * --------------------------------------- * ---------------------------------------

Löwenzian

  • Newbie
  • *
  • Posts: 6
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #1 on: February 28, 2023, 11:26:30 AM »

Ich wüßte gerne mehr. Die Pressemitteilung ist hier verlinkt:

https://press.rsna.org/pressrelease/2022_resources/2381/abstract.pdf

[*quote*]
RADIOLOGICAL SOCIETY OF NORTH AMERICA
820 JORIE BLVD, OAK BROOK, IL 60523
TEL. 1-630-571-2670 FAX 1-630-571-7837
RSNA.ORG

Susceptibility-Weighted Magnetic Resonance Imaging Highlights Brain Alterations in COVID Survivors

PURPOSE

The purpose of this study was to investigate the effects of COVID-19 on the human brain using susceptibility weighted imaging (SWI). We hypothesized that the COVID recovered subjects have developed alterations in the brain which can be measured through susceptibility differences in various regions of the brain compared to healthy controls (HCs).

METHODS AND MATERIALS

In this study, SWI volumes from 46 (15 females; mean age = 35.09 ± 11.37 years) COVID subjects and 30 (8 females; mean age = 34.67 ± 9.5 years) HCs were included. The COVID patients were imaged within six months of their recovery. In the pre-processing step, we registered the SWI volumes to the Montreal Neurological Institute space, followed by signal intensity normalization. We then performed an unpaired two-sample t-test over the pre-processed volumes of both the groups with age and sex as covariates of no interest. Finally, cluster-based thresholding was applied at a height threshold of punc < 0.01, with family-wise error correction at pFWE < 0.05 for multiple comparisons.

RESULTS

The group analysis showed that COVID recovered subjects had significantly higher susceptibility values in regions of the frontal lobe and brain stem. The clusters obtained in the frontal lobe primarily show differences in the white matter (WM) regions. Portions of left and right orbito-inferior frontal gyrus along with their respective adjacent WM areas constitute the two clusters. We also found a significant cluster in the right ventral diencephalon region of the brain stem.

CONCLUSIONS

Our results highlight group-level effects in COVID recovered patients, showing differences in the WM regions and brain stem. These observations are consistent with results reported in the literature of single-patient case studies of COVID patients on SWI volumes.

CLINICAL RELEVANCE/APPLICATIONS

Our study demonstrates that COVID-19 affects the susceptibility values in different human brain regions. The present research will help the community to understand the impact of the SARS-CoV-2 virus on the human brain.
[*/quote*]


Die Website der Radiologen:

https://www.rsna.org
« Last Edit: July 11, 2024, 08:25:43 PM by Pangwall »
Logged

Löwenzian

  • Newbie
  • *
  • Posts: 6
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #2 on: February 28, 2023, 11:58:48 AM »

Keine Bilder? Nicht mal eines? Das ist nicht gut. Ich habe nach dem Original gesucht. Es gibt eines! Mit Bildern! Das muß die originale Studie sein. Der Name Mishra, von Medscape genannt, taucht als einer der Autoren auf.

In dem PDF sind die Bilder.

https://www.medrxiv.org/content/10.1101/2022.11.21.22282600v1
https://www.medrxiv.org/content/10.1101/2022.11.21.22282600v1.full.pdf

[*quote*]
medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Susceptibility-Weighted Magnetic Resonance Imaging Highlights
Brain Alterations in COVID Recovered Patients.

Sapna S Mishra a , Rakibul Hafiz b , Rohit Misra a , Tapan K. Gandhi a,∗ , Alok Prasad c ,
Vidur Mahajan d and Bharat B. Biswal b,∗∗
a Department
of Electrical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India
of Biomedical Engineering, New Jersey Institute of Technology (NJIT), 323 Dr Martin Luther King Jr Blvd, Newark, 07102, NJ, USA
c Metro Heart and Super-specialty Hospital, Haryana, India
d Mahajan Imaging Center, Hauz Khas, New Delhi, India
b Department
ARTICLE INFO ABSTRACT
Keywords:
COVID-19
Post-COVID symptoms
Long COVID

Susceptibility Weighted Imaging

Fatigue The increasing number of reports of mild to severe psychological, behavioral, and cognitive sequelae in COVID-19 survivors motivates a need for a thorough assessment of the neurological effects of the disease. In this regard, we have conducted a neuroimaging study to understand the neurotropic behavior of the coronavirus. We hypothesize that the COVID recovered subjects have developed alterations in the brain which can be measured through susceptibility differences in various regions of brain when compared to healthy controls (HCs). Hence we performed our investigations on susceptibility weighted imaging (SWI) volumes. Fatigue, being of the most common symptoms of Long COVID has also been studied in this work. SWI volumes of 46 COVID and 30 HCs were included in this study. The COVID patients were imaged within six months of their recovery. We performed unpaired two-sample t-test over the pre-processed SWI volumes of both the groups and multiple linear regression was performed to observe group differences and correlation of fatigue with SWI values. The group analysis showed that COVID recovered subjects had significantly higher susceptibility imaging values in regions of the frontal lobe and the brain stem. The clusters obtained in the frontal lobe primarily show differences in the white matter regions. The COVID group also demonstrated significantly higher fatigue levels than the HC group. The regression analysis on the COVID group yielded clusters in anterior cingulate gyrus and midbrain which exhibited negative correlations with fatigue scores. This study suggests an association of Long COVID with prolonged effects on the brain and also indicates the viability of SWI modality for analysis of post-COVID symptoms.

1. Introduction

Coronaviruses (CoV) are a large family of viruses that cause illnesses ranging from the common cold to more severe diseases such as middle east respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A novel coronavirus (nCoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a strain of coronavirus recently found in humans. In December 2019, the first case of coronavirus disease 2019 (COVID-19) was reported. Since then, the virus has caused a global pandemic claiming over 6.3 million lives worldwide as of June 2022 [1]. Most of these deaths are consequences of the pulmonary complications caused by the coronavirus infection.
However, there has been an increase in reports of the virus attacking the human central nervous system (CNS) [2]. Neurological symptoms and signs like confusion, delirium, headache, loss of memory, and disorder of consciousness have been observed and reported worldwide [3]. Apart from the direct impact of the CNS by the virus, the reported neurological manifestations might be related to pathophysiological mechanisms of para-infections or post-infections.
Moreover, newer studies report the neurological manifestations of coronavirus in those who survive the virus infection [4]. This situation is worrisome considering the large population affected by this pandemic, including over 524 million people worldwide and 42 million in India [1]. The increasing number of reports of mild to severe psychological, behavioral, and cognitive sequelae in the survivors motivates a need for an adequate and thorough assessment of the neurological effects of COVID-19. A neuroimaging-based study to understand the post-COVID effects, also known

∗ Corresponding
author
corresponding author
eez208443@ee.iitd.ac.in (S.S. Mishra); rh298@njit.edu (R. Hafiz); rohit.misra@ee.iitd.ac.in (R. Misra);
tgandhi@ee.iitd.ac.in (T.K. Gandhi); bharat.biswal@njit.edu (B.B. Biswal)
ORCID (s): 0000-0002-5304-7131 (S.S. Mishra); 0000-0001-6416-0490 (R. Hafiz)
∗∗ Principal
Mishra et al.: Preprint submitted to Elsevier
Page 1 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SWI Analysis of COVID-19

as Long COVID, can aid the research community to determine the neurotropic behavior of coronavirus and detect the brain regions being affected directly or indirectly by the virus.
Susceptibility weighted imaging (SWI) combines the phase and the magnitude information obtained from magnetic resonance imaging [5]. The three-dimensional high-resolution gradient echo (GRE) sequence used in the SWI modality enables it to utilize the phase data. When combined in a specific manner with these phase data the magnitude data yields SWI volumes. This fully flow-compensated MR imaging technique employs long echo time and short flip angles. It exploits magnitude susceptibility differences of various compounds, such as blood, paramagnetic iron, and diamagnetic calcium, present in different brain tissue types [6]. Thus SWI technique is useful in detecting several pathologies and conditions such as microhemorrhages, cerebral microbleeds, vascular malformations, trauma, and multiple sclerosis [5, 7, 8, 9].

Neurological effects of COVID-19 can be inferred from several symptoms, including loss of smell and taste, brain fog, and headaches [3]. Some people have complained about debilitating fatigue, loss of memory, and difficulty concentrating. In early research on the effects of COVID-19 on the brain, in-depth examinations were carried out on human brain tissues of patients who died after COVID contamination [10, 11]. A study by Lee and colleagues [10] found signs of inflammation and unusually bright and dark spots in the brain’s olfactory bulb, but it also reports no presence of SARS-CoV-2 in the brain. On the other hand, the work by Song and colleagues [11] suggests that the virus may directly infect the human CNS as the authors detected the presence of the virus in the brain’s cerebral cortex. In both these studies, the number of subjects is small. Hence, we could not make conclusive deductions about whether the coronavirus directly affects the brain or the pathologies present are secondary effects of the physiological complications caused by the virus in the human body. Later, to diagnose the abnormalities in living patients’ brains, the research community used neuroimaging techniques to further investigate the preliminary findings of deformities. A descriptive review in by Gulko and colleagues has reported on multi-sequence MRI scans of 126 patients across seven countries and established the neurological pathologies caused by COVID-19, as observed in their surveyed research works [12]. This review includes observations of acute infarct, posterior reversible encephalopathy syndrome (PRES), leukoencephalopathy, cortical abnormality, and microhemorrhages in the different regions of the brain. Kremer and colleagues [13] conducted a retrospective study on 64 subjects’ neuroimaging data collected over multiple centers. This study reports several neurological aberrations in the accumulated data of COVID patients, with over 56% of the cohort having abnormalities. The significant pathologies seen by the authors were ischemic strokes and encephalitis. In other studies, loss of gray matter in the frontal lobe [14], arterial wall thickening [15],and inflammatory vascular pathologies [16] have also been reported in the MRI scans. In the reports of [17], researchers reported abnormal findings in brain computed tomography (CT)/MRI scans of 40% of the 35 COVID-19 patients during their hospitalization. Most common pathologies observed were microbleedings and restricted diffusion lesions. On the other hand, the arterial spin labeling (ASL) based study in [18] was carried out on 39 non-hospitalized COVID-19 recovered adults and compared with 11 healthy controls. This work revealed decreased cerebral blood flow (CBF) in the thalamus, orbitofrontal cortex, and basal ganglia.

The multi-sequence investigation by Griffanti and colleagues [19] showed lower gray matter density in frontal gyrus, lower gray matter metric in hippocampus, left superior division of the lateral occipital cortex from the structural imaging. The SWI exploration of the same study reported changes in the thalamus, and left hippocampus. In the SWI study of COVID patients on mechanical ventilation [20], Conklin and colleagues observed abnormal susceptibility signals in 11/16 patients whereas >10 lesions were reported in 50% of the subjects. These lesions were primarily identified in the corpus callosum region, subcortical, and deep white matter, with variable inclusion of the cerebellum and brainstem. In the case report of 68 year old male hospitalized with a diagnosis of coronavirus (SARS-CoV-2), hypointense areas were observed in bilateral thalamus, in the genu of the corpus callosum, and in the parietal juxtacortical white matter [21]. Another SWI study reported leukoencephalopathy and microbleeds in patients with COVID-19 [22]. To the best of our knowledge, no work on SWI based group-level analysis of COVID recovered patients has been reported in literature.

In this study, we attempt to understand the effects of COVID on the human brain using the SWI modality of MRI. The literature reports ischemic microvascular diseases occurring in COVID patients [22], which makes SWI an adequate modality for the analysis. However, there are limited literature reporting group-level results on the SWI analysis of COVID patients compared with respect to healthy controls (HCs). We started by recruiting a sample of patients who had been tested positive for the PCR test for COVID-19. We scanned these patients within six months of subsequent PCR negative status. We hypothesize that the COVID recovered subjects will develop alterations in the brain’s anatomy, which can be measured through susceptibility differences in various regions of brain, when compared

Mishra et al.: Preprint submitted to Elsevier
Page 2 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19

to HCs. We expect that these surviving COVID-negative patients would have altered susceptibility values of brain tissues, compared to the HC group. Further we anticipate to observe a significant correlation between altered brain regions (gray or white matter) of COVID recovered subjects and self-reported fatigue scores. SWI modality of MR imaging can provide such information and enable us to test our hypothesis.

2. Materials and Methods

2.1. Participants

In this study MRI volumes of 46 (15 females) COVID-19 recovered patients, termed as COVID group in the scope of this work, and 30 (8 females) HCs were included with mean age of 34.67 ± 9.51 years for COVID group and 35.09 ± 11.37 years for HCs. These participants were recruited by the Indian Institute of Technology (IIT), Delhi, India, where they were imaged following all Institutional Review Board (IRB) guidelines and all patients gave informed consent prior to providing any behavioral or physical data.

2.2. Clinical Assessment

We have clinical details of 38 out 46 patients of the COVID group during their COVID-19 infection period and we also managed to gather post-COVID symptoms of 29 (12 females; mean age = 32.62 ± 8.19 years) out of the 46 patients. These 29 volunteers and 19 (5 females; mean age = 30.63 ± 9.79 years) random samples from the HC cohort also filled-up a form of fatigue analysis where they were asked to rate the effects of fatigue in different spheres (work, education, personal and social) of their daily lives from 0 to 5.

Most common symptoms during COVID-19 were reported to be fever (33/38), cough (26/38) and body ache (25/38). Loss of sense of smell (16/38) and taste (12/38) were also highly observed symptoms along with difficulty in breathing (20/38). The severity of these manifestations of COVID-19 varied among the subjects recruited for our scans. We had 18 patients who had been hospitalized and had severe COVID-19 whereas 5 of them reported moderate and the remaining 15 of them suffered from mild symptoms among the 38 patients whose details were made available to us.

On the other hand, 29 of 46 scanned patients who agreed to share their post-COVID symptoms showed a range of post-COVID symptoms. After negative RT-PCR test, these subjects reported to suffer from frequent body ache (achy muscle: 55.17% and achy joints: 44.83%), fatigue (72.41%), headache (44.83%) and hair loss (37.93%). Persistent breathing issues (13.8%) and bowel irritation (24.14%) were also detailed by some of the subjects. On the other hand, some specific complaints of lack of attention (48.27%), issues with memory (31.03%), and lack of sleep (41.38%) were common among these 29 patients. As mentioned earlier, these patients along with 19 HCs filled up a form to mention how the fatigue has affected different spheres of their respective lives: work, study, social and personal life. In this study, we mainly focused on the impact on the work sphere, where the average fatigue score in the sub-set of the COVID group was found to be 2.93/5 with standard deviation of 1.067 and that of the HC group was 0.63 ± 0.76.

2.3. Imaging

2.3.1. Anatomical MRI

T1-weighted images were acquired using a 3T GE scanner in 3D imaging mode with a fast BRAVO sequence. The scanner had a 32 channel head coil. The imaging parameters were inversion time (TI) = 450 ms; Flip angle = 12 ◦ , field of view (FOV) = 256 mm × 256 mm, number of slices = 152 (sagittal), slice thickness = 1.00 mm and spatial isotropic resolution of 1 mm.

2.3.2. Susceptibility-Weighted MRI

SWI scans were acquired using the same scanner in 3D imaging mode with a fast SWAN sequence. The imaging parameters were, echo time (TE) = 25.0 ms and low repetition time(TR); Flip angle = 15 ◦ and FOV = 224 mm × 224 mm; number of slices = 256, 256, and 196 in axial, coronal and sagittal plane respectively; slice thickness = 1.4 mm.

2.4. Data Pre-processing

For the SWI sequence, we have used FSL (https://fsl.fmrib.ox.ac.uk/fsl) software for data pre-processing. After dicom to nifti conversion, the brain extraction tool (BET) of FSL was used for skull stripping of SWI and anatomical brain images. The skull-stripped T1-weighted volumes were co-registered to the SWI images using inter-modality registration of FLIRT algorithm [23]. These co-registered T1-weighted anatomical images were Mishra et al.: Preprint submitted to Elsevier

Page 3 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SWI Analysis of COVID-19

Table 1

Group level statistics on participant demographics in HC and COVID group. The included demographics are age, sex and fatigue scores (for 29 COVID and 19 HC subjects). Keys: p = p-value, stat = test statistics, t = two-sample t-test statistic, χ = Chi-Squared statistic, τ = Wilcoxon Rank Sum test score, M = Male, F = Female, HC: Healthy Controls Measures

Age (years)
Sex
Fatigue
p
0.8673
0.5815
1.178e-07
stat
-0.1677 (t)
0.3038 (χ)
5.297 (τ)
HC, mean (SD)
34.667 (9.50)
22M (8F)
0.632 (0.76)
COVID, mean (SD)
35.087 (11.37)
31M (15F)
2.93 (1.067)

then warped to the MNI reference template and the transformation matrices thus obtained were utilized to register the SWI images to the MNI space, resulting in a cascaded spatial registration of the individual image. Since, susceptibility-weighted images are not absolute values but relative in nature, we normalize them before carrying out the analysis.

We assumed a constant SWI value of the cerebrospinal fluid and normalized all registered individual images to the “water” value of the left and the right lateral ventricles [24], by using the Harvard-Oxford Subcortical Structural Atlas template [25].

2.5. Statistical Analysis

To determine the differences in participants’ demographics, we performed two sample t-test on age and chi-squared test for sex differences between the two groups. For voxel-wise assessment of COVID-19 vs HC on SWI modality, we performed unpaired two-sample t-test over the pre-processed volumes of COVID and HC groups. Significant clusters were identified and the main effect of interest from the corresponding contrast maps representing the difference in mean beta scores from two groups was obtained by thresholding the t-score map values that survived the corrected threshold.
To account for confounding effects that may explain some of the variances in the data, age and sex were also added as covariates of no interest. Cluster-based thresholding was applied at a height threshold of p unc < 0.01, with family-wise error (FWE) correction at p F W E < 0.05 for multiple comparisons. The cluster extent threshold (k E ) obtained from this step was used to generate corrected statistical maps for the contrasts with significant effects. The clusters obtained after surviving FWE for extent threshold, k E = 506 have been illustrated in Figure 1 with their respective cluster sizes and peak intensities.

In the fatigue study, the relationship of fatigue scores (in the work-sphere) with the COVID-19 recovered patients was analyzed. Initially, the reported scores of the COVID and HC cohorts were compared and a significant difference in fatigue levels was observed between the two groups. Since the fatigue scores deviated from normality (Shapiro Wilk: p < 0.05), we used Wilcoxon’s rank-sum test to assess the group difference between HCs and COVID-19 subjects. Subsequently, to evaluate the correlation of fatigue score in work-sphere with the susceptibility values of the subset of COVID group, we performed a multiple linear regression analysis. Here, the voxel-wise SWI value was considered the response variable, the fatigue score was regarded as the covariate of interest, and sex and age were the confounding variables. Regions with a significant correlation between susceptibility values and fatigue score were identified using cluster-based thresholding at height threshold p unc < 0.01 and FWE corrected at p F W E < 0.05, for multiple comparisons.

3. Results

Group analysis on susceptibility-weighted images highlighted three major clusters in COVID group when compared to HCs (Figure 1). The first two clusters (Figure 1 (a) and (b)) were observed bilaterally in the white matter near the orbitofrontal gyri and the gray/white matter junctions. The left cluster had a volume of 711 voxels and a peak value of 4.0341, while the right cluster covered 1586 voxels and had a maximum t-value of 4.0913. The clusters bilaterally covered the uncinate fasciculus tract and anterior parts of the inferior fronto-occipital fasciculus tracts of white matter (JHU White-Matter Tractography Atlas). In addition, the third cluster was observed in the midbrain region of the brain stem with a volume of 506 voxels and maximum intensity of 3.8679.

In the fatigue study, the COVID group demonstrated significantly higher fatigue levels compared to HC group (using Wilcoxon’s rank-sum test: τ = 5.297, p = 1.178e-07). To evaluate the correlation of fatigue scores with SWI values, multiple linear regression analysis yielded four significant clusters in COVID-19 patients when compared with HCs (Figure 2). The cluster shown in Figure 2 (a), with a size of 1637 voxels, showed a peak intensity of 5.9 in a region covering the forceps minor tract, the thalamic radiations, and the anterior cingulate and paracingulate gyrus

Mishra et al.: Preprint submitted to Elsevier
Page 4 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19
(a)
`
(b)
(c)

Figure 1: Group analysis on susceptibility weighted imaging exhibiting higher SWI values (lower susceptibilities) in the COVID group when compared to healthy controls. Three significant clusters were found primarily in the white matter regions of pre-frontal cortex and in the brainstem. The clusters (a) and (b) are observed bilaterally in the cerebral white matter near the orbito-frontal gyrus whereas (c) lies in the midbrain region.

Table 2

Lists all significant clusters in SWI signal intensity between COVID and HC groups. Significant FWE corrected differences were observed for COVID versus HC in WM and brainstem regions, while the inverse comparison of HC versus COVID yielded no supra-threshold clusters. Keys: HC: Healthy Controls, FWE: Family-wise Error, WM: White Matter.

Peak MNI Coordinates
X
Y
Z COG MNI Coordinates
X
Y
Z
4.034 -28 29 3 -28
43
2
1586 4.09 34 42 -1 30
40
3
506 3.87 3 -19 -15 7
-28
-12
Cluster Index Number of Voxels Peak Intensity
1 711 2 3
Anatomic
Location
Left Cerebral White Matter
in frontal lobe
Right Cerebral White Matter
in frontal lobe
Midbrain
(Brainstem)

Table 3

Information related to the negatively correlated clusters of SWI with fatigue scores of work-sphere across the 29 subjects of COVID recovered group. Significant clusters were obtained in the frontal lobe, anterior cingulate cortex and brainstem. All four cluster showed negative correlation with the fatigue scores. No cluster was found with positive correlation.

Cluster Index Number of Voxels Peak Intensity
1
2
3
4 1637
469
595
1040 5.953
5.844
4.74
4.46
Peak
X
-12
-14
-3
-6
MNI Cordinates
Z
Y
14
41
2
51
-5
-8
-10
41
COG
X
-13
-14
-4
-8
MNI Cordinates
Z
Y
9
34
4
53
-5
-9
-11
43
Anatomic
Location
Left Anterior Cingulate Cortex
Left Superior Medial Frontal Gyrus

Midbrain

Medial Orbitofrontal Gyrus

on the left side. The second cluster (Figure 2 (b)) was also observed in the left extension of the forceps minor tract in white matter areas whereas the peak intensity is observed in the left superior medial frontal gyrus. It covered 469 voxels and had a peak intensity of 5.844. Figure 2 (c) highlights a cluster of 595 voxels in the region encompassing midbrain and the left thalamus with peak intensity of 4.745. Further, the fourth cluster was again observed in a region covering the left anterior cingulate gyrus, the medial orbitofrontal cortex, and the subcallosal gyrus (Figure 2 (d)). The cluster had a volume of 1040 voxels and a peak intensity of 4.4573. Moreover, the SWI values in all the above clusters exhibited negative correlation with the fatigue scores in work-sphere (Spearman rank-order correlation coefficient, ρ ∈ [−0.6014, −0.647]).

Mishra et al.: Preprint submitted to Elsevier
Page 5 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SWI Analysis of COVID-19
 
(a) Cluster in left cerebral white matter, left anterior cingulate gyrus

Cluster size: 1637, Peak Intensity: 5.9
 
(c) Cluster in left Thalamus, midbrain

Cluster size: 595, Peak Intensity: 4.745
 
(b) Cluster in left cerebral white matter, left medial frontal gyrus

Cluster size: 469, Peak Intensity: 5.844


 
(d) Cluster in left anterior cingulate gyrus, left medial frontal cortex

Cluster size: 1040, Peak Intensity: 4.4573
.
Figure 2: Results of group-level Susceptibility Weighted Imaging (SWI) analysis demonstrating significantly negatively correlated clusters with self-reported fatigue scores of work-sphere across the COVID recovered group. Here, ρ stands for the Spearman rank-order correlation coefficient. The blue colored dots represent the COVID recovered patients. The Avg. values in the x-axis denote the residuals plus the mean SWI values of the cluster across subjects added back after linear regression. The linear plot (red) represents the least squares regression line, and the shaded pink area depicts the 95% confidence interval.

4. Discussions

The ability of SWI modality to detect abnormalities in the brain has been widely reported in literature, where it has been demonstrated as a useful imaging technique for detecting microvascular pathologies and cerebral ischemia in white matter [26] and gray matter [27] regions. This motivates the use of SWI in investigating the effect of COVID-19 on the brain. In this study, the susceptibility weighted MR images of 46 COVID-19 recovered subjects and 30 healthy controls were acquired and group differences in susceptibility in the brain were studied. In the COVID-19 recovered cohort, nature of COVID infection ranged from mild to severe as inferred from self-reported symptoms. In the group comparison study, we have found significant clusters of abnormal susceptibility in the brain stem as well as

Mishra et al.: Preprint submitted to Elsevier
Page 6 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19

in the white matter regions of the inferior frontal lobe which extend to the cortical gray/white matter junctions. These clusters with high SWI values may be a result of microvascular pathologies, cerebral ischemia, or other edematous pathophysiological in the brain. Similar decreased susceptibility in the brain has been reportedly associated with mild cognitive impairment [24] and post traumatic epilepsy [28].

Susceptibility weighted imaging has been used to investigate the effect of acute COVID-19 infection on the brain. Conklin and colleagues [20] have used SWI and presented their observations based on case-reports of 16 patients who were admitted to the intensive care unit with severe COVID-19 and showed neurological deficits. The investigation has revealed cerebral microvascular lesions in deep white matter (9/16 patients), cortical regions (9/16 patients) and the brainstem (3/16 patients). Moreover, a study conducted in France by Helms and colleagues [29] on COVID-19 patients admitted in the ICU with acute respiratory distress syndrome has also reported white matter micro-haemorrhages in the frontal lobe using SWI. On similar lines, the clusters found in our group based study also suggest abnormalities in corresponding regions of the brain. While, both these discussed studies have reported their observations on critically-ill COVID-infected patients, we have conducted our analysis on patients who have recovered from different levels of severity of COVID-19 infection.

The present study has shown significant bilateral SWI hyperintensities in the frontal, more specifically, orbitofrontal region, damage to which has consistently been reported in other studies on COVID patients as well [30]. Structural analysis between COVID affected and healthy brains by [31] has shown reduced cortical thickness and tissue contrast in the orbito-frontal gyrus. A perfusion study [32] using ASL has reported decreased cerebral blood flow in the orbital and medial frontal cortices. Multiple studies on COVID patients using positron emission tomography (PET)/CT imaging have also consistently reported hypometabolism of Fludeoxyglucose (FDG) in the frontal lobe [33, 34, 35, 36].

Abnormalities in the midbrain region of the brainstem highlighted in this study have also been reported in multiple studies on COVID patients [37]. In critically ill patients, there have been reports of cerebral microhemorrhages in the brain stem [38]. These may be secondary effects of COVID caused by severe hypoxia in these patients. In another study [39], neuroinflammatory changes were observed in the brainstem while investigating neuropathological features of the COVID affected brains. A study on COVID patients using FLAIR imaging reported 4 out of 6 patients showing abnormalities in the brain stem [40]. A study on a 62 year old COVID patient using PET imaging also revealed hypometabolism of FDG in the brain stem area [41], while another study employing PET reported increased voxel weights in the same region [36]. Consistent reports of COVID-19 affecting similar regions of the brain strengthens the evidence of neurotropic behavior of the virus.

It was observed that several symptoms reported in COVID and Long COVID patients such as loss of smell and taste, insomnia, fatigue, cognitive problems, and mental health issues could be attributed to the regions of abnormal susceptibilities in our study. While the frontal lobe is generally associated with cognitive control functions, influencing attention and memory [42], the orbitofrontal gyrus is essentially the secondary cortex for taste and smell processing [43]. It is connected directly to the primary olfactory and taste cortices. The orbitofrontal cortex is also associated with regulation of mood and emotions. On the other hand, the inferior frontal gyrus is linked to cognitive control over memory [44]. The clusters found in the frontal lobe are primarily located in the WM areas, which overlap with the uncinate fasciculus tract. This tract connects the limbic and paralimbic regions with the orbito-frontal gyrus [45]. Functional and structural abnormalities in these regions have been consistently reported in studies on COVID patients [46]. The limbic, paralimbic and orbito-frontal regions play a central role in emotion processing. The decreased connectivity amongst these regions may be linked to mental health issues and reduced memory [47]. Susceptibility differences were also observed in the brainstem, which is vital for cardio-respiratory regulation in the body, and injuries to this area are long lasting in nature [48]. Specifically, abnormalities in the midbrain and pons have been connected to multiple symptoms of Long COVID like fatigue, insomnia, anxiety, depression, headaches, and cognitive problems [49]. These observations are notable and consolidate our findings in relation to the behavioral and cognitive manifestations of COVID-19. They also supplement our understanding of the nature of neurotropism exhibited by the virus.

In the fatigue study, four clusters were identified in the brain that showed a significant negative correlation of mean SWI values of the clusters with self-reported fatigue scores of work-sphere. These correlations can be interpreted as positive correlations of the score with average susceptibilities of the clusters [28]. The obtained Spearman rank-order correlation coefficients for these clusters ranged from -0.647 to -0.601, with p < 0.001 for all the clusters (refer to Figure 2). Similar to our study, areas in the brain have been found to be related to fatigue in other reports as well. A functional connectivity analysis [50] has reported a negative correlation between fatigue and connectivity in the precuneus network which involves the left superior parietal lobule, the superior occipital gyrus, the angular gyrus,

Mishra et al.: Preprint submitted to Elsevier
Page 7 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19

and precuneus. A volumetric study [51] on the brain of COVID affected patients has reported fatigue to be positively correlated to volume of the left posterior cingulate cortex, precuneus, and the superior parietal lobule. Another study [18] on blood perfusion in non-hospitalized COVID patients has reported increased CBF in superior occipital and parietal regions along with decreased perfusion in the inferior occipital regions.

The neural correlates of fatigue have been studied extensively using neuroimaging methods [52]. Fatigue has been shown to be associated with higher functional connectivity between regions, including the bilateral superior frontal gyri, the anterior cingulate gyrus, precuneus, right angular gyrus and posterior central gyrus, supplementary motor area, posterior cingulate gyrus and the thalamus [53]. In patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS), studies using single-photon emission computerized tomography (SPECT) [54] have reported a significantly higher perfusion in the anterior cingulate region along with reduced perfusion in other areas. The thalamus has been known to show significant changes in association with fatigue. In addition to the thalamus, the midbrain, cingulate, amygdala, pons, and the hippocampus have been reported to show inflammation in cases of fatigue [55]. In older people, the thalamus has been reported to exhibit neural correlates of perceived physical and mental fatigability [56]. These regions show substantial coherence with the gray and white matter regions identified to be correlated with fatigue in this study.

In this study, we have identified multiple clusters in gray matter as well as white matter brain regions of COVID patients where average susceptibility values are positively correlated (or average SWI values values are negatively correlated) with self-reported fatigue scores. The anterior cingulate cortex (ACC) is commonly known to be responsible for emotions and attention processing. The dorsal parts of the ACC contribute to cognitive functions while the ventral regions are involved in emotional processing [57]. The role of medial pre-frontal cortex in memory consolidation and retrieval of long term memory is also established in literature [58]. In studies on patients with depression, there have been reports of abnormal metabolic activity in the subcallosal gyrus [59]. This region was also identified in our study and may be related to emotional processing issues reported in Long COVID. The forceps minor tract and the anterior thalamic radiations connect the right and left frontal lobes. These neural circuits play a vital role in attention control and damage to these tracts has been associated with vascular cognitive impairments [60]. It must be observed that the established roles of the regions identified in this study have strong agreement with commonly reported symptoms of Long COVID.

Using high resolution T1 weighted anatomical images from the same subjects, we have also reported significant gray matter volume alterations in multiple brain regions from the limbic system and basal ganglia obtained using Voxel-Based Morphometry (VBM) analysis in [51]. The results from the present report complements the findings of the aforementioned conventional T1-weighted MR study. Both these studies together provide a holistic view into the neurological sequelae of COVID-19 as they utilize different mechanisms to investigate distinct properties of the brain. They suggest that the SARS-CoV-2 virus has structural and compositional effects on the brain. These neuroimaging impacts and their behavioral manifestations are visible even after months of recovery from the infection.

In conclusion, our results demonstrate group-level effects in COVID recovered patients, showing susceptibility differences in the GM and WM regions of the frontal lobe and brainstem. These observations are consistent with results reported in single-patient case studies carried out on SWI volumes and group studies using other MRI modalities.

The present research will help the community to understand the impact of the SARS-CoV-2 virus on the human brain and hence propose some rehabilitative measures. In this study, we have also identified multiple clusters in gray matter, and white matter brain regions of COVID recovered patients where the average SWI values are negatively correlated with the self-reported fatigue scores. The roles of the clusters identified in this study have substantial agreement with commonly reported behavioral manifestations of post-COVID-19 fatigue. These brain regions have also been associated with fatigue in other neurodegenerative diseases. These deductions also indicate the viability of SWI modality for analysis of post-COVID symptoms. It also suggests an association of Long COVID with prolonged effects on the brain.

5. Limitations

While this study on the neurological basis of post-COVID symptoms using SWI has revealed significant abnormalities in susceptibilities of brain regions, there remain certain limitations that may be addressed to improve the impact and reliability of the study. Firstly, our study presents a group based analysis with a limited number of subjects which limits its transferability owing to unpredictable individual effects of each patient. Further, the application of

Mishra et al.: Preprint submitted to Elsevier
Page 8 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19

SWI modality in clinical settings is slowly gaining relevance which hinders the immediate utility of our inferences for postulating the neuroimaging characteristics of post-COVID symptoms.

CRediT authorship contribution statement

Sapna S Mishra: Investigation, Methodology, Software, Formal Analysis, Resources, Data Curation, Writing -
Original draft preparation, review and editing.

Rakibul Hafiz: Investigation, Formal Analysis, Data Curation, Writing - Review and editing.

Rohit Misra: Investigation, Formal Analysis, Writing - Review and editing.

Tapan K. Gandhi: Conceptualization, Investigation, Resources, Supervision, Writing - Review and editing.

Alok Prasad: Data Curation, Writing - Review and editing.

Vidur Mahajan: Writing - Review and editing.

Bharat B. Biswal: Conceptualization, Resources, Project Administration, Supervision, Writing - Review and editing.

References

[1] World health organization (WHO,) coronavirus disease (COVID-19) dashboard, https://covid19.who.int/table, ????
[2] K. C. Ng Kee Kwong, P. R. Mehta, G. Shukla, A. R. Mehta, Covid-19, sars and mers: A neurological perspective, Journal of Clinical
Neuroscience 77 (2020) 13–16.
[3] M. A. Ellul, L. Benjamin, B. Singh, S. Lant, B. D. Michael, A. Easton, R. Kneen, S. Defres, J. Sejvar, T. Solomon, Neurological associations
of COVID-19, The Lancet Neurology 19 (2020) 767–783. Publisher: Elsevier.
[4] G. Tsivgoulis, L. Palaiodimou, A. H. Katsanos, V. Caso, M. Köhrmann, C. Molina, C. Cordonnier, U. Fischer, P. Kelly, V. K. Sharma, A. C.
Chan, R. Zand, A. Sarraj, P. D. Schellinger, K. I. Voumvourakis, N. Grigoriadis, A. V. Alexandrov, S. Tsiodras, Neurological manifestations
and implications of covid-19 pandemic, Therapeutic Advances in Neurological Disorders 13 (2020) 1756286420932036. PMID: 32565914.
[5] S. Sood, R. Gupta, J. Modi, J. Sharma, et al., Susceptibility weighted imaging: physics and clinical applications in neuroimaging at 3 tesla,
in: European Congress of Radiology, volume 2014, 2014.
[6] A. M. Halefoglu, D. M. Yousem, Susceptibility weighted imaging: clinical applications and future directions, World journal of radiology 10
(2018) 30.
[7] S. Mittal, Z. Wu, J. Neelavalli, E. M. Haacke, Susceptibility-weighted imaging: technical aspects and clinical applications, part 2, American
Journal of neuroradiology 30 (2009) 232–252.
[8] M. Akter, T. Hirai, Y. Hiai, M. Kitajima, M. Komi, R. Murakami, H. Fukuoka, A. Sasao, R. Toya, E. M. Haacke, M. Takahashi, T. Hirano,
Y. Kai, M. Morioka, K. Hamasaki, J. ichi Kuratsu, Y. Yamashita, Detection of hemorrhagic hypointense foci in the brain on susceptibility-
weighted imaging: Clinical and phantom studies, Academic Radiology 14 (2007) 1011–1019.
[9] J. P. Larsen, W. Britt III, D. Kido, B. L. B. Olson, B. A. Holshouser, W. M. Kirsch, Susceptibility-weighted magnetic resonance imaging in
the evaluation of dementia, Radiology Case Reports 2 (2007) 102.
[10] M.-H. Lee, D. P. Perl, G. Nair, W. Li, D. Maric, H. Murray, S. J. Dodd, A. P. Koretsky, J. A. Watts, V. Cheung, E. Masliah, I. Horkayne-Szakaly,
R. Jones, M. N. Stram, J. Moncur, M. Hefti, R. D. Folkerth, A. Nath, Microvascular injury in the brains of patients with covid-19, New England
Journal of Medicine 384 (2021) 481–483. PMID: 33378608.
[11] E. Song, C. Zhang, B. Israelow, A. Lu-Culligan, A. V. Prado, S. Skriabine, P. Lu, O.-E. Weizman, F. Liu, Y. Dai, K. Szigeti-Buck, Y. Yasumoto,
G. Wang, C. Castaldi, J. Heltke, E. Ng, J. Wheeler, M. M. Alfajaro, E. Levavasseur, B. Fontes, N. G. Ravindra, D. Van Dijk, S. Mane, M. Gunel,
A. Ring, S. A. Jaffar Kazmi, K. Zhang, C. B. Wilen, T. L. Horvath, I. Plu, S. Haik, J.-L. Thomas, A. Louvi, S. F. Farhadian, A. Huttner,
D. Seilhean, N. Renier, K. Bilguvar, A. Iwasaki, Neuroinvasion of sars-cov-2 in human and mouse brain, bioRxiv (2020).
[12] E. Gulko, M. Oleksk, W. Gomes, H. Mehta, P. Overby, F. Almufti, A. Rozenshtein, Mri brain findings in 126 patients with covid-19: Initial
observations from a descriptive literature review, AJNR. American journal of neuroradiology 41 (2020).
[13] S. Kremer, F. Lersy, M. Anheim, H. Merdji, M. Schenck, H. Oesterlé, F. Bolognini, J. Messie, A. Khalil, A. Gaudemer, S. Carré, M. Alleg,
C. Lecocq, E. Schmitt, R. Anxionnat, F. Zhu, L. Jager, P. Nesser, Y. T. Mba, G. Hmeydia, J. Benzakoun, C. Oppenheim, J.-C. Ferré, A. Maamar,
B. Carsin-Nicol, P.-O. Comby, F. Ricolfi, P. Thouant, C. Boutet, X. Fabre, G. Forestier, I. de Beaurepaire, G. Bornet, H. Desal, G. Boulouis,
J. Berge, A. Kazémi, N. Pyatigorskaya, A. Lecler, S. Saleme, M. Edjlali-Goujon, B. Kerleroux, J.-M. Constans, P.-E. Zorn, M. Mathieu,
S. Baloglu, F.-D. Ardellier, T. Willaume, J.-C. Brisset, S. Caillard, O. Collange, P. M. Mertes, F. Schneider, S. Fafi-Kremer, M. Ohana,
F. Meziani, N. Meyer, J. Helms, F. Cotton, Neurologic and neuroimaging findings in patients with covid-19, Neurology 95 (2020) e1868–
e1882.
[14] K. Duan, E. Premi, A. Pilotto, V. Cristillo, A. Benussi, I. Libri, M. Giunta, H. J. Bockholt, J. Liu, R. Campora, A. Pezzini, R. Gasparotti,
M. Magoni, A. Padovani, V. D. Calhoun, Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults
with covid-19, Neurobiology of Stress 14 (2021) 100326.
[15] F. Lersy, M. Anheim, T. Willaume, A. Chammas, J.-C. Brisset, F. Cotton, S. Kremer, Cerebral vasculitis of medium-sized vessels as a possible
mechanism of brain damage in covid-19 patients, Journal of Neuroradiology 48 (2020).
[16] E. Keller, G. Brandi, S. Winklhofer, L. L. Imbach, D. Kirschenbaum, K. Frontzek, P. Steiger, S. Dietler, M. Haeberlin, J. Willms, F. Porta,
A. Waeckerlin, M. Huber, I. A. Abela, A. Lutterotti, C. Stippich, C. Globas, Z. Varga, I. Jelcic, Large and small cerebral vessel involvement
in severe covid-19, Stroke 51 (2020) 3719–3722.
[17] M. d. F. V. V. Aragao, M. de Carvalho Leal, O. Q. Cartaxo Filho, T. M. Fonseca, L. V. Aragao, M. R. V. C. Leao, M. A. Valenca, P. H. P.
de Andrade, J. P. V. Aragao, S. d. S. C. Neto, et al., Comparative study-the impact and profile of covid-19 patients who are indicated for
neuroimaging: Vascular phenomena are been found in the brain and olfactory bulbs, Medrxiv (2021) 2020–12.

Mishra et al.: Preprint submitted to Elsevier
Page 9 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19

[18] W. S. Kim, X. Ji, E. Roudaia, J. J. Chen, A. Gilboa, A. Sekuler, F. Gao, Z. Lin, A. Jegatheesan, M. Masellis, M. Goubran, J. S. Rabin, B. Lam,
I. Cheng, R. Fowler, C. Heyn, S. E. Black, S. J. Graham, B. J. MacIntosh, Decreased cerebral blood flow in non-hospitalized adults who
self-isolated due to covid-19, medRxiv (2022).
[19] L. Griffanti, B. Raman, F. Alfaro-Almagro, N. Filippini, M. P. Cassar, F. Sheerin, T. W. Okell, F. A. Kennedy McConnell, M. A. Chappell,
C. Wang, C. Arthofer, F. J. Lange, J. Andersson, C. E. Mackay, E. M. Tunnicliffe, M. Rowland, S. Neubauer, K. L. Miller, P. Jezzard, S. M.
Smith, Adapting the uk biobank brain imaging protocol and analysis pipeline for the c-more multi-organ study of covid-19 survivors, Frontiers
in Neurology 12 (2021).
[20] J. Conklin, M. P. Frosch, S. S. Mukerji, O. Rapalino, M. D. Maher, P. W. Schaefer, M. H. Lev, R. Gonzalez, S. Das, S. N. Champion,
C. Magdamo, P. Sen, G. K. Harrold, H. Alabsi, E. Normandin, B. Shaw, J. E. Lemieux, P. C. Sabeti, J. A. Branda, E. N. Brown, M. B.
Westover, S. Y. Huang, B. L. Edlow, Susceptibility-weighted imaging reveals cerebral microvascular injury in severe covid-19, Journal of the
Neurological Sciences 421 (2021) 117308.
[21] L. Saitta, A. Molin, F. Villani, A. Insorsi, L. Roccatagliata, M. Inglese, M. Bassetti, P. Pelosi, L. Castellan, S. Gerevini, et al., Brain
microvascular occlusive disorder in covid-19: a case report, Neurological Sciences 41 (2020) 3401–3404.
[22] S. Agarwal, R. Jain, S. Dogra, P. Krieger, A. Lewis, V. Nguyen, K. Melmed, S. Galetta, Cerebral microbleeds and leukoencephalopathy in
critically ill patients with covid-19, Stroke 51 (2020) 2649–2655.
[23] M. Jenkinson, P. Bannister, M. Brady, S. Smith, Improved optimization for the robust and accurate linear registration and motion correction
of brain images, NeuroImage 17 (2002) 825–841.
[24] S. Haller, A. Bartsch, D. Nguyen, C. Rodriguez, J. Emch, G. Gold, K.-O. Lövblad, P. Giannakopoulos, Cerebral microhemorrhage and iron
deposition in mild cognitive impairment: Susceptibility-weighted mr imaging assessment, Radiology 257 (2010) 764–73.
[25] J. A. Frazier, S. Chiu, J. L. Breeze, N. Makris, N. Lange, D. N. Kennedy, M. R. Herbert, E. K. Bent, V. K. Koneru, M. E. Dieterich, S. M.
Hodge, S. L. Rauch, P. E. Grant, B. M. Cohen, L. J. Seidman, V. S. Caviness, J. Biederman, Structural brain magnetic resonance imaging of
limbic and thalamic volumes in pediatric bipolar disorder, American Journal of Psychiatry 162 (2005) 1256–1265. PMID: 15994707.
[26] D. F. Tate, M. Gusman, J. Kini, M. Reid, C. S. Velez, A. M. Drennon, D. B. Cooper, J. E. Kennedy, A. O. Bowles, E. D. Bigler, J. D. Lewis,
J. Ritter, G. E. York, Susceptibility Weighted Imaging and White Matter Abnormality Findings in Service Members With Persistent Cognitive
Symptoms Following Mild Traumatic Brain Injury, Military Medicine 182 (2017) e1651–e1658.
[27] J. Hu, Y. Yu, C. Juhasz, Z. Kou, Y. Xuan, Z. Latif, K. Kudo, H. T. Chugani, E. M. Haacke, Mr susceptibility weighted imaging (swi)
complements conventional contrast enhanced t1 weighted mri in characterizing brain abnormalities of sturge-weber syndrome, Journal of
Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine 28 (2008) 300–307.
[28] H. A. Ferreira, A. Andrade, R. Manaças, P. Gonçalves-Pereira, Whole-brain voxel-based susceptibility-weighted imaging (swi) analysis:
normal cortical and subcortical values, and preliminary results in post-traumatic epilepsy, Cerebellum 14 (????) 6–7.
[29] J. Helms, S. Kremer, H. Merdji, M. Schenck, F. Severac, R. Clere-Jehl, A. Studer, M. Radosavljevic, C. Kummerlen, A. Monnier, et al.,
Delirium and encephalopathy in severe covid-19: a cohort analysis of icu patients, Critical Care 24 (2020) 1–11.
[30] S. Toniolo, F. Di Lorenzo, M. Scarioni, K. S. Frederiksen, F. Nobili, Is the frontal lobe the primary target of sars-cov-2?, Journal of Alzheimer’s
Disease 81 (2021) 75–81.
[31] G. Douaud, S. Lee, F. Alfaro-Almagro, C. Arthofer, C. Wang, P. McCarthy, F. Lange, J. L. Andersson, L. Griffanti, E. Duff, et al., Sars-cov-2
is associated with changes in brain structure in uk biobank, Nature 604 (2022) 697–707.
[32] M. Yus, J. A. Matias-Guiu, L. Gil-Martínez, N. Gómez-Ruiz, C. Polidura, M. Jorquera, C. Delgado-Alonso, M. Díez-Cirarda, J. Matías-
Guiu, J. Arrazola, Persistent olfactory dysfunction after covid-19 is associated with reduced perfusion in the frontal lobe, Acta Neurologica
Scandinavica (2022).
[33] M. Karimi-Galougahi, A. Yousefi-Koma, M. Bakhshayeshkaram, N. Raad, S. Haseli, 18fdg pet/ct scan reveals hypoactive orbitofrontal cortex
in anosmia of covid-19, Academic radiology 27 (2020) 1042.
[34] C. Delorme, O. Paccoud, A. Kas, A. Hesters, S. Bombois, P. Shambrook, A. Boullet, D. Doukhi, L. Le Guennec, N. Godefroy, et al., Covid-
19-related encephalopathy: a case series with brain fdg-positron-emission tomography/computed tomography findings, European journal of
neurology 27 (2020) 2651–2657.
[35] A. Kas, M. Soret, N. Pyatigoskaya, M.-O. Habert, A. Hesters, L. Le Guennec, O. Paccoud, S. Bombois, C. Delorme, The cerebral network of
covid-19-related encephalopathy: a longitudinal voxel-based 18f-fdg-pet study, European journal of nuclear medicine and molecular imaging
48 (2021) 2543–2557.
[36] J. A. Hosp, A. Dressing, G. Blazhenets, T. Bormann, A. Rau, M. Schwabenland, J. Thurow, D. Wagner, C. Waller, W. D. Niesen, et al.,
Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of covid-19, Brain 144 (2021) 1263–1276.
[37] R. Manca, M. De Marco, P. G. Ince, A. Venneri, Heterogeneity in regional damage detected by neuroimaging and neuropathological studies
in older adults with covid-19: A cognitive-neuroscience systematic review to inform the long-term impact of the virus on neurocognitive
trajectories, Frontiers in aging neuroscience 13 (2021) 646908.
[38] L. Dixon, C. McNamara, P. Gaur, D. Mallon, C. Coughlan, F. Tona, W. Jan, M. Wilson, B. Jones, Cerebral microhaemorrhage in covid-19: a
critical illness related phenomenon?, Stroke and Vascular Neurology 5 (2020) e000652.
[39] J. Matschke, M. Lütgehetmann, C. Hagel, J. P. Sperhake, A. S. Schröder, C. Edler, H. Mushumba, A. Fitzek, L. Allweiss, M. Dandri, et al.,
Neuropathology of patients with covid-19 in germany: a post-mortem case series, The Lancet Neurology 19 (2020) 919–929.
[40] C. W. Freeman, J. Masur, A. Hassankhani, R. L. Wolf, J. M. Levine, S. Mohan, Covid-19-related disseminated leukoencephalopathy (crdl):
A retrospective study of findings on brain mri., AJR. American Journal of Roentgenology (2020).
[41] E. Guedj, M. Million, P. Dudouet, H. Tissot-Dupont, F. Bregeon, S. Cammilleri, D. Raoult, 18f-fdg brain pet hypometabolism in post-sars-cov-2
infection: substrate for persistent/delayed disorders?, European journal of nuclear medicine and molecular imaging 48 (2021) 592–595.
[42] D. Baldauf, R. Desimone, Neural mechanisms of object-based attention, Science 344 (2014) 424–427.
[43] E. T. Rolls, The functions of the orbitofrontal cortex, Brain and cognition 55 (2004) 11–29.

Mishra et al.: Preprint submitted to Elsevier
Page 10 of 11medRxiv preprint doi: https://doi.org/10.1101/2022.11.21.22282600 ; this version posted November 22, 2022. The copyright
holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license
to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
SWI Analysis of COVID-19

[44] M. Tops, M. A. Boksem, A potential role of the inferior frontal gyrus and anterior insula in cognitive control, brain rhythms, and event-related
potentials, Frontiers in psychology 2 (2011) 330.
[45] R. J. Von Der Heide, L. M. Skipper, E. Klobusicky, I. R. Olson, Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis,
Brain 136 (2013) 1692–1707.
[46] P. Najt, H. L. Richards, D. G. Fortune, Brain imaging in patients with covid-19: A systematic review, Brain, behavior, & immunity-health 16
(2021) 100290.
[47] K. A. Lindquist, T. D. Wager, H. Kober, E. Bliss-Moreau, L. F. Barrett, The brain basis of emotion: a meta-analytic review, The Behavioral
and brain sciences 35 (2012) 121.
[48] H. Basinger, J. P. Hogg, Neuroanatomy, brainstem (2019).
[49] S. J. Yong, Persistent brainstem dysfunction in long-covid: a hypothesis, ACS chemical neuroscience 12 (2021) 573–580.
[50] R. Hafiz, T. K. Gandhi, S. Mishra, A. Prasad, V. Mahajan, B. H. Natelson, X. Di, B. B. Biswal, Assessing functional connectivity differences
and work-related fatigue in surviving covid-negative patients, bioRxiv (2022).
[51] R. Hafiz, T. K. Gandhi, S. Mishra, A. Prasad, V. Mahajan, X. Di, B. H. Natelson, B. B. Biswal, Higher limbic and basal ganglia volumes in
surviving covid-negative patients and the relations to fatigue, Neuroimage: Reports 2 (2022) 100095.
[52] R. Maksoud, S. du Preez, N. Eaton-Fitch, K. Thapaliya, L. Barnden, H. Cabanas, D. Staines, S. Marshall-Gradisnik, A systematic review
of neurological impairments in myalgic encephalomyelitis/chronic fatigue syndrome using neuroimaging techniques, PloS one 15 (2020)
e0232475.
[53] J. Boissoneault, J. Letzen, S. Lai, A. O’Shea, J. Craggs, M. E. Robinson, R. Staud, Abnormal resting state functional connectivity in patients
with chronic fatigue syndrome: an arterial spin-labeling fmri study, Magnetic resonance imaging 34 (2016) 603–608.
[54] K. B. Schmaling, D. H. Lewis, J. I. Fiedelak, R. Mahurin, D. S. Buchwald, Single-photon emission computerized tomography and
neurocognitive function in patients with chronic fatigue syndrome, Psychosomatic medicine 65 (2003) 129–136.
[55] Y. Nakatomi, K. Mizuno, A. Ishii, Y. Wada, M. Tanaka, S. Tazawa, K. Onoe, S. Fukuda, J. Kawabe, K. Takahashi, et al., Neuroinflammation
in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11c-(r)-pk11195 pet study, Journal of Nuclear Medicine 55 (2014)
945–950.
[56] D. Angioni, K. Virecoulon Giudici, M. Montoya Martinez, Y. Rolland, B. Vellas, P. de Souto Barreto, Neuroimaging markers of chronic
fatigue in older people: a narrative review, Aging Clinical and Experimental Research 33 (2021) 1487–1492.
[57] G. Bush, P. Luu, M. I. Posner, Cognitive and emotional influences in anterior cingulate cortex, Trends in cognitive sciences 4 (2000) 215–222.
[58] D. R. Euston, A. J. Gruber, B. L. McNaughton, The role of medial prefrontal cortex in memory and decision making, Neuron 76 (2012)
1057–1070.
[59] C. Hamani, H. Mayberg, S. Stone, A. Laxton, S. Haber, A. M. Lozano, The subcallosal cingulate gyrus in the context of major depression,
Biological psychiatry 69 (2011) 301–308.
[60] M. Duering, N. Zieren, D. Hervé, E. Jouvent, S. Reyes, N. Peters, C. Pachai, C. Opherk, H. Chabriat, M. Dichgans, Strategic role of frontal white
matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL, Brain 134 (2011) 2366–2375.

Mishra et al.: Preprint submitted to Elsevier
Page 11 of 11
[*/quote*]
« Last Edit: July 11, 2024, 08:26:23 PM by Pangwall »
Logged

Löwenzian

  • Newbie
  • *
  • Posts: 6
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #3 on: February 28, 2023, 12:13:39 PM »

Es gibt auch den Fulltext mit Bildern:

https://www.medrxiv.org/content/10.1101/2022.11.21.22282600v2.full-text

Da sieht man, welchen Matsch Covid im Kopf hinterläßt:



https://www.medrxiv.org/content/medrxiv/early/2022/12/05/2022.11.21.22282600/F1.large.jpg

[*quote*]
Figure 1:

Group analysis on susceptibility weighted imaging exhibiting higher SWI values (lower susceptibilities) in the COVID group when compared to healthy controls. Three significant clusters were found primarily in the white matter regions of pre-frontal cortex and in the brainstem. The clusters (a) and (b) are observed bilaterally in the cerebral white matter near the orbito-frontal gyrus whereas (c) lies in the midbrain region.
[*/quote*]




https://www.medrxiv.org/content/medrxiv/early/2022/12/05/2022.11.21.22282600/F2.large.jpg

[*quote*]
Figure 2:

Results of group-level Susceptibility Weighted Imaging (SWI) analysis demonstrating significantly negatively correlated clusters with self-reported fatigue scores of work-sphere across the COVID recovered group. Here, ρ stands for the Spearman rank-order correlation coefficient. The blue colored dots represent the COVID recovered patients. The Avg. values in the x-axis denote the residuals plus the mean SWI values of the cluster across subjects added back after linear regression. The linear plot (red) represents the least squares regression line, and the shaded pink area depicts the 95% confidence interval.
[*/quote*]
« Last Edit: July 11, 2024, 08:27:17 PM by Pangwall »
Logged

Pangwall

  • Jr. Member
  • *
  • Posts: 1675
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
« Reply #4 on: March 07, 2023, 07:44:30 PM »

Hier ist noch ein Artikel:


https://www.nature.com/articles/s41586-022-04569-5

[*quote*]
    Article
    Open Access
    Published: 07 March 2022

SARS-CoV-2 is associated with changes in brain structure in UK Biobank

    Gwenaëlle Douaud, Soojin Lee, Fidel Alfaro-Almagro, Christoph Arthofer, Chaoyue Wang, Paul McCarthy, Frederik Lange, Jesper L. R. Andersson, Ludovica Griffanti, Eugene Duff, Saad Jbabdi, Bernd Taschler, Peter Keating, Anderson M. Winkler, Rory Collins, Paul M. Matthews, Naomi Allen, Karla L. Miller, Thomas E. Nichols & Stephen M. Smith

Nature volume 604, pages 697–707 (2022)Cite this article

    812k Accesses
    323 Citations
    16922 Altmetric
    Metrics details

Abstract

There is strong evidence of brain-related abnormalities in COVID-191,2,3,4,5,6,7,8,9,10,11,12,13. However, it remains unknown whether the impact of SARS-CoV-2 infection can be detected in milder cases, and whether this can reveal possible mechanisms contributing to brain pathology. Here we investigated brain changes in 785 participants of UK Biobank (aged 51–81 years) who were imaged twice using magnetic resonance imaging, including 401 cases who tested positive for infection with SARS-CoV-2 between their two scans—with 141 days on average separating their diagnosis and the second scan—as well as 384 controls. The availability of pre-infection imaging data reduces the likelihood of pre-existing risk factors being misinterpreted as disease effects. We identified significant longitudinal effects when comparing the two groups, including (1) a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; (2) greater changes in markers of tissue damage in regions that are functionally connected to the primary olfactory cortex; and (3) a greater reduction in global brain size in the SARS-CoV-2 cases. The participants who were infected with SARS-CoV-2 also showed on average a greater cognitive decline between the two time points. Importantly, these imaging and cognitive longitudinal effects were still observed after excluding the 15 patients who had been hospitalised. These mainly limbic brain imaging results may be the in vivo hallmarks of a degenerative spread of the disease through olfactory pathways, of neuroinflammatory events, or of the loss of sensory input due to anosmia. Whether this deleterious effect can be partially reversed, or whether these effects will persist in the long term, remains to be investigated with additional follow-up.

Main

The global pandemic of SARS-CoV-2 has now claimed millions of lives across the world. There has been an increased focus by the scientific and medical community on the effects of mild-to-moderate COVID-19 in the longer term. There is strong evidence for brain-related pathologies, some of which could be a consequence of viral neurotropism1,2,14 or virus-induced neuroinflammation3,4,5,15, including the following: neurological and cognitive deficits demonstrated by patients6,7, with an incidence of neurological symptoms in more than 80% of the severe cases8, radiological and post mortem tissue analyses demonstrating the impact of COVID-19 on the brain9,10, and the possible presence of the coronavirus in the central nervous system11,12,13.

In particular, one consistent clinical feature, which can appear before the onset of respiratory symptoms, is the disturbance in olfaction and gustation in patients with COVID-1916,17. In a recent study, 100% of the patients in the subacute stage of the disease were displaying signs of gustatory impairment (hypogeusia), and 86%, signs of either hyposmia or anosmia18. Such loss of sensory olfactory inputs to the brain could lead to a loss of grey matter in olfactory-related brain regions19. Olfactory cells—whether neuronal or supporting—concentrated in the olfactory epithelium are also particularly vulnerable to coronavirus invasion, and this seems to be also the case specifically with SARS-CoV-217,20,21,22. Within the olfactory system, direct neuronal connections from and to the olfactory bulb encompass regions of the piriform cortex (the primary olfactory cortex), parahippocampal gyrus, entorhinal cortex and orbitofrontal areas23,24.

Most brain imaging studies of COVID-19 to date have focussed on acute cases and radiological reports of single cases or case series based on computed tomography (CT), positron emission tomography (PET) or magnetic resonance imaging (MRI) scans, revealing a broad array of gross cerebral abnormalities,  including white matter hyperintensities, hypoperfusion and signs of ischaemic events spread throughout the brain, but found more consistently in the cerebrum9. Of the few larger studies focussing on cerebrovascular damage using CT or MRI, some have either found no clear marker of abnormalities in the majority of their patients, or importantly no spatially consistent pattern for the distribution of white matter hyperintensities or microhaemorrhages, except perhaps in the middle or posterior cerebral artery territories and the basal ganglia9. Imaging cohort studies of COVID-19, quantitatively comparing data across participants through automated preprocessing and co-alignment of images, are much rarer. For example, a recent PET cohort study focussing on correlates of cognitive impairment demonstrated, in 29 patients with COVID-19 at a subacute stage, the involvement of fronto-parietal areas revealed as fluorodeoxyglucose (18F-FDG) hypometabolism18. Another glucose PET study has shown bilateral hypometabolism in the bilateral orbital gyrus rectus and the right medial temporal lobe25. One multiorgan imaging study26 (and its brain-focussed follow-up27) in over 50 previously hospitalised patients with COVID-19 suggested modest abnormalities in T2* of the left and right thalami compared with matched controls. However, it remains unknown whether any of these abnormalities predates the infection by SARS-CoV-2. These effects could be associated with a pre-existing increased brain vulnerability to the deleterious effects of COVID-19 and/or a higher probability to show more pronounced symptoms, rather than being a consequence of the COVID-19 disease process.

UK Biobank offers a unique resource to elucidate these questions. With the data from this large, multimodal brain imaging study, we used for the first time a longitudinal design whereby participants had been already scanned as part of UK Biobank before being infected by SARS-CoV-2. They were then imaged again, on average 38 months later, after some had either medical and public health records of COVID-19, or had tested positive for SARS-CoV-2 twice using rapid antibody tests. Those participants were then matched with control individuals who had undergone the same longitudinal imaging protocol but had tested negative using the rapid antibody test or had no medical record of COVID-19. In total, 401 participants with SARS-CoV-2 infection with usable imaging data at both time points were included in this study, as well as 384 control individuals, matched for age, sex, ethnicity and time elapsed between the two scans. These large numbers may enable us to detect subtle, but consistent spatially distributed sites of damage associated with the infection, therefore underlining in vivo the possible spreading pathways of the effects of the disease within the brain (whether such effects relate to the invasion of the virus itself11,14,20, inflammatory reactions3,4,15, possible anterograde degeneration starting with the olfactory neurons in the nose, or through sensory deprivation19,28,29). The longitudinal aspect of the study aims to help to tease apart which of the observed effects between the first and second scans are probably related to the infection, rather than due to pre-existing risk factors between the two groups.

Our general approach in this study was therefore as follows: (1) use brain imaging data from 785 participants who visited the UK Biobank imaging centres for two scanning sessions, on average 3 years apart, with 401 of these having been infected with SARS-CoV-2 in between their two scans; (2) estimate—from each participant’s multimodal brain imaging data—hundreds of distinct brain imaging-derived phenotypes (IDPs), each IDP being a measure of one aspect of brain structure or function; (3) model confounding effects, and estimate the longitudinal change in IDPs between the two scans; and (4) identify significant SARS-CoV-2 versus control group differences in these longitudinal effects, correcting for multiple comparisons across IDPs. We did this for both a focussed set of a priori-defined IDPs, testing the hypothesis that the olfactory system is particularly vulnerable in COVID-19, as well as an exploratory set of analyses considering a much larger set of IDPs covering the entire brain. In both cases, we identified significant effects associated with SARS-CoV-2 infection primarily relating to greater atrophy and increased tissue damage in cortical areas directly connected to the primary olfactory cortex, as well as to changes in global measures of brain and cerebrospinal fluid volume.

Participants

UK Biobank has been releasing data from the COVID-19 re-imaging study on a rolling basis. As of 31 May 2021, 449 adult participants met the re-imaging study inclusion criteria (see the ‘Study design’ section of the Methods) and were identified as having been infected with SARS-CoV-2 based on either their primary care (GP) data, hospital records, results of their diagnostic antigen tests identified through record linkage to the Public Health datasets in England, Wales and Scotland, or two concordant antibody-based home lateral flow kit positive results. Of these 449 adult participants who had tested positive for SARS-CoV-2, a total of 401 had usable brain scans at both time points (Tables 1 and 2). For the 351 individuals for whom we had a diagnosis date based on their medical records or antigen tests, the time between diagnosis (a proxy for infection) and their second imaging scan was on average 141 days (Table 2 and Supplementary Fig. 1).

Table 1 Main demographics of the participants
Full size table

Table 2 Main clinical information for SARS-CoV-2 cases
Full size table

In total, 384 adult control participants met the inclusion criteria (see the ‘Study design’ section of the Methods) and had usable brain scans at both time points (Table 1). SARS-CoV-2 positive or negative status was identified using UK Biobank Showcase variable 41000.

Despite the original matched pairing of the SARS-CoV-2 cases and controls, their age distributions were slightly—albeit not statistically significantly—different, due to different patterns of missing/usable data (Extended Data Fig. 1). Note that the control group is on average slightly (albeit not significantly) older than the SARS-CoV-2-positive group, which would be expected to make any change between the two time points more difficult to detect in the group comparisons, rather than easier. Histograms of interval of time between the two scans in the two groups are shown in Extended Data Fig. 2.

The two groups showed no statistical differences across all 6,301 non-imaging phenotypes after false-discovery rate (FDR) or family-wise error (FWE) correction for multiple comparisons (lowest PFWE = 0.12, and no uncorrected P values survived FDR correction). However, owing to the stringent correction for multiple comparisons that this analysis imposes, we investigated further whether subtle patterns of baseline differences could be observed using dimension reduction with principal component analysis on all 6,301 variables, and using a separate principal component analysis focussed on baseline cognition (Supplementary Analysis 1). We found no principal components that differed significantly between the two groups when examining all of the non-imaging variables. With respect to cognitive tests, although no single cognitive score was significantly different at baseline between control individuals and participants who were later infected (future cases), we identified two cognitive principal components that were different (Supplementary Analysis 1). These subtle baseline cognitive differences suggest that the future cases had slightly lower cognitive abilities compared with the control individuals. Importantly, none of these principal components—cognitive or otherwise—could statistically account for the longitudinal imaging results (see the ‘Additional baseline investigations’ section below).

Through hospital records, we identified 15 participants in the SARS-CoV-2-positive group who had been hospitalised with COVID-19, including 2 who received critical care (Tables 2 and 3). These hospitalised patients were on average older, had higher blood pressure and weight, and were more likely to have diabetes and be men, compared with non-hospitalised cases (Table 3).
Table 3 Comparison between hospitalised versus non-hospitalised SARS-CoV-2 cases

Full size table

Hypothesis-driven results

The main case-versus-control analysis between the 401 SARS-CoV-2 cases and 384 controls (Model 1) on 297 olfactory-related cerebral IDPs yielded 68 significant results after FDR correction for multiple comparisons, including 6 that survived FWE correction (Table 4 and Fig. 1; a full list of the results is provided in Supplementary Table 1). Focussing on the top 10 most significant associations, 8 of these IDPs covered similar brain regions that are functionally connected to the primary olfactory cortex (see the ‘Hypothesis-driven approach’ section in the Methods), showing overlap especially in the anterior cingulate cortex, orbitofrontal cortex and insula, as well as in the ventral striatum, amygdala, hippocampus and parahippocampal gyrus30. We found a greater longitudinal increase in diffusion indices for the SARS-CoV-2 group in these tailored IDPs defining the functional connections with the frontal and temporal piriform cortex, as well as the olfactory tubercle and anterior olfactory nucleus (Table 4, Fig. 1 and Supplementary Table 1). The other two of the top 10 IDPs encompassed the left lateral orbitofrontal cortex and parahippocampal gyrus, both showing a greater reduction in grey matter thickness or intensity contrast over time for cases compared with controls (Table 4, Fig. 1 and Supplementary Table 1). For those significant IDPs, the average differences in percentage change between the two groups were moderate, ranging from around 0.2% to about 2%, with the largest differences observed in the volume of the parahippocampal gyrus and entorhinal cortex (Supplementary Table 1). Scatter and box plots, as well as plots showing the percentage changes with age are available for the top 10 longitudinal IDPs (Supplementary Information, Longitudinal Plots).

Table 4 Top 10 of the 68 significant results for the hypothesis-driven olfactory approach
Full size table

Fig. 1: The most significant longitudinal group comparison results from the hypothesis-driven approach.
figure 1



https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-022-04569-5/MediaObjects/41586_2022_4569_Fig1_HTML.png

a–d, The top four regions consistently showing longitudinal differences across the three models comparing SARS-CoV-2 cases and controls demonstrated either a significantly greater reduction in grey matter thickness and intensity contrast, or an increase in tissue damage (largest combined |Z| across Models 1–3). All three models pointed to the involvement of the parahippocampal gyrus (a), whereas Models 1 and 2 also showed the significant involvement of the left orbitofrontal cortex (b) and of the functional connections of the primary olfactory cortex (c, d). For each region, the IDP’s spatial region of interest is shown at the top left in blue, overlaid either on the FreeSurfer average inflated cortical surface, or the T1 template (left is shown on the right). For each IDP, the longitudinal percentage changes are shown with age for the two groups (control participants in blue, participants with infection in orange), obtained by normalising ΔIDP using the values for the corresponding IDPs across the 785 participants’ scans as the baseline. These are created using a 10-year sliding window average, with s.e.m. values shown in grey. The counter-intuitive increase in thickness in the orbitofrontal cortex in older controls has been previously consistently reported in studies of ageing57,58. The difference in cortical thickness, intensity contrast or diffusion indices between the two time points is shown for the 384 controls (blue) and 401 infected participants (orange), enabling a visual comparison between the two groups in a binary manner (therefore underestimating the effects estimated when modulating with age; see the ‘Main longitudinal model, deconfounding’ section in the Methods). The 15 hospitalised patients are indicated (red circles). ISOVF, isotropic volume fraction; OD, orientation dispersion. All y axes represent the percentage change.

Full size image

As secondary analyses, we found that significant longitudinal differences remained in the same set of significant brain regions that survived FDR or FWE correction when removing from the SARS-CoV-2 group those patients who had been hospitalised with COVID-19 (Model 2, 47 IDPs significant after FDR correction, 3 of which were also significant after FWE correction; Supplementary Table 1). Although fewer results were significant for the comparison between the 15 hospitalised patients and 384 control individuals (Model 3, 4 results were significant after FDR correction; Supplementary Table 1), probably due to the large reduction in sample size for this model, this additional group comparison showed effects in the same regions of the parahippocampal gyrus, orbital cortex and superior insula. Finally, we found no significant differences between the 15 hospitalised patients and 386 non-hospitalised SARS-COV-2 cases, probably due to the large reduction in sample size, but effect sizes and direction of these effects suggested stronger detrimental effects for the hospitalised cases in the orbitofrontal, insula, parahippocampal and frontal piriform cortex functionally connected brain regions (all |Z| ≥ 3, Model 4; Supplementary Table 1).

Across the three models comparing SARS-CoV-2 cases with controls (Models 1–3), the top 4 longitudinal differences were found in the functionally connected regions of the temporal piriform cortex (diffusion index: orientation dispersion) and of the olfactory tubercle (diffusion index: isotropic volume fraction), as well as in the parahippocampal gyrus (intensity contrast) and lateral orbitofrontal cortex (thickness) (largest combined |Z| across Models 1–3; Fig. 1). For these results across Models 1–3, the percentage of participants infected with SARS-CoV-2 who showed a greater longitudinal change than the median value in the control individuals was 56% for the regions connected to the temporal piriform cortex, 62% for the regions connected to the olfactory tubercle, 57% for the left parahippocampal gyrus and 60% for the left orbitofrontal cortex.

Although significant IDPs related to grey matter thickness were found, using our main case-versus-control analysis (Model 1), to be bilateral for both the anterior parahippocampal gyrus (perirhinal cortex) and entorhinal cortex, 10 out of the 11 remaining significant IDP were left-lateralised (Supplementary Table 1). Thus, we directly investigated left–right differences in the group with SARS-CoV-2 only for those significant IDPs, and found that the participants with an infection did not have a significantly greater reduction in grey matter thickness in the left hemisphere compared with in the right hemisphere (lowest Puncorr = 0.30).

Of the top 10 IDPs showing a longitudinal effect between first and second scans, none correlated significantly with the time interval between their infection and their second scan, in the participants who tested positive for SARS-CoV-2 for whom we had a date of diagnosis (n = 351; lowest Puncorr = 0.08).

Exploratory results

In total, 2,047 IDPs passed the initial tests of reproducibility (Extended Data Fig. 3) and data completeness. The main analysis (Model 1) revealed 65 significant longitudinal differences between the cases and controls that passed FDR correction, including 5 that were significant after FWE correction (Table 5; a complete list of reproducible IDPs and results is provided in Supplementary Table 1). Extended Data Figs. 4 and 5 show the QQ plot relating to the FDR thresholding, and a summary figure of Z-statistics results for all 2,047 IDPs grouped into different IDP classes.

Table 5 Top 10 of 65 significant results for the exploratory approach
Full size table

In particular, in this exploratory analysis covering the entire brain, 33 out of the 65 significant IDPs overlapped with the IDPs selected a priori for our hypothesis-driven approach of the involvement of the olfactory system. Moreover, we found significant longitudinal effects in global measures of volume, such as the cerebrospinal fluid (CSF) volume normalised for head size and the ratio of the volume of the segmented brain to the estimated total intracranial volume generated by FreeSurfer, as well as in the volume of the left crus II of the cerebellum, the thickness of the left rostral anterior cingulate cortex and diffusion index in the superior fronto-occipital fasciculus (Table 5 and Supplementary Table 1; examples are provided in Extended Data Fig. 6). For those significant IDPs, average differences in the percentage change between the two groups were moderate, ranging from around 0.2% to about 2% (except for two diffusion measures in the fimbria at >6%, due to the very small size of these regions of interest), with the largest differences observed in the volume of the parahippocampal gyrus and caudal anterior cingulate cortex (Supplementary Table 1). Scatter and box plots, as well as plots showing the percentage longitudinal changes with age are available for the top 10 longitudinal IDPs (Supplementary Information, Longitudinal Plots).

For the secondary analyses, when comparing the non-hospitalised cases with the controls (Model 2), the same general pattern emerged, albeit with a reduced number of significant results: one olfactory-related region, the functionally connected areas to the temporal piriform cortex, showed a significant longitudinal difference between the two groups in a diffusion index, as well as one global volume measure (CSF normalised), and a diffusion index in the superior fronto-occipital fasciculus (Model 2; 4 after FDR correction, 1 after FWE correction; Supplementary Table 1). Despite the considerably limited degrees of freedom in Models 3 and 4, many results remained significant after correction for multiple comparison, particularly for IDPs of cortical thickness, with an emphasis on the anterior cingulate cortex for Model 3 (66 results after FDR correction, 3 results after FWE correction), and a wide distribution across prefrontal, parietal and temporal lobes for Model 4 (29 FDR-corrected results; Fig. 2).

Fig. 2: Vertex-wise and voxel-wise longitudinal group differences in grey matter thickness and mean diffusivity changes.
figure 2



https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-022-04569-5/MediaObjects/41586_2022_4569_Fig2_HTML.png

Top, the main analysis (Model 1): the thresholded map (|Z| > 3) shows that the strongest, localised reductions in grey matter thickness in the 401 infected participants compared with the 384 controls are bilaterally in the parahippocampal gyrus, anterior cingulate cortex and temporal pole, as well as in the left orbitofrontal cortex, insula and supramarginal gyrus. Similarly, the strongest longitudinal differences in mean diffusivity (|Z| > 3, left is shown on the right) could be seen in the orbitofrontal cortex and anterior cingulate cortex, as well as in the left insula and amygdala (top). Bottom, secondary analysis (Model 4): the thresholded cortical thickness map (|Z| > 3) demonstrated longitudinal differences between the 15 hospitalised and 386 non-hospitalised SARS-CoV-2-positive cases in the orbitofrontal frontal cortex and parahippocampal gyrus bilaterally, right anterior cingulate cortex, as well as marked widespread differences in fronto-parietal and temporal areas, especially in the left hemisphere. We show the voxel-wise or vertex-wise longitudinal effects for illustrative purposes, avoiding any thresholding based on significance (as this would be statistically circular), similar to our previous analyses59.
Full size image

As many of the top exploratory and hypothesis-driven results included IDPs of cortical thickness and of mean diffusivity, we further conducted an exploratory visualisation of the vertex-wise thickness, and voxel-wise mean diffusivity longitudinal differences between the cases and controls over the entire cortical surface and brain volume, respectively (Fig. 2). Grey matter thickness showed bilateral longitudinal differences in the parahippocampal gyrus, anterior cingulate cortex and temporal pole, as well as in the left orbitofrontal cortex, insula and supramarginal gyrus.

When visually comparing hospitalised and non-hospitalised cases, these longitudinal differences showed a similar pattern, especially in the parahippocampal gyrus, orbitofrontal and anterior cingulate cortex, but also markedly extending, particularly in the left hemisphere, to many fronto-parietal and temporal regions. Mean diffusivity differences in longitudinal effects between cases and controls were seen mainly in the orbitofrontal cortex, anterior cingulate cortex, as well as in the left insula and amygdala.

Although the results seen in IDPs of grey matter thickness seemed to indicate that the left hemisphere is more strongly associated with SARS-CoV-2 infection, direct (left–right) comparisons of all lateralised IDPs of thickness across the entire cortex showed no overall statistical difference between the two groups (lowest PFWE = 0.43, with no significant results after FDR correction).
Cognitive results

Using the main model used to compare longitudinal imaging effects between SARS-CoV-2-positive participants and controls (Model 1), we explored differences between the two groups in ten scores from six cognitive tasks. These ten scores were selected using a data-driven approach based on out-of-sample participants who are the most likely to show cognitive impairment (Supplementary Analysis 2). After FDR correction, we found a significantly greater increase in the time taken to complete trails A (numeric) and B (alphanumeric) of the Trail Making Test in the group with SARS-CoV-2 infection (trail A: 7.8%, Puncorr = 0.0002, PFWE = 0.005; trail B: 12.2%, Puncorr = 0.00007, PFWE = 0.002; Fig. 3). These findings remained significant when excluding the 15 hospitalised cases (Model 2: trail A: 6.5%, Puncorr = 0.002, PFWE = 0.03; trail B: 12.5%, Puncorr = 0.00009, PFWE = 0.002).

Fig. 3: Significant longitudinal differences in cognition.
figure 3



https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41586-022-04569-5/MediaObjects/41586_2022_4569_Fig3_HTML.png

a, b, The percentage longitudinal change for SARS-CoV-2-positive cases and controls in the duration to complete trails A (a) and B (b) of the UK Biobank Trail Making Test. The absolute baseline (used to convert longitudinal change into percentage change) was estimated across the 785 participants. These curves were created using a ten-year sliding window across cases and controls (s.e. values are shown in grey).
Full size image

In the SARS-CoV-2 group only, post hoc associations between the most significant cognitive score showing longitudinal effect using Model 1 (duration to complete trail B, as reported above) and the top 10 results from each of the hypothesis-driven and exploratory approaches revealed a significant longitudinal association with the volume of the mainly cognitive lobule crus II of the cerebellum (r = −0.19, PFWE = 0.020).
Additional baseline investigations

When looking at binary baseline differences between controls and individuals who were later infected, none of the IDPs with significant longitudinal effects for either the hypothesis-driven or the exploratory approach demonstrated significant differences at baseline between the two groups (lowest PFWE = 0.59, none were significant after FDR correction; Supplementary Table 2). When applying age modulation in the two-group modelling of IDPs at baseline, a few of the IDPs demonstrated significant differences between the control and future SARS-CoV-2 groups, mainly for diffusion indices in the olfactory functional networks, as well as in the subcortical grey matter. As some IDPs cover spatially extended regions of the brain, we visually examined whether these baseline differences had any spatial overlap with our longitudinal results, but found none (Supplementary Fig. 2). The full list of binary and age-modulated results from group comparisons between the two groups at baseline is available in Supplementary Table 2 (and separately, at the second time point, in Supplementary Table 3). We also provide the scatter plots and box plots, as well as the percentage changes with age at baseline for the top 10 significant longitudinal IDPs from the hypothesis-driven and exploratory approaches (Supplementary Information, Baseline Plots).

Furthermore, none of the 10 preselected cognitive variables showed a significant difference at baseline between the group with SARS-CoV-2 and the control group (minimum Puncorr = 0.08). With age modulation, only one cognitive score—time to complete pairs matching round—showed a trend difference at baseline (Puncorr < 0.05, PFWE = 0.29, not significant after FDR correction). This is a different cognitive score from the one showing longitudinal cognitive effects between the two groups—the UK Biobank Trail Making Test.

We also repeated the main analysis modelling for those top 10 IDPs that were found to show longitudinal differences between the group with SARS-CoV-2 and the control group, across both hypothesis-driven and exploratory approaches. For each of the 6,301 non-imaging variables available (see the ‘Additional analyses—baseline group comparisons’ section in the Methods), we included that variable as an additional confounder in the longitudinal analyses. On the basis of the regression Z-statistic values, the strength of the original associations was not reduced by more than 25% for any of the non-imaging variables.

We further carried out the same analyses, but using dimension reduction (principal component analysis) applied to these 6,301 non-imaging phenotypes (d = 1 to d = 700), and also focussing only on cognition, with 540 cognitive variables (d = 10). We found no substantial reduction in our longitudinal results with any of these principal components. In particular, for cognition in which two components were significantly different at baseline (PC1 and PC4; Supplementary Analysis 1), the strongest reduction in Z was found for crus II of the cerebellum when adding PC1 to the model, with a decrease in Z of only 5.7% (from Z = 4 to Z = 3.77), whereas the Z values associated with all of the other IDPs were reduced by less than 5%. Adding PC4 to our main model reduced Z by 0.4% at most.
Longitudinal effects of pneumonia and influenza

To investigate whether pneumonia might have had an impact on our longitudinal findings, we assessed the age-modulated effects associated with pneumonia in an out-of-sample UK Biobank cohort that had been scanned twice. We identified 11 participants who contracted pneumonia not related to COVID-19 between the two scans, matched these to 261 controls and applied our main analysis (Model 1) to these two groups. This longitudinal investigation showed some significant group differences in IDPs, but with no overlap with those IDPs that we found for SARS-CoV-2 (all in the white matter; Supplementary Analysis 3). Overall, the correlation between the (unthresholded) Z-statistics of all of the IDPs from pneumonia and SARS-CoV-2 longitudinal group comparisons was very low (r = 0.057).

The sample size of cases who contracted influenza between the two scans in the out-of-sample UK Biobank cohort was unfortunately much smaller (n = 5, including n = 3 hospitalised cases), likely due to the low probability of influenza being recorded by a medical professional (GP or hospital). Nevertheless, for completeness, we also assessed longitudinally these two very small groups, compared with 127 matched controls. No result was significant for the 5 influenza cases, although a few IDPs showed significant longitudinal age-modulated effects, with just one IDP in the brainstem common to the SARS-CoV-2 findings (Supplementary Analysis 4). Correlation of Z-statistics between influenza and SARS-CoV-2 longitudinal group comparisons was again low (r = 0.077).
Discussion

This is to our knowledge the first longitudinal imaging study of SARS-CoV-2 in which the participants were initially scanned before any of them had been infected. Our longitudinal analyses revealed a significant, deleterious impact associated with SARS-CoV-2. This effect could be seen mainly in the limbic and olfactory cortical system, for example, with a change in diffusion measures—proxies for tissue damage—in regions that are functionally connected to the piriform cortex, olfactory tubercle and anterior olfactory nucleus, as well as a more pronounced reduction of grey matter thickness and contrast in the participants infected with SARS-CoV-2 in the left parahippocampal gyrus and lateral orbitofrontal cortex. Although the greater atrophy for the participants who tested positive for SARS-CoV-2 was localised to a few, mainly limbic, regions, the increase in CSF volume and decrease in whole-brain volume suggests an additional diffuse loss of grey matter superimposed onto the more regional effects observed in the olfactory-related areas. Note that these structural and microstructural longitudinal significant differences are modest in size—the strongest differences in changes observed between the SARS-CoV-2-positive and control groups, corresponding to around 2% of the mean baseline IDP value (Supplementary Table 1). This additional loss in the infected participants of 0.7% on average across the olfactory-related brain regions—and specifically ranging from 1.3% to 1.8% for the FreeSurfer volume of the parahippocampal/perirhinal and entorhinal cortex—can be helpfully compared with, for example, the longitudinal loss per year of around 0.2% (in middle age) to 0.3% (in older age) in hippocampal volume in community-dwelling individuals31. Our statistics also represent an average effect; not every infected participant will display longitudinal brain abnormalities. Comparing the few patients (n = 15) who had been hospitalised with COVID-19 against non-hospitalised cases showed a more widespread pattern of a greater reduction in grey matter thickness in the fronto-parietal and temporal regions (Fig. 2). Finally, significantly greater cognitive decline, which persisted even after excluding the hospitalised patients, was observed in the SARS-CoV-2-positive group between the two time points, and this decline was associated with greater atrophy of crus II—a cognitive lobule of the cerebellum.
Logged
Stoppt die deutschen Massenmörder!
Stoppt die österreichischen Massenmörder!
Stoppt die schweizer Massenmörder!

Revolution jetzt. Sonst ist es zu spät.

Pangwall

  • Jr. Member
  • *
  • Posts: 1675
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #5 on: March 07, 2023, 07:45:01 PM »

Much has been made of the benefit of using a longitudinal design to estimate, for example, trajectories of brain ageing and cognitive decline32,33. The longitudinal nature of the UK Biobank COVID-19 re-imaging study, with the baseline scan acquired before infection by SARS-CoV-2 and the second scan after infection, reveals differences over time above and beyond any potential baseline differences, thereby helping to disentangle the direct or indirect contribution of the pathogenic process from pre-existing differences in the brain, or risk factors, of future patients with COVID-19. An illustrative example of the benefit of a longitudinal design is that, if looking solely at cross-sectional group comparisons at the second time point after infection (that is, the analysis that would, by necessity, be carried out in post hoc studies), the strongest effect is observed in the volume of the thalamus. However, this effect disappears when taking into account the baseline scans, as the thalamus of the participants who were later infected appears to already differ from the control participants years before infection. This highlights the difficulties in interpreting cross-sectional post-infection imaging differences as being necessarily the consequence of the infection itself. When looking at brain imaging baseline differences between the two groups across all IDPs, particularly in an age-modulated manner, we did find a few further significant baseline differences beyond the volume of the thalamus (Supplementary Table 2). These were principally using diffusion imaging, but also using grey matter volume in the subcortical structures. Importantly, none of these baseline imaging differences spatially overlapped with the regions that were found to be different longitudinally (Supplementary Fig. 2). However, as this study is observational, as opposed to a randomised interventional study, one cannot make claims of disease causality with absolute certainty, but interpretational ambiguities are greatly reduced compared with post hoc cross-sectional studies. The question remains as to whether the two groups are actually perfectly matched, as controls and cases could not be randomised a priori. Across the main risk factors, as well as thousands of lifestyle, health data and environment variables available in UK Biobank, we did not identify any significant differences when looking at each variable in isolation (only a few variables showed some trends at Puncorr < 0.001; Supplementary Table 4). This does not preclude the possibility of a subthreshold pattern of baseline differences making one group more at risk of being infected by SARS-CoV-2, and this risk perhaps interacting with the effects of the coronavirus. This motivated the use of principal component analyses, which revealed two significant components suggesting subtle lower cognitive abilities in the participants who were infected later on (Supplementary Analysis 1). Importantly, neither of these two cognitive components had any bearing on our longitudinal imaging results (reducing at most the strength of Z-statistics from Z = 4 to Z = 3.77 for crus II of the cerebellum, when added in as an extra confound to the longitudinal analysis). Whether any of these imaging and cognitive differences at baseline had a subsequent role in those patients being more likely to be infected by the coronavirus, or to develop symptoms from infection, needs further investigation.

Our cohort-based, quantitative imaging study, in contrast to the majority of single-case and case-series studies published so far, does not focus on gross abnormalities that could be observed at the single-participant level with the naked eye, such as microhaemorrhages or (sub)acute ischaemic infarctions9. However, it does rely on an anatomically consistent pattern of abnormalities caused by the disease process, a common spatial distribution of these pathological alterations across the infected participants, which could be uncovered by aligning all of the images together in a common space, followed by applying a pipeline of modality-specific image-processing algorithms. This automated, objective and quantitative processing of the images facilitates the detection of subtle changes that would not be visible at the individual level, but which point to a possible mechanism for the neurological effects of the coronavirus infection. Our hypothesis-driven analyses revealed a clear involvement of the olfactory cortex, which was also found in the exploratory analyses and the vertex-wise and voxel-wise maps of cortical thickness and mean diffusivity. Although no differences were seen in the olfactory bulbs or piriform cortex per se (both of which are located in a region above the sinuses that is prone to susceptibility distortions in the brain images, and both are difficult to segment in MRI data), we identified significant longitudinal differences in a network of regions that is functionally connected to the piriform cortex, mainly consisting of the anterior cingulate cortex and orbitofrontal cortex, as well as the ventral striatum, amygdala, hippocampus and parahippocampal gyrus30. Some of the most consistent abnormalities across hypothesis-driven and exploratory analyses, and all of the group comparisons, were revealed in the left parahippocampal gyrus (Table 4, Fig. 2 and Supplementary Table 1)—a limbic region of the brain that has a crucial, integrative role for the relative temporal order of events in episodic memory34,35,36. Importantly, it is directly connected to the piriform cortex and entorhinal cortex, which are both part of the primary olfactory cortex24,37. Similarly, the orbitofrontal cortex, which we also found was altered in the SARS-CoV-2-positive group, is often referred to as the secondary olfactory cortex, as it possesses direct connections to both the entorhinal and piriform cortex37, as well as to the anterior olfactory nucleus23,30. In fact, in a recent functional connectivity study of the primary olfactory cortex, the orbitofrontal cortex was found to be connected to all four primary olfactory regions investigated (frontal and temporal piriform cortex, anterior olfactory nucleus and olfactory tubercle), possibly explaining why it is reliably activated even in basic and passive olfactory tasks30. Using the same olfactory connectivity maps, which overlap cortically in the orbitofrontal cortex, anterior cingulate cortex and insula, we found a more pronounced increase in diffusion metrics indicative of tissue damage in the SARS-CoV-2 group. The voxel-wise map of mean diffusivity revealed that these longitudinal differences were located in the orbitofrontal and anterior cingulate cortex, as well as in the insula and the amygdala. The insula is not only directly connected to the primary olfactory cortex23, but is also considered to be the primary gustatory cortex. 'Area G' (that is, the dorsal part of the insula at the junction with the frontal and parietal operculum), in turn, connects with the orbitofrontal cortex38. The vertex-wise and voxel-wise visualisation of both greater loss of grey matter and increase in mean diffusivity in the insula spatially correspond in particular to the area of consistent activation to all basic taste qualities39. Finally, the exploratory analysis revealed a more pronounced loss of grey matter in crus II, part of the cognitive and olfactory-related lobule VII of the cerebellum40. These results are consistent with previous post-infection PET findings showing, in more severe cases, FDG hypometabolism in the insula, orbitofrontal and anterior cingulate cortex, as well as lower grey matter volume in the insula and hippocampus41,42.

Early neurological signs in COVID-19 include hyposmia and hypogeusia, which appear to precede the onset of respiratory symptoms in the majority of affected patients2,20,43. Furthermore, a heavily debated hypothesis has been that an entry point of SARS-CoV-2 to the central nervous system is through the olfactory mucosa, or the olfactory bulb2,11,20 (the coronavirus itself would not necessarily need to enter the central nervous system; anterograde degeneration from olfactory neurons might suffice to generate the pattern of abnormalities revealed in our longitudinal analyses). The predominance observed in other studies of hyposmic and anosmic symptoms—whether caused directly by loss of olfactory neurons or by perturbation of supporting cells of the olfactory epithelium17,22—could also, through repeated sensory deprivation, lead to a loss of grey matter in these olfactory-related brain regions. A highly focal reduction in grey matter in the orbitofrontal cortex and insula has been observed, for example, in patients with severe olfactory dysfunction in a cross-sectional study of chronic rhinosinusitis29. A more extensive study of congenital and acquired (post-infectious, chronic inflammation due to rhinosinusitis or idiopathic) olfactory loss also demonstrated an association between grey matter volume and olfactory function in the orbitofrontal cortex19. It also showed that the duration of olfactory loss for those with acquired olfactory dysfunction, ranging from 0 to over 10 years, was related to a more pronounced loss of grey matter in the gyrus rectus and orbitofrontal cortex19. By contrast, it has been reported in a longitudinal study that patients with idiopathic olfactory loss had higher grey matter volume after undergoing olfactory training in various brain regions including the orbitofrontal cortex and gyrus rectus44. This raises the interesting possibility that the pattern of longitudinal abnormalities observed here in the limbic, olfactory brain regions of SARS-CoV-2-positive participants,if they are indeed related to olfactory dysfunction, might be attenuated over time if the infected participants go on to recover their sense of smell and taste. For example, there is some very preliminary evidence, in a few previously hospitalised patients with COVID-19, that brain hypometabolism becomes less pronounced when followed up 6 months later, even if it does not entirely resolve41,45. In our milder cohort, structural (as opposed to functional) changes might take longer and require larger numbers to be detected. When we tested whether the time between infection and the second brain scan had any relationship—positive, indicative of recovery, or negative, indicative of an ongoing degenerative process—with the grey matter loss or increase in diffusivity in the significant IDPs, we found no significant effect. This result is also possibly due to the relatively small range in the interval between infection and second brain scan at the time of this study—between 1 and 13 months for those 351 infected participants for whom we had a diagnosis date and, particularly, less than 20% of these participants had been infected more than 6 months prior to their second scan (Supplementary Fig. 3). Another source of variability is that each individual in our cohort was infected between the months of March 2020 and April 2021, periods that saw various dominant strains of SARS-CoV-2. Of those 351 participants for whom we have a proxy date of infection, but no formal way of assessing the strain responsible for the infection, a small minority of the participants were probably infected with the original strain, and a majority with the variants of concern present in the UK from October 2020 onwards (predominantly Alpha, but also Beta and Gamma), while presumably very few participants, if any, were infected with the Delta variant, which appeared in the UK in April 2021. As the second scans were acquired over a relatively short period in these positive participants (February–May 2021), SARS-CoV-2 strains and the time between infection and second scan are also highly collinear. Additional follow-up of this cohort, not only increasing the number of cases that became infected 6 months or longer before their second scan, but also including individuals infected by the Delta variant, would be particularly valuable in determining the longer-term effects of infection on these limbic structures, as well as possible differential effects between the various strains.

Various possible explanations for our longitudinal brain results are provided in the Supplementary Discussion.

Many of our results were found using imaging biomarkers of grey matter thickness or volume, which can be sensitive markers of a neurodegenerative process compared with other imaging modalities46, and are robust measurements that makes them ideal in a longitudinal setting47. In fact, the longitudinal differences between the SARS-CoV-2-positive and control groups, although significantly localised in a limbic olfactory and gustatory network, seemed also—at a lower level—to be generalised, as illustrated by the significant shift in the distribution of Z values over the entire cortical surface (Supplementary Fig. 4). This means that there is an overall stronger decrease in grey matter thickness across the entire cortex in the infected participants, but that this effect is particularly dominant in the olfactory system. A marked atrophy of fronto-parietal and temporal regions can also be seen when contrasting hospitalised and non-hospitalised cases, suggesting that there is increased damage in the less mild cases, with an additional significant shift in Z values (Supplementary Fig. 4). The pattern of loss of grey matter in the hospitalised patients compared with the milder cases is consistent with PET-FDG reports showing fronto-parietal and temporal decrease in glucose in hospitalised patients with COVID-1918,45.

The overlapping olfactory- and memory-related functions of the regions shown to alter significantly over time in SARS-CoV-2—including the parahippocampal gyrus/perirhinal cortex, entorhinal cortex and hippocampus in particular (Supplementary Table 1)—raise the possibility that longer-term consequences of SARS-CoV-2 infection might in time contribute to Alzheimer’s disease or other forms of dementia2. This has led to the creation of an international consortium including the Alzheimer’s Association and representatives from more than 30 countries to investigate these questions2. In our sample of participants who mainly had mild infection, we found no signs of memory impairment. However, these participants who tested positive for SARS-CoV-2 showed a worsening of executive function, taking a significantly greater time to complete trail A and particularly trail B of the Trail Making Test (Fig. 3). These findings remained significant after excluding the few hospitalised cases. Although the UK Biobank version of the Trail Taking Test is carried out online and unsupervised, there is good to very good agreement with the standard paper-and-pencil Trail Making Test on its measurements for completion of the two trails48, two measures that are known to be sensitive to detect impairment of executive function and attention, for example, in affective disorders and in schizophrenia49,50, and to discriminate mild cognitive impairment and dementia from healthy ageing51. In turn, the duration to complete the alphanumeric trail B was associated post hoc with the longitudinal changes in the cognitive part of the cerebellum, namely crus II, which is also specifically activated by olfactory tasks40,52. Consistent with this result, this particular part of the cerebellum has been recently shown to have a key role in the association with (and prediction of future) cognitive impairment in patients with stroke (subarachnoid haemorrhage)53. By contrast,the parahippocampal gyrus and other memory-related regions did not show in our study any alteration at a functional level, that is, any post hoc association with the selected cognitive tests. It remains to be determined whether the loss of grey matter and increased tissue damage seen in these specific limbic regions may in turn increase the risk for these participants of developing memory problems54, and perhaps dementia in the longer term2,4,55.

The limitations of this study include a lack of stratification of the severity of the cases, beyond the information of whether they had been hospitalised (information on O2 saturation levels and details of treatment or hospital procedures is currently available for only a few participants); a lack of clinical correlates as they are not currently available as part of the UK Biobank COVID-19-related links to health records (of particular relevance, potential hyposmic and hypogeusic symptoms and blood-based markers of inflammation); a lack of identification of the specific SARS-CoV-2 strain that infected each participant; a small number of participants from Asian, Black or other ethnic background other than white; and some of the cases' and controls' SARS-CoV-2 infection status was identified using antibody lateral flow test kits that have varied diagnostic accuracy56. However, note that any potential misclassification of controls as positive cases (due to false positives in testing) and positive cases as controls (due to the absence of confirmed negative status and/or false negative tests) could only bias our results towards the null hypothesis of no difference between cases and controls. For cases, no distinction is possible at present to determine whether a positive test is due to infection or vaccination, so potential cases identified only through lateral flow test in vaccinated participants were not included in this study. Information on the vaccination status, and how both vaccination dates might interact with the date of infection, is also currently unavailable. Although the two groups were not significantly different across major demographic and risk-factor variables, we identified a subtle pattern of lower cognitive abilities in the participants who went on to be infected, but this could not explain away our longitudinal findings. The individuals who were later infected also showed a lower subcortical volume, and higher diffusion abnormalities at baseline compared with the control individuals, in brain regions that did not overlap with our longitudinal results. One issue that is inherent to the recruitment strategy of UK Biobank, based on participants volunteering after being contacted at home for a possible re-imaging session, is the high number of mild cases. However, this can be seen as a strength of this study: the majority of the brain imaging publications to date have focussed on moderate to severe cases of COVID-199; there is therefore a fundamental need for more information on the cerebral effects of the disease in its milder form. The UK Biobank COVID-19 re-imaging study is ongoing, and further information will eventually be made available. For the statistical approach, we chose a model form given strong priors of highly increased detrimental effects of SARS-CoV-2 and greater vulnerability of the brain with age. Using this objective model and rigorous statistical inference, we found significant and interpretable results. We have not tested all possible models for all of the possible IDPs; instead, we focussed on one possible model drawn from independent, existing literature and found that it is useful, that is, statistically significant. The model may not be optimal for every feature considered; in other words, this model might not be the most sensitive possible model for every IDP. However, the main expected outcome of using a suboptimal model would be that we would fail to find significant results, and not that there would be any inflation of false-positive results. Finally, on the imaging side, our exploratory approach revealed significant longitudinal differences in the volume of the whole brainstem, but the UK Biobank scanning protocol and processing does not allow us to clarify which specific nuclei (for example, potentially those that are key autonomic and respiratory control centres) might be involved, with the exception of the substantia nigra.

This is to our knowledge the first longitudinal imaging study comparing brain scans acquired from individuals before and after SARS-CoV-2 infection with those scans from a well-matched control group. It also is one of the largest COVID-19 brain imaging studies, with 785 participants including 401 individuals infected by SARS-CoV-2. Its unique design makes it possible to more confidently tease apart the pathogenic contribution associated, directly or indirectly, with the infection from pre-existing risk factors. By using automated, objective and quantitative methods, we uncovered a consistent spatial pattern of longitudinal abnormalities in limbic brain regions forming a mainly olfactory network. Whether these abnormal changes are a hallmark of the spread of the pathogenic effects, or of the virus itself in the brain, and whether these abnormalities may indicate a future vulnerability of the limbic system in particular, including memory, for these participants remains to be investigated.
Methods
Ethics

Human participants: UK Biobank has approval from the North West Multi-Centre Research Ethics Committee (MREC) to obtain and disseminate data and samples from the participants (http://www.ukbiobank.ac.uk/ethics/), and these ethical regulations cover the work in this study. Written informed consent was obtained from all of the participants.
Study design

As part of the UK Biobank imaging study60, thousands of participants had received brain scans before the start of the COVID-19 pandemic. Multimodal brain imaging data, collected at four sites with identical imaging hardware, scanner software, and protocols, and passing quality controls, were obtained from 42,729 participants over the age of 45 years, and made available to researchers worldwide.

Before the COVID-19 pandemic, longitudinal (first- and second-time-point scanning) had already begun in the UK Biobank imaging study, with about 3,000 participants returning for a second scan before scanning was paused in 2020 as a result of the pandemic. More recently, starting in February 2021, hundreds of UK Biobank participants who had already taken part in UK Biobank imaging before the pandemic were invited back for a second scan (the response rate was 60% for the cases, and 55% for the controls). This COVID-19 re-imaging study was set up to investigate the effects of SARS-CoV-2 infection by comparing imaging scans taken from the participants before versus after infection.

The full list of inclusion criteria for the participants in this re-imaging study is as follows (further details are provided in the online documentation:
https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/casecontrol_covidimaging.pdf
):

    Had already attended an imaging assessment at one of the three imaging sites (the fourth opened just before the pandemic began).

    Still lived within the catchment area of the clinic they attended for their first imaging assessment.

    Had no incidental findings identified from their scans taken at the first imaging visit.

    Had not withdrawn or died.

    Had a valid email and postal address.

    Had high-quality scans from the first imaging visit.

    Lived within 60 km of the clinic (extended to 75 km in Feb 2021), due to travel restrictions during the lockdown period.

Among those, some participants were identified as having been infected with SARS-CoV-2 based on: (1) the results of diagnostic antigen tests identified through linkage to health-related records, (2) their primary care (GP) data or hospital records, or (3) the results of two antibody tests.

The diagnostic antigen tests results data for England, Scotland and Wales are made available on an ongoing basis by UK Biobank, and these data are provided by Public Health England (PHE), Public Health Scotland (PHS) and Secure Anonymised Information Linkage (SAIL, the databank from Wales), respectively. The data contain information on the date when the specimen was taken, origin (binary code for whether the patient was an inpatient when the specimen was taken) and result (binary code or positive and negative for SARS-CoV-2) of the tests along with encoded participant IDs. Further information on how regular updates of SARS-CoV-2 test results in England are made in UK Biobank is available online (
biobank.ctsu.ox.ac.uk/crystal/ukb/docs/c19link_phe_sgss.pdf
).

For the primary care (GP) data, UK Biobank used the following set of codes: (1) TPP: Y213a, Y228d, XaLTE (if the event date was after 1 January 2020), Y22b8, Y23f7, Y20d1, Y24ad, Y246f, Y269d, Y23f0, Y2a3b, Y2a15, Y212f, Y26a1, Y26b2, Y23e9, Y211c, Y23ec, Y2a3d; (2) EMIS: EMISNQCO303, 720293000, 720294006, 840535000, 840536004, 870361009, 870362002, 871552002, 871553007, 871555000, 871556004, 871557008, 871558003, 871559006, 871560001, 871562009, 1240581000000104, 1300721000000109, 1321541000000108, 1321551000000106, 1321661000000108, 1324881000000100. For the hospital records, the code used to identify positive SARS-CoV-2 cases was ICD10: U07.1. The dates of the records for both GP and hospital data were extracted along with the encoded participant IDs. In particular, the hospital records contain information on admission and discharge, including episode start and end dates, primary and secondary causes for admission, critical care if applicable and types of operations or procedures performed. We first identified hospitalised infected patients who had the ICD code U07.1 as a primary or secondary cause, and extracted information (such as admission/discharge date) relating to the episodes. OPCS-4 codes E85.1, E85.6, E85.2 and X52.9, as well as X52.8,E85.8, E85.9, E87.8 andE87.9, were used to find out whether the patients were provided respiratory support during the episodes. No other information, for example symptoms such as hyposmia or hypogeusia of particular relevance, was made available in these medical records.

Participants were also invited to take a home-based lateral flow test (Fortress Fast COVID-19 Home test, Fortress Diagnostics and ABC-19TM Rapid Test, Abingdon Health) to detect the presence of SARS-CoV-2 antibodies. A second kit was sent to all of the participants who recorded an initial positive result and who had indicated they had not yet been vaccinated, to reduce the number of false positives.

Participants were classified as SARS-CoV-2-positive cases if they had a positive test record in any of the three data sources described above. Date of diagnosis (Table 2) was determined on the basis of the information available in the public health-related records (1) and primary care and hospital records (2). For participants with multiple positive test records, we took the earliest date as the date of diagnosis.

Control participants were then selected by identifying, from the remaining previously imaged UK Biobank participants, those who had a negative antibody test result, as determined from the home-based lateral flow kits, and/or who had no record of confirmed or suspected COVID-19 from primary care, hospital records or diagnostic antigen test data. Control participants were selected to match 1:1 to positive SARS-CoV-2 cases according to five criteria: sex; ethnicity (white/non-white, as numbers were too low to allow for a finer distinction); date of birth (±6 months); location of first imaging assessment clinic; and date of first imaging assessment (±6 months).

Permission to use the UK Biobank Resource was obtained through Material Transfer Agreement (
http://www.ukbiobank.ac.uk/media/p3zffurf/biobank-mta.pdf
).
Image processing

For this work, we primarily used the IDPs generated by our team on behalf of UK Biobank, and made available to all researchers by UK Biobank60,61. The IDPs are summary measures, each describing a different aspect of brain structure or function, depending on what underlying imaging modality was used60,61.

The protocol includes three structural MRI scans (T1, T2 fluid attenuation inversion recovery (FLAIR) and susceptibility-weighted MRI), as well as diffusion MRI, and resting and task functional MRI. T1 scans make it possible to derive global measures of brain and CSF volumes, as well as localised measures of grey matter volume and cortical thickness. The T2 FLAIR scan identifies differences that might be indicative of inflammation or tissue damage. Susceptibility-weighted MRI is sensitive to iron and myelin content. Diffusion MRI measurements provide insights into the tissue microstructure integrity. Resting-state functional MRI is performed on an individual who is not engaged in any particular activity or task, and can provide indices related to the functional connectivity between brain regions62. Functional connectivity is intrinsically noisy when each region–pair connection is considered individually, so we focussed here our analysis on 6 dimensionally reduced functional connectivity networks59. We also did not consider a priori task-fMRI activation IDPs, as these have previously been found to have very low reproducibility and heritability63.

We used 1,524 existing UK Biobank IDPs, including: regional grey matter, brain and CSF volume, local cortical surface area, volume and thickness, cortical grey–white contrast, white matter hyperintensity volume, white matter microstructural measures such as fractional anisotropy and mean diffusivity, resting-state amplitude and dimensionally reduced connectivity measures. Furthermore, we also generated 1,106 new IDPs, as described below.

We computed additional IDPs obtained using quantitative susceptibility mapping (QSM), which has recently been added into our UK Biobank processing pipeline64. Magnitude and phase data from the susceptibility-weighted MRI acquisitions were processed to provide quantitative measures reflecting clinically relevant tissue susceptibility properties. Median T2* was calculated within 17 subcortical structures (with their regions of interest (ROIs) estimated from the T1) as IDPs; 14 of these are the same subcortical regions that were already estimated by the core UK Biobank pipeline, and here we added 3 more subcortical ROIs: left and right substantia nigra65 and regions of white matter hyperintensities (lesions)66. Second, susceptibility-weighted MRI phase data were processed for QSM following a pipeline that was recently developed for UK Biobank27,67. QSM (CSF-referenced) IDPs were calculated in the same 17 subcortical structures as the T2* IDPs.

Additional IDPs were created using subsegmentations of the hippocampus, amygdala and thalamus as implemented in FreeSurfer68,69,70,71. We extracted these ROI masks from the FreeSurfer processing and applied them to the T2* and diffusion images (diffusion tensor model: MD and FA; NODDI model: OD, ISOVF, ICVF) to generate additional subcortical IDPs.

Finally, we generated new IDPs tailored to the olfactory and gustatory systems, as described below.
Hypothesis-driven approach

On the basis of prior expectations from animal models and post mortem findings, we chose to focus a priori our primary analyses on a subset of 332 ROIs (297 of which passed the reproducibility thresholding; see the ‘Reproducibility’ section below) from the available 2,630 IDPs23,24,38; these correspond anatomically to the telencephalic primary and secondary connections of the olfactory and gustatory cortex. In brief, these include the piriform cortex, parahippocampal gyrus, entorhinal cortex, amygdala, insula, frontal/parietal operculum, medial and lateral orbitofrontal cortex, hippocampus and basal ganglia. As no labelling of the piriform cortex exists in any of the atlases used in the UK Biobank imaging processing, we refined a previously published ROI of the piriform cortex (frontal and temporal), anterior olfactory nucleus and olfactory tubercle, by limiting it to the cortical ribbon of our UK Biobank T1-weighted standard space (https://github.com/zelanolab/primaryolfactorycortexparcellation30). We further used maps from the same study’s resting-state fMRI analysis of the functional connectivity of each of the four parts of this ROI (piriform frontal, piriform temporal, anterior olfactory nucleus and olfactory tubercle) to the rest of the brain to generate four additional extended ROIs of the functionally connected cortical and subcortical regions to these primary olfactory areas30. For this, we thresholded their connectivity t-value maps to retain only significant voxels (PFWE < 0.05, with threshold-free cluster enhancement), and used the maps as weighted (and, separately, binarised) masks, to further extract grey matter volume, T2* and diffusion values; this was done by (1) regressing each of these maps into the GM, T2* or diffusion images in their respective native spaces and, separately, (2) by binarising the maps and extracting mean and 95th percentile values.

Moreover, masks for the left and right olfactory bulbs were generated by manually drawing a binary mask for the right olfactory bulb on an averaged template-space T2 FLAIR volume generated from 713 UK Biobank participants, and mirroring this to obtain the mask for the left (having confirmed by visual inspection that the symmetry in this region allowed for this to be effective). Both masks were then modulated by the T2 intensities in their respective ROIs to account for partial volume effects, generating the final label maps with values ranging between 0 and 1. For the hypothalamus, we combined and refined ROIs from two previously published and publicly available atlases of a probabilistic hypothalamus map (https://neurovault.org/collections/3145/65) and hypothalamic subregions72. Both the probabilistic hypothalamus map and the binarised map obtained from fusing the 26 hypothalamic subregions were transformed to our standard space in which the probabilistic map was then masked by the binarised map. We then extracted volume, and T2 mean and 95th percentile intensity measurements in the participants’ native spaces, using the olfactory bulb and hypothalamus maps (unthresholded and thresholded at 0.3 to reduce concerns about arbitrariness of threshold selection when rebinarising these very thin ROI masks after interpolation, a step which is unavoidable when transforming masks from one space to another). For the hypothalamus, we also extracted these metrics from T2* and diffusion images. All of the above preprocessing steps were defined and completed before any analyses of longitudinal change and case–control modelling.

The full list of 297 predetermined and reproducible IDPs is provided in Supplementary Table 1.
Exploratory approach

The full set of 2,630 IDPs described above was used for a more exploratory, inclusive analysis of SARS-CoV-2 infection effects on brain structure and function (the full list of reproducible IDPs is provided in Supplementary Table 1).
Statistical modelling

The following modelling was applied in the same manner to both the hypothesis-driven analyses of a subset of IDPs, and the all-IDP exploratory analyses.
Outlier identification of the IDPs

All of the IDPs from all of the participants were pooled for initial processing (at this stage blinded to the SARS-CoV-2 status of the participants): 42,729 scan 1 datasets (all pre-pandemic); 2,943 pre-pandemic scan 2 datasets; and 890 scan 2 datasets acquired after the beginning of the COVID-19 pandemic. Outlier values (individual IDPs from individual scanning sessions) were removed on the basis of being more extreme than eight times the median absolute deviation from the median for a given IDP. Missing data for individual participants and specific IDPs can therefore occur because of this step, or because the IDP was missing in the original data (for example, because a given modality was not usable from a given participant). The fraction of total non-missing data, averaged across IDPs, is 0.93; all full results tables include the number of usable measurements for each IDP and for each statistical test. Importantly, there was no imbalance in amount of missing/outlier data between cases and controls: the number of cases with usable data, normalised by the total number of participants with usable data, has the following percentiles across IDPs: percentiles [0, 1, 50, 99, 100] = 0.50, 0.50, 0.52, 0.52, 0.60, that is, the median percentile is 0.52. From this analysis, the only three IDPs for which this fraction was greater than 0.53 were thalamic nuclei diffusion IDPs, which do not appear in any of our main results. These are also the only three IDPs with more than 24% missing/outlier data.

The IDPs from the 890 participants imaged during the pandemic (SARS-CoV-2-positive cases and controls), from both time points, were then retained. Participants were retained if at least the T1-weighted structural image was usable from both time points, resulting in IDPs at both time points (IDP1 and IDP2) from 785 participants. The data were then pooled into a single dataset comprising 785 × 2 = 1,570 imaging sessions, and cross-sectional deconfounding, treating all scans equivalently, was performed for head size, age, scanner table position and image motion in the diffusion MRI data. This deconfounding is part of the data preprocessing, and is done at the level of individual scan sessions; thus, this needs to be carried out before combining all scans and participants together in the main modelling. These imaging confound variables first had outlier removal applied as described above, although using a higher threshold of 15 times the median absolute deviation, because some important confounds have extremely non-Gaussian underlying distributions (such as MRI scanner table position), and we found that a threshold of 8 was too aggressive for these variables for values that are perfectly acceptable when considered with the domain knowledge of these variables61,73.
Reproducibility of the IDPs

We next evaluated the scan–rescan reproducibility of IDPs to discard IDPs that were not reasonably reproducible between scans. For each IDP, we correlated the IDP1 with IDP2 values, separately for cases and controls, resulting in two reproducibility measures (Pearson correlation r) for each IDP. The vectors of r values (one value per IDP) derived from cases and from controls were extremely highly correlated (r = 0.98), showing that potential effects associated with infection are subtle compared with between-subject variability and IDP noise; we therefore averaged these cases and controls’ r values to give a single reproducibility measure for each IDP. From the initial set of 2,630 IDPs, the least reproducible IDPs (r < 0.5) were discarded, leaving 2,048 IDPs. Finally, IDPs with high levels of missing data (usable values from fewer than 50 participants) were discarded, leaving in total 2,047 IDPs.
Main longitudinal model, deconfounding

Despite initial case–control participant pairing (resulting in case and control groups being well matched), missing/outlier data potentially disrupted this exact paired matching, and we therefore also included in the modelling confound variables derived from those factors that were originally used as pairing criteria: the difference between the participants’ ages at each of their two scans, the difference in the squares of the ages (to account for quadratic dependencies of IDPs on age), genetic sex and ethnicity (white versus non-white).

Longitudinal IDP change (ΔIDP) was estimated by regressing IDP2 on IDP1 (ref. 74), as well as including in the regression the confound variables listed above.

The case-versus-control difference in this longitudinal IDP effect was modelled with a group difference regressor comprising the case-versus-control binary variable modulated by a function of age at scan 2 (Age2, a close proxy for age at infection for the SARS-CoV-2 group, with an error of less than a year). We chose to focus on an objective age model given the strong prior knowledge of a highly increased detrimental effect, at older ages, of SARS-CoV-2 infection and a greater vulnerability of the brain with age. The age dependence has been found to be exponential in studies of the effects of COVID-19 on hospitalisation and fatality rate75,76. Here we used the exact age dependence found by a data-driven meta-regression of 28 studies, with no free or subjectively chosen parameters, to modulate the binary case-versus-control variable, based on age at scan 2 (ref. 76).

The main case-versus-control group difference regressor of interest is therefore:
$${\rm{Case-versus-Control}}={\rm{demeaned}}({\rm{Case-versus-Control\; binary\; variable}})\times {10}^{{\rm{Age}}2\times 0.0524-3.27},$$
(1)

where the age-dependence constants are taken from the meta-regression analysis76 (Supplementary Analysis 5). To ensure that the fitting of this term is not influenced by an effect that is common to controls and cases, we added a matching confound variable of 10Age2 × 0.0524 − 3.27, that is, the same ageing term without the group-difference multiplier.

Our main model of interest therefore simply combines IDP1 and IDP2, the above group-difference model and the confounds matrix:
$${\rm{IDP}}2 \sim {\rm{Case-versus-Control}}+{\rm{IDP}}1+{\rm{Confounds}},$$
(2)

where the confound matrix comprises the terms described above: Age2 − Age1, Age22 − Age12, ethnicity, sex and 10Age2 × 0.0524 − 3.27.

By using a simple, single case-versus-control regressor for the main effect of interest, we optimised power for finding effects that follow this form, at the risk of suboptimal power (sensitivity to finding true effects) if the effect does not follow this form.

Many forms for the case-versus-control model might be used. Possible models include: a binary regressor; single-regressors with age-modulated differences (such as the one primarily used here); more flexible models with multiple-regressors. Without testing a huge number of possible different models, one cannot make claims of absolute optimality. Nevertheless, our primary aim is not to prove model optimality, but to identify the effects of disease. To that aim, we have found statistically significant results with the simple model used here. Importantly, the exact choice of exponential model also had little bearing on our findings. Even opting for a binary case-versus-control regressor—that is, without any age modulation—yielded similar, albeit a little weaker, primary results, consistent with our expectation of increased effects at higher ages (further details and discussion of non-modulated modelling results are provided in Supplementary Table 5 and Supplementary Analysis 5). Supplementary Analysis 6 provides further model-fitting validity and robustness evaluations, including diagnostic residual scatter-plots and residual QQ plots, showing no obvious evidence of structured problems in model residuals or of model misspecifications.

The group-difference regressor is scaled to have average peak–peak height 1, such that the regression parameter from fitting case-versus-control can easily be converted into a percentage change measure, when normalised by the mean baseline value for a given IDP. For the main longitudinal modelling, this represents the average group difference in the longitudinal IDP change and, for the separate modelling of baseline IDPs only, this percentage reflects the average group difference in the baseline values. In addition to reporting percentage effects and associated s.e. values, we also report the statistical significance as Z-statistics (Gaussianised regression model t-statistics) and P values. Here, Z is more useful than t, because different IDPs have different patterns of missing data and, therefore, Z is more usefully comparable across IDPs. The regression inference automatically takes care of the degrees-of-freedom, including accounting for missing data and confound variables. For each IDP, any missing data are ignored (that participant is left out for that analysis). As part of the estimation of the longitudinal IDP changes, ΔIDP outliers (for each IDP, and each participant) were removed (set as missing), if they were more than 8 times the median absolute deviation from the median.
Correction for multiple comparisons

We used permutation testing to estimate PFWE values, that is, correcting for the multiple comparisons across IDPs while accounting for the dependences among IDPs. We randomly permuted the residualised case-versus-control regressor relative to the residualised IDP2s, with 10,000 random permutations. At each permutation, we computed the association Z value for each IDP, and recorded the maximum absolute value across all IDPs. By taking the absolute value, we corrected for the two-tailed nature of the test, that is, we did not pre-assume the direction of any effect. After building up the null distribution of the maximum |Z| across IDPs, we then tested the original |Z| values against this distribution to obtain PFWE values, fully correcting for multiple comparisons across all IDPs. We also computed for each test the FDR at 5%, generating a threshold that can be applied to uncorrected P values to determine their FDR significance.

We therefore computed both FDR- and FWE-corrected inferences as two distinct measures of strength of evidence for a given effect. In this study, we primarily rely on FDR correction, which provides good power while controlling for multiple testing in a principled manner, but we wish to also indicate when a result additionally attains FWE significance. We therefore always specify the findings obtained using both correction methods in the main text and Supplementary Tables 1, 2, 3 and 5.
Group comparisons

In the rest of the manuscript, we refer to the main age-modulated group comparison analysis (comparing IDPs at second time point controlling for IDPs at baseline) between SARS-CoV-2-positive cases and control individuals, as described above, as Model 1.

As secondary follow-up analyses, we also applied the same hypothesis-driven and exploratory approaches as described above to compare non-hospitalised SARS-CoV-2-positive cases against controls (Model 2), and hospitalised patients against controls (Model 3). Separately, we also carried out the same analysis between hospitalised and non-hospitalised cases, adding as covariates three risk factors showing significant differences between these two SARS-CoV-2 groups (Model 4). For these secondary models (2–4), we again used age-modulated group-difference regressors as described above for Model 1. The power to detect effects in the two latter models, considering the hospitalised patients as a separate group, is of course considerably reduced given the small number of hospitalised cases in this cohort.

For all 4 models, testing was carried out twice: first using the a priori focussed subset of IDPs identified for the hypothesis-driven analyses, and then using the full set of IDPs for the exploratory analyses. In both cases, IDPs were identified as having significant group differences, corrected for multiple comparisons.

Thus, we carried out eight imaging group comparison longitudinal analyses:

    The primary analysis comparing all cases versus all controls (Model 1), first in the set of olfactory-related IDPs a priori drawn, then in the exploratory set of IDPs.

    Secondary ancillary analyses, using both hypothesis-driven and exploratory sets of IDPs:

    All non-hospitalised cases versus all controls (Model 2).

    All hospitalised cases versus all controls (Model 3).

    All hospitalised cases versus all non-hospitalised cases (Model 4).

Cognitive analysis

Although cognitive testing offers limited measurements of cognitive function in UK Biobank, we included in our ancillary cognitive analysis 10 variables sensitive to cognitive impairment. For this, we drew these variables using a data-driven approach based on identifying out-of-sample current and future dementia cases in UK Biobank, and comparing them to matched control individuals (Supplementary Analysis 2). The top most significant variables from this out-of-sample analysis were:

    Three variables from the UK Biobank Trail Making Test: both durations to complete trails A and B, as well as the total number of errors made traversing trail B.

    One variable from the Symbol Digit Test: the number of symbol digit matches made correctly.

    One measure of reaction time: mean time to correctly identify matches at the card game ‘Snap’.

    One measure of reasoning: the ‘fluid intelligence’ score.

    One measure of numeric memory: the maximum number of digits remembered correctly.

    Three variables of the pairs matching test: numbers of correct and incorrect matches, and the time to complete the test.

On the basis of these 10 variables from 6 different cognitive tests, we carried out two analyses: (1) the same group comparison between SARS-CoV-2 cases and controls of the longitudinal effect as described above, but substituting ΔCOG for ΔIDP, (2) a post hoc regression analysis, in the SARS-CoV-2 group only, of the ΔCOG showing the most significant difference between cases and controls against the top 10 most significant ΔIDPs for the hypothesis-driven approach and the top 10 for the exploratory approach. All of the results were evaluated for FWE and FDR significance, correcting for multiple comparisons across all cognitive or IDP variables where applicable.
Additional analyses
Baseline group comparisons
Risk factors

We compared the group positive for SARS-CoV-2 and the control group at baseline across common risk factors for infection and severity of disease: age, sex, blood pressure (systolic and diastolic), weight (including BMI and waist–hip ratio), diabetes, smoking, alcohol consumption and socioeconomic status (using the Townsend deprivation index). For this, we used the 'last observation carried forward' (LOCF) imputation method, for which we considered all the values available closest to the scan 1 visit (for the majority of the values, these were available from the same visit, on the same day that scan 1 was acquired); we also tested that there was no difference between the group with SARS-CoV-2 and the control group in the distribution of the visits used to collect the LOCF values.
All other non-imaging phenotypes

We also examined whether the group with SARS-CoV-2 and the control group differed at baseline across all non-imaging phenotypes (lifestyle, environmental, health-related, dietary), across all UK Biobank visits. We assessed the 6,301 pre-scan 2 non-imaging phenotypes with at least 3% of values distinct from the majority value, and the results were corrected for multiple comparisons using FDR and FWE (that is, where relevant, we refer to both in the main text).
IDPs

To complement our longitudinal analyses, we performed a baseline-only (and, separately, second time point only) cross-sectional group comparison between SARS-CoV-2 cases and controls, across all 2,047 IDPs, correcting for multiple comparisons across all IDPs using the same permutation-testing procedure as described above.

In particular, this approach is of interest to test whether brain regions showing significant longitudinal changes demonstrate initial differences between the two groups that exist before the infection.
Cognition

We finally assessed whether the two groups differed at baseline in their cognition, based on the results from the ten variables from six different cognitive tests preselected above, correcting for multiple comparisons across cognitive variables.
Lateralised effects

As a post hoc analysis, we examined whether the longitudinal effects observed in grey matter thickness were lateralised, by subtracting the right ΔIDP from the corresponding left ΔIDP, for (1) all ΔIDPs of grey matter thickness showing significance in the main case-control analyses (across the hypothesis-driven and exploratory approaches), within the group with SARS-CoV-2 only (to avoid circularity); (2) all ΔIDPs of grey matter thickness across the entire cortex (151 pairs of left–right matched IDPs), and testing for associations between the left–right difference and the case-versus-control age modulated regressor. Results were corrected for multiple comparisons using FDR and FWE.
Effect of time of SARS-CoV-2 infection

For 351 SARS-CoV-2-positive participants who had an available date of infection (thus, in effect, excluding those identified through antibody lateral flow tests), we further looked post hoc at the possible effect of time interval between infection and second brain scan (acquired post-infection) on the significant IDPs from our hypothesis-driven approach to evaluate whether a longer interval might mean either a reduced loss of grey matter through, for  example, potential progressive recovery of sensory inputs (olfaction), or a greater loss as a function of a longer, ongoing degenerative process.
The effect of non-imaging factors

We ran an additional analysis to test whether any non-imaging variables measured before SARS-CoV-2 infection might explain post hoc the longitudinal effects observed in our significant IDPs. We considered non-imaging variables with at least 50% non-missing data in the participants (n = 6,301). We included individually each of these variables as an additional confounder for a repeat of the original Model 1 regression tests for those IDPs that were found to show significant longitudinal differences between the two groups, for both hypothesis-driven and exploratory approaches. If the strength of the original association was reduced by more than 25%, based on the regression Z-statistics, we considered a non-imaging variable to potentially explain the IDP–infection association. Further details are provided in Supplementary Analysis 7.
Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability

All source data are available on application for data access from UK Biobank.
Code availability

Analysis code used in this study is available online (https://www.fmrib.ox.ac.uk/ukbiobank/covid/ and https://doi.org/10.5281/zenodo.5903258).
References

    Paterson, R. W. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 143, 3104–3120 (2020).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    de Erausquin, G. A. et al. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 17, 1056–1065 (2021).

    Article
     
    PubMed
     
    CAS
     
    Google Scholar
     

    Yang, A. C. et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature 595, 565–571 (2021).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Deleidi, M. & Isacson, O. Viral and inflammatory triggers of neurodegenerative diseases. Sci. Transl. Med. 4, 121ps123 (2012).

    Article
     
    CAS
     
    Google Scholar
     

    Butowt, R., Meunier, N., Bryche, B. & von Bartheld, C. S. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathol. 141, 809–822 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Taquet, M., Geddes, J. R., Husain, M., Luciano, S. & Harrison, P. J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8, 416–427 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Taquet, M., Luciano, S., Geddes, J. R. & Harrison, P. J. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 8, 130–140 (2021).

    Article
     
    PubMed
     
    Google Scholar
     

    Helms, J. et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 382, 2268–2270 (2020).

    Article
     
    PubMed
     
    Google Scholar
     

    Manca, R., De Marco, M., Ince, P. G. & Venneri, A. Heterogeneity in regional damage detected by neuroimaging and neuropathological studies in older adults with COVID-19: a cognitive-neuroscience systematic review to inform the long-term impact of the virus on neurocognitive trajectories. Front. Aging Neurosci. 13, 646908 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Mukerji, S. S. & Solomon, I. H. What can we learn from brain autopsies in COVID-19? Neurosci. Lett. 742, 135528 (2021).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 24, 168–175 (2021).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).

    Article
     
    PubMed
     
    Google Scholar
     

    Matschke, J. et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 19, 919–929 (2020).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Chertow, D. et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-1139035/v1 (2021).

    Philippens, I. H. C. H. M. et al. SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques. Preprint at bioRxiv https://doi.org/10.1101/2021.02.23.432474 (2021).

    Lechien, J. R. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Otorhinolaryngol. 277, 2251–2261 (2020).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Cooper, K. W. et al. COVID-19 and the chemical senses: supporting players take center stage. Neuron 107, 219–233 (2020).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Hosp, J. A. et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain 144, 1263–1276 (2021).

    Article
     
    PubMed
     
    Google Scholar
     

    Postma, E. M., Smeets, P. A. M., Boek, W. M. & Boesveldt, S. Investigating morphological changes in the brain in relation to etiology and duration of olfactory dysfunction with voxel-based morphometry. Sci. Rep. 11, 12704 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Butowt, R. & Bilinska, K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem. Neurosci. 11, 1200–1203 (2020).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Netland, J., Meyerholz, D. K., Moore, S., Cassell, M. & Perlman, S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 82, 7264–7275 (2008).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Brann, D. H. et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 6, eabc5801 (2020).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Carmichael, S. T., Clugnet, M. C. & Price, J. L. Central olfactory connections in the macaque monkey. J. Comp. Neurol. 346, 403–434 (1994).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Palouzier-Paulignan, B. et al. Olfaction under metabolic influences. Chem. Senses 37, 769–797 (2012).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Guedj, E. et al. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur. J. Nucl. Med. Mol. Imaging 48, 592–595 (2021).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Raman, B. et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 31, 100683 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Griffanti, L. et al. Adapting the UK Biobank brain imaging protocol and analysis pipeline for the C-MORE multi-organ study of COVID-19 survivors. Front. Neurol. 12, 753284 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Reichert, J. L. & Schopf, V. Olfactory loss and regain: lessons for neuroplasticity. Neuroscientist 24, 22–35 (2018).

    Article
     
    PubMed
     
    Google Scholar
     

    Han, P. et al. Olfactory brain gray matter volume reduction in patients with chronic rhinosinusitis. Int. Forum Allergy Rhinol. 7, 551–556 (2017).

    Article
     
    PubMed
     
    Google Scholar
     

    Zhou, G., Lane, G., Cooper, S. L., Kahnt, T. & Zelano, C. Characterizing functional pathways of the human olfactory system. eLife 8, e47177 (2019).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Fraser, M. A. et al. Longitudinal trajectories of hippocampal volume in middle to older age community dwelling individuals. Neurobiol. Aging 97, 97–105 (2021).

    Article
     
    PubMed
     
    Google Scholar
     

    Ronnlund, M., Nyberg, L., Backman, L. & Nilsson, L. G. Stability, growth, and decline in adult life span development of declarative memory: cross-sectional and longitudinal data from a population-based study. Psychol. Aging 20, 3–18 (2005).

    Article
     
    PubMed
     
    Google Scholar
     

    Vidal-Pineiro, D. et al. Individual variations in ‘brain age’ relate to early-life factors more than to longitudinal brain change. eLife 10, e69995 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Diana, R. A., Yonelinas, A. P. & Ranganath, C. Imaging recollection and familiarity in the medial temporal lobe: a three-component model. Trends Cogn. Sci. 11, 379–386 (2007).

    Article
     
    PubMed
     
    Google Scholar
     

    Staresina, B. P., Duncan, K. D. & Davachi, L. Perirhinal and parahippocampal cortices differentially contribute to later recollection of object- and scene-related event details. J. Neurosci. 31, 8739–8747 (2011).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Naya, Y. & Suzuki, W. A. Integrating what and when across the primate medial temporal lobe. Science 333, 773–776 (2011).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Doty, R. L. Olfaction: smell of change in the air. Cerebrum 2017, cer-10-17 (2017).

    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Avery, J. A. et al. Taste quality representation in the human brain. J. Neurosci. 40, 1042–1052 (2020).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Chikazoe, J., Lee, D. H., Kriegeskorte, N. & Anderson, A. K. Distinct representations of basic taste qualities in human gustatory cortex. Nat. Commun. 10, 1048 (2019).

    Article
     
    ADS
     
    PubMed
     
    PubMed Central
     
    CAS
     
    Google Scholar
     

    Ferdon, S. & Murphy, C. The cerebellum and olfaction in the aging brain: a functional magnetic resonance imaging study. Neuroimage 20, 12–21 (2003).

    Article
     
    PubMed
     
    Google Scholar
     

    Kas, A. et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur. J. Nucl. Med. Mol. Imaging 48, 2543–2557 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Qin, Y. et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J. Clin. Invest. 131, e147329 (2021).

    Article
     
    PubMed Central
     
    Google Scholar
     

    Tsai, S. T., Lu, M. K., San, S. & Tsai, C. H. The neurologic manifestations of coronavirus disease 2019 pandemic: a systemic review. Front. Neurol. 11, 498 (2020).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Han, P., Musch, M., Abolmaali, N. & Hummel, T. Improved odor identification ability and increased regional gray matter volume after olfactory training in patients with idiopathic olfactory loss. iPerception 12, 20416695211005811 (2021).

    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Blazhenets, G. et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J. Nucl. Med. 62, 910–915 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Douaud, G. et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer’s disease. Neuroimage 55, 880–890 (2011).

    Article
     
    PubMed
     
    Google Scholar
     

    Douaud, G. et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl Acad. Sci. USA 110, 9523–9528 (2013).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Fawns-Ritchie, C. & Deary, I. J. Reliability and validity of the UK Biobank cognitive tests. PLoS ONE 15, e0231627 (2020).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Mahlberg, R., Adli, M., Bschor, T. & Kienast, T. Age effects on trail making test during acute depressive and manic episode. Int. J. Neurosci. 118, 1347–1356 (2008).

    Article
     
    PubMed
     
    Google Scholar
     

    Mahurin, R. K. et al. Trail making test errors and executive function in schizophrenia and depression. Clin. Neuropsychol. 20, 271–288 (2006).

    Article
     
    PubMed
     
    Google Scholar
     

    Ashendorf, L. et al. Trail making test errors in normal aging, mild cognitive impairment, and dementia. Arch. Clin. Neuropsychol. 23, 129–137 (2008).

    PubMed
     
    Google Scholar
     

    Sobel, N. et al. Odorant-induced and sniff-induced activation in the cerebellum of the human. J. Neurosci. 18, 8990–9001 (1998).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Rowland, M. J. et al. Early brain injury and cognitive impairment after aneurysmal subarachnoid haemorrhage. Sci. Rep. 11, 23245 (2021).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Zhao, S. et al. Rapid vigilance and episodic memory decrements in COVID-19 survivors. Brain Commun. 4, fcab295 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    CAS
     
    Google Scholar
     

    Heneka, M. T., Kummer, M. P. & Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463–477 (2014).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Deeks, J. J. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst. Rev. 6, CD013652 (2020).

    PubMed
     
    Google Scholar
     

    Salat, D. H. et al. Thinning of the cerebral cortex in aging. Cereb. Cortex 14, 721–730 (2004).

    Article
     
    PubMed
     
    Google Scholar
     

    Zhao, L. et al. Age-related differences in brain morphology and the modifiers in middle-aged and older adults. Cereb. Cortex 29, 4169–4193 (2019).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Elliott, L. T. et al. Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature 562, 210–216 (2018).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Miller, K. L. et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat. Neurosci. 19, 1523–1536 (2016).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Alfaro-Almagro, F. et al. Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage 166, 400–424 (2018).

    Article
     
    PubMed
     
    Google Scholar
     

    Littlejohns, T. J. et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nat. Commun. 11, 2624 (2020).

    Article
     
    ADS
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Smith, S. M. et al. An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank. Nat. Neurosci. 24, 737–745 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Wang, C. et al. Phenotypic and genetic associations of quantitative magnetic susceptibility in UK Biobank brain imaging. Preprint at bioRxiv https://doi.org/10.1101/2021.06.28.450248 (2021).

    Pauli, W. M., Nili, A. N. & Tyszka, J. M. A high-resolution probabilistic in vivo atlas of human subcortical brain nuclei. Sci. Data 5, 180063 (2018).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Griffanti, L. et al. BIANCA (Brain Intensity AbNormality Classification Algorithm): a new tool for automated segmentation of white matter hyperintensities. Neuroimage 141, 191–205 (2016).

    Article
     
    PubMed
     
    Google Scholar
     

    Wang, C. et al. Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. Neuroimage 222, 117216 (2020).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Iglesias, J. E. et al. A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. Neuroimage 183, 314–326 (2018).

    Article
     
    PubMed
     
    Google Scholar
     

    Iglesias, J. E. et al. Bayesian longitudinal segmentation of hippocampal substructures in brain MRI using subject-specific atlases. Neuroimage 141, 542–555 (2016).

    Article
     
    PubMed
     
    Google Scholar
     

    Iglesias, J. E. et al. Bayesian segmentation of brainstem structures in MRI. Neuroimage 113, 184–195 (2015).

    Article
     
    PubMed
     
    Google Scholar
     

    Saygin, Z. M. et al. High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas. Neuroimage 155, 370–382 (2017).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Neudorfer, C. et al. A high-resolution in vivo magnetic resonance imaging atlas of the human hypothalamic region. Sci. Data 7, 305 (2020).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Alfaro-Almagro, F. et al. Confound modelling in UK Biobank brain imaging. Neuroimage 224, 117002 (2021).

    Article
     
    PubMed
     
    Google Scholar
     

    Vickers, A. J. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med. Res. Methodol. 1, 6 (2001).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Papst, I. et al. Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada. BMC Public Health 21, 706 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Levin, A. T. et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1123–1138 (2020).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

Download references
Acknowledgements

We thank UK Biobank for making the data available, and all of the UK Biobank study participants, who generously donated their time to make this resource possible; B. Fischl and D. Greve for guidance with the FreeSurfer analyses. Analysis was carried out at the Oxford Biomedical Research Computing (BMRC) facility. BMRC is a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute, supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. This work was primarily supported by a Wellcome Trust Collaborative Award (215573/Z/19/Z). K.L.M. was supported by a Wellcome Trust Senior Research Fellowship (202788/Z/16/Z). The Wellcome Centre for Integrative Neuroimaging (WIN FMRIB) is supported by centre funding from the Wellcome Trust (203139/Z/16/Z). S.L. was supported by the Rina M. Bidin Foundation Fellowship in Research of Brain Treatment and the Pacific Parkinson’s Research Institute. P.K. was supported by the UK Research and Innovation (MR/S034978/1). A.M.W. is supported by the NIH through ZIA-MH002781 and ZIA-MH002782. P.M.M. acknowledges personal and research support from the Edmond J. Safra Foundation and L. Safra, an NIHR Senior Investigator Award, the UK Dementia Research Institute and the NIHR Biomedical Research Centre at Imperial College London. This research has been conducted in part using the UK Biobank Resource under application number 8107.
Author information
Authors and Affiliations

    FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

    Gwenaëlle Douaud, Soojin Lee, Fidel Alfaro-Almagro, Christoph Arthofer, Chaoyue Wang, Paul McCarthy, Frederik Lange, Jesper L. R. Andersson, Ludovica Griffanti, Eugene Duff, Saad Jbabdi, Bernd Taschler, Karla L. Miller & Stephen M. Smith

    OHBA, Wellcome Centre for Integrative Neuroimaging (WIN), Department of Psychiatry, University of Oxford, Oxford, UK

    Ludovica Griffanti

    Department of Paediatrics, University of Oxford, Oxford, UK

    Eugene Duff

    Ear Institute, University College London, London, UK

    Peter Keating

    National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA

    Anderson M. Winkler

    Nuffield Department of Population Health, University of Oxford, Oxford, UK

    Rory Collins & Naomi Allen

    UK Dementia Research Institute and Department of Brain Sciences, Imperial College, London, UK

    Paul M. Matthews

    Big Data Institute, University of Oxford, Oxford, UK

    Thomas E. Nichols

Contributions

G.D., S.L., F.A.-A., C.A., C.W., P.M., F.L., J.L.R.A., L.G., E.D., S.J., K.L.M. and S.M.S. created, extracted and organised the imaging and clinical data. S.M.S. carried out the imaging analyses. B.T., A.M.W. and T.E.N. co-supervised the statistical analyses. R.C., P.M.M., N.A., K.L.M. and S.M.S. contributed to the creation of the UK Biobank COVID-19 re-imaging project. G.D., P.K., K.L.M. and S.M.S. conceived the brain imaging study. G.D. interpreted the results. G.D. and S.M.S. wrote the paper. All of the authors revised the paper.
Corresponding author

Correspondence to Gwenaëlle Douaud.
Ethics declarations
Competing interests

R.C. has been seconded from the University of Oxford as chief executive and principal investigator of UK Biobank, which is a charitable company. N.A. is chief scientist for UK Biobank. P.M.M. acknowledges consultancy fees from Novartis and Biogen; he has received recent honoraria or speakers’ honoraria and research or educational funds from Novartis, Bristol Myers Squibb and Biogen. P.M.M. serves as the honorary chair of the UK Biobank Imaging Working Group and as an unpaid member of the UK Biobank Steering Committee; he is chair of the UKRI Medical Research Council Neurosciences and Mental Health Board.
Peer review
Peer review information

Nature thanks Randy L. Gollub, John Van Horn and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Age distributions for SARS-CoV-2 positive participants and controls at each time point do not differ significantly.

Two-sample Kolmogorov-Smirnov was used to compute the P values for age comparisons, since age for each group was not normally distributed (Lilliefors P = 1e-03 for each group, and both age at Scan 1 or Scan 2). This showed no significant difference in age distribution between SARS-CoV-2 participants and controls at Scan 1: P = 0.15 or at Scan 2: P = 0.08.
Extended Data Fig. 2 Histograms showing the well-matched distributions of Scan 1 - Scan 2 intervals for case and control groups.

The below IDP reproducibility Extended Data Fig. 3 shows, for comparison against the cases and controls, reproducibility from around 3,000 (2,943) UK Biobank participants who had returned for a second scan prior to the pandemic; hence we also show here the interscan intervals for this “3k” group, with tighter control over this interval (we have normalised each of those 3 groups to have a peak of 1, to make the relative comparison easier).
Extended Data Fig. 3 Scan-rescan reproducibility for all 2,047 IDPs used in the main modelling.

Each dot represents a single IDP, arranged into different classes of IDPs. For each IDP, the vector of values for each subject (i.e., 785x1 vector) from the first scan was correlated with the equivalent vector of IDP values from the second scan. The y axis shows the resulting correlation coefficient. These calculations are made separately for the pre-pandemic scan-rescan datasets ("3k DPUK"), and for cases and controls, demonstrating highly similar distributions within each IDP class for all 3 subject groups.
Extended Data Fig. 4 QQ plot for −log10[Puncorr] against the theoretical null distribution.

The black line at y=x shows the expected plot if no effects were present in the data. Orange points reflect ΔIDPs where the case-control effect passes FDR significance, and blue reflects those that do not.
Extended Data Fig. 5 Model Z-statistics (one point per IDP, arranged in IDP classes) for the 4 main models.

Note that these are model Z-statistics, not raw effect size. Some IDP classes (e.g., cortical thickness and grey-white intensity contrast) show consistent group-difference effect directions across most IDPs (i.e., different brain regions), and all 4 models.
Extended Data Fig. 6 Examples of percentage change in some of the most significant longitudinal group comparison results from the exploratory approach.

Four amongst the top IDPs consistently showing longitudinal differences between SARS-CoV-2 cases and controls. All demonstrate either a greater reduction in local or global brain thickness and volume, or an increase in CSF volume. For each four IDP are the percentage changes with age for the two groups, obtained by normalising ΔIDP using as baseline the values for the corresponding IDPs across the 785 scans (created using a 10-year sliding window across cases and controls, with standard errors in grey). The counterintuitive increase in thickness in the rostral anterior cingulate cortex in older controls has been previously consistently reported in studies of ageing, together with that of the orbitofrontal cortex57,58.
Supplementary information
Supplementary Information

Supplementary Discussion and additional references, Supplementary Figs. 1–4, Supplementary Longitudinal Plots, Supplementary Baseline Plots, Supplementary Analyses 1–7, including Supplementary Figs. 5–7, Supplementary Tables 6–11 and additional references.
Reporting Summary
Peer Review File
Supplementary Table 1

Full list of the reproducible IDPs used in the hypothesis-driven and exploratory approaches, and corresponding statistics for the longitudinal analyses (models 1–4).
Supplementary Table 2

Full list of the reproducible IDPs used in the hypothesis-driven and exploratory approaches, and corresponding statistics for the cross-sectional, baseline analysis comparing the SARS-CoV-2 and control groups (binary and age-modulated).
Supplementary Table 3

Full list of the reproducible IDPs used in the hypothesis-driven and exploratory approaches, and corresponding statistics for the cross-sectional, second time point analysis comparing the SARS-CoV-2 and control groups (binary and age-modulated).
Supplementary Table 4

Full list of the nIDPs used for the cross-sectional, baseline comparison between the SARS-CoV-2 and control groups, and corresponding statistics (binary).
Supplementary Table 5

Full list of reproducible IDPs used in the hypothesis-driven and exploratory approaches, and corresponding statistics for the longitudinal analyses using a binary regressor for group comparisons.
Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions
About this article
Verify currency and authenticity via CrossMark
Cite this article

Douaud, G., Lee, S., Alfaro-Almagro, F. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604, 697–707 (2022). https://doi.org/10.1038/s41586-022-04569-5

Download citation

    Received19 August 2021

    Accepted21 February 2022

    Published07 March 2022

    Issue Date28 April 2022

    DOIhttps://doi.org/10.1038/s41586-022-04569-5

Share this article

Anyone you share the following link with will be able to read this content:

Provided by the Springer Nature SharedIt content-sharing initiative
Subjects

    Encephalopathy
    Olfactory cortex

This article is cited by

    Cortical Grey matter volume depletion links to neurological sequelae in post COVID-19 “long haulers”
        Ted L. Rothstein

    BMC Neurology (2023)
    Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms
        Pei HuangLin-Yuan ZhangSheng-Di Chen

    Translational Neurodegeneration (2023)
    Nicotine exposure decreases likelihood of SARS-CoV-2 RNA expression and neuropathology in the hACE2 mouse brain but not moribundity
        Ayland C. LetsingerJames M. WardJerrel L. Yakel

    Scientific Reports (2023)
    Innate immune evasion strategies of SARS-CoV-2
        Judith M. MinkoffBenjamin tenOever

    Nature Reviews Microbiology (2023)
    Long COVID: major findings, mechanisms and recommendations
        Hannah E. DavisLisa McCorkellEric J. Topol

    Nature Reviews Microbiology (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Download PDF
https://www.nature.com/articles/s41586-022-04569-5.pdf


Associated Content
Brain changes after COVID revealed by imaging

    Randy L. Gollub

Nature News & Views 08 Mar 2022

    Abstract
    Main
    Participants
    Hypothesis-driven results
    Exploratory results
    Cognitive results
    Additional baseline investigations
    Longitudinal effects of pneumonia and influenza
    Discussion
    Methods
    Data availability
    Code availability
    References
    Acknowledgements
    Author information
    Ethics declarations
    Peer review
    Additional information
    Extended data figures and tables
    Supplementary information
    Rights and permissions
    About this article
    This article is cited by
    Comments

Advertisement

Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print)
nature.com sitemap


    Legal notice Accessibility statement Terms & Conditions California Privacy Statement Cancel contracts here

Springer Nature

© 2023 Springer Nature Limited
[*/quote*]
« Last Edit: July 11, 2024, 08:28:05 PM by Pangwall »
Logged
Stoppt die deutschen Massenmörder!
Stoppt die österreichischen Massenmörder!
Stoppt die schweizer Massenmörder!

Revolution jetzt. Sonst ist es zu spät.

Julian

  • Boltbender
  • Jr. Member
  • *
  • Posts: 2214
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #6 on: March 07, 2023, 10:41:42 PM »

Zur Erinnerung an schon bekanntes Wissen:

https://www.dw.com/de/toxoplasmose-parasiten-ver%C3%A4ndern-die-synapsen-im-gehirn/a-46157359

[*quote*]
THEMEN / Wissen & Umwelt
Zoonosen
Toxoplasmose-Parasiten verändern die Synapsen im Gehirn

Wissenschaftler haben nachgewiesen, dass der Toxoplasmose-Parasit den Stoffwechsel im Gehirn beeinflusst. Veränderte Synapsen werden mit Depressionen, Schizophrenie und Autismus in Verbindung gebracht.

Katze spielt mit Beutemaus

Mit Toxoplasmen infizierte Mäuse verhalten sich seltsam: Sie verlieren ihre natürliche Furcht vor Katzen. Das hatten Magdeburger Wissenschaftler bereits in früheren Versuchen herausgefunden. Und wenn man den Nagern den Geruch von Katzenurin präsentierte, schienen sie sogar eine Präferenz für Katzen entwickelt zu haben, so die überraschten Forscher.

Toxoplasmose wird durch den Erreger Toxoplasma gondii ausgelöst, einen einzelligen Parasit, der weltweit verbreitet ist. Er befällt Vögel und Säugetiere - also auch den Menschen. Seine Endwirte sind jedoch Katzen, die den Toxoplasmose-Erreger mit ihrem Kot ausscheiden. Menschen können sich beim Säubern der Katzentoilette infizieren oder wenn sie anderweitig - etwa bei der Gartenarbeit - mit dem Erreger in Kontakt kommen kommen und ihn über den Mund aufnehmen. Gefahr besteht auch wenn sie verunreinigte Lebensmittel essen.

Die Hälfte aller Erwachsenen ist mit Toxoplasmen infiziert. Davon merken sie normalerweise nichts, da die Toxoplasmose meist unbemerkt verläuft. Der Körper bildet Abwehrstoffe gegen den Erreger und ist dann gewöhnlich lebenslang immun gegen die Krankheit. Nur selten kommt es bei einer Infektion kurzzeitig zu einem grippeähnlichen Krankheitsbild mit Fieber, Schlappheit, Muskelschmerzen und Durchfällen.

Ist ein Mensch aber erst einmal infiziert, bleibt der Parasit oft dauerhaft im Organismus – etwa im Muskelgewebe oder im Gehirn. Mediziner sprechen deshalb von einer "versteckt fortbestehenden" Infektion.

Mehr dazu: Fünf Krankheitserreger, die Ungeborenen schaden können
Symbolbild Katze schmust mit Frauchen

Endwirte der Toxoplasmose Erreger sind Katzen - von dort können sie zum Menschen gelangen

Gefährlich ist Toxoplasmose für Menschen mit einem geschwächten Immunsystem oder Patienten, die gerade eine Organtransplantation hinter sich haben. Gefährdet sind aber auch Schwangere: Hat sich eine Mutter bereits vor der Schwangerschaft infiziert und eine Immunität gegenüber Toxoplasmose aufgebaut, ist das ungeborene Kind normalerweise nicht gefährdet. Steckt sie sich aber erst in der Schwangerschaft an, kann dies zu Netzhautentzündungen, Entwicklungsverzögerungen und Krampfanfällen beim Kind oder sogar zur Fehlgeburt führen.

Parasiten beeinflussen Signalübertragung im Gehirn

Die Existenz von Toxoplasmose ist schon lange bekannt. Neu sind allerdings die Erkenntnisse, wie der Toxoplasmose-Parasit die Synapsen im Gehirn umbaut. Wissenschaftler vom Institut für Inflammation und Neurodegeneration der Otto-von-Guericke-Universität Magdeburg (OVGU) und vom Leibniz-Institut für Neurobiologie (LIN) haben nachgewiesen, dass der Parasit den Stoffwechsel im Gehirn seiner Wirte beeinflusst und die molekulare Zusammensetzung von Synapsen verändert. Die Ergebnisse wurden im Fachmagazin Journal of Neuroinflammation veröffentlicht.

Der Parasit nistet sich nicht nur im Gehirn und Muskelgewebe infizierter Tiere ein: "Toxoplasma gondii wird vom Menschen über die Verdauung aufgenommen, gelangt in den Blutkreislauf und wandert auch ins Gehirn, um sich dort lebenslang in Nervenzellen einzunisten", beschreibt Dr. Karl-Heinz Smalla vom Speziallabor Molekularbiologische Techniken am LIN.
Maus und Katze

Das Beutetier Maus verliert durch die Toxosplamose-Parasiten die Angst vor Katzen

Um die seltsamen Verhaltensänderungen bei den Mäusen zu erklären, untersuchten die Forscher Veränderungen in den Mäusegehirnen – insbesondere die molekulare Zusammensetzung von Synapsen, da die für die Signalverarbeitung im Gehirn verantwortlich sind.

In einer Kooperation mit dem Helmholtz-Zentrum für Infektionsforschung in Braunschweig konnten sie dabei nachweisen, dass sich durch die Infektion die Mengen bei insgesamt 300 synaptischen Proteinen im Gehirn verändern. Besonders stark reduziert waren vor allem Proteine in der Nähe von Glutamat-freisetzenden erregenden Synapsen. Gleichzeitig wurden erhöhte Mengen an Proteinen gefunden, die an Immunantworten beteiligt sind.

Behandlung mit Sulfadiazin vielversprechend

Zur Therapie von Toxoplasmose-Infektionen wird oft Sulfadiazin eingesetzt, das die Vermehrung der Toxoplasmen teilweise behindert. Diese Behandlung zeigte bei den untersuchten Mäusehirnen Wirkung: "Alle untersuchten Proteine, die für die glutamaterge Signalübertragung zuständig sind, waren wieder im Normalbereich. Und auch die Entzündungsaktivität ging messbar zurück," sagte der Psychiater und Neurowissenschaftler Dr. Björn Schott.
Symbolbild Mann genervt

Fehlfunktionen glutamaterger Synapsen werden mit Depressionen, Schizophrenie und Autismus in Verbindung gebracht.

Diese Erkenntnisse könnten auch für den Menschen relevant sein. "Sie unterstützen die Vermutung, dass Toxoplasma gondii ein Risikofaktor für neuropsychische Erkrankungen ist. Fehlfunktionen glutamaterger Synapsen werden mit Depressionen, Schizophrenie und Autismus in Verbindung gebracht. Auch Komponenten der Immunantwort zeigen Bezüge zu diesen Erkrankungen", so die Neuroimmunologin Dr. Ildiko Rita Dunay. "Das legt den Verdacht nahe, dass möglicherweise durch Immunreaktionen Veränderungen an der Synapse verursacht werden, die zu neuropsychiatrischen Störungen führen können."

    Datum 05.11.2018
    Autorin/Autor Alexander Freund

    Permalink https://p.dw.com/p/37fdX

Mehr zum Thema
A man gets a swab test at a nucleic acid testing station, following a coronavirus disease (COVID-19) outbreak, in Beijing, China, July 14, 2022. REUTERS/Thomas Peter
Klimawandel macht krank: drohende Gesundheitskrise weltweit 11.08.2022
[...]
© 2023 Deutsche Welle | Datenschutz | Erklärung zur Barrierefreiheit | Impressum | Kontakt | Mobile Version
[*/quote*]


Jetzt das aktuelle Problem:

https://twitter.com/schokoschocker/status/1632275948824403969

[*quote*]
omarzipania @schokoschocker

Was Corona mit dem Gehirn anrichten kann:
Freundin, Team Super Vorsicht, konsequent gesunde Ernährung und Sport, Gesundheit ist ihr das Wichtigste.

6 Wochen nach Covidinfektion:
"Ich schütze mich nicht mehr, möchte Spaß haben, ist mir wichtiger als langes Leben 🥳"


🤯🤯

8:04 AM · Mar 5, 2023
35.6K Views 51 Retweets 4 Quote Tweets 625 Likes
[*/quote*]


Bei Toxoplasmose ist die Katze für eine gewisse Zeit erkrankt. Aber danach hat sie erstaunlicherweise Vorteile: Wenn Mäuse von ihr mit dem Erreger infiziert werden, kann die Katze sie leichter fangen. Der Katze wird die Jagd erleichtert. Insofern macht es Sinn, daß die Katze der Entwirt des Erregers ist.


Kann es sein, daß durch SarsCoV2 wie bei Toxoplasmose Änderungen des Verhaltens ausgelöst werden? Änderungen der Hirnmasse wurde bereits festgestellt. Aber wie ist es mit dem Verhalten? Kann es sein, daß Infizierte fahrlässig reagieren, daß ihnen alles egal ist, und sie deswegen auf Masken, Impfungen und anderes verzichten, daß sie bedenkenlos Andere infizieren?

Falls ja: Die aus den Horrorfilmen bekannte Armee der Zombies is keine Fiktion mehr, sondern real. Wie wird das erst in 2 oder 3 Jahren sein, nach mindestens 6 weiteren Infektionen PRO PERSON?
« Last Edit: July 11, 2024, 08:28:28 PM by Pangwall »
Logged
StarCruiser http://WWW.ALLAXYS.COM
-----  Travelling beyond c   -----

Krik

  • Jr. Member
  • *
  • Posts: 1724
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #7 on: November 03, 2023, 07:54:57 AM »

Why did this study not get to the surface internationally!?

This study uses markers. Result: ALL infected have vessel damages. This means nothing else but that ALL infected have a brain damage.

So this is one more proof.


https://www.chop.edu/news/chop-researchers-find-elevated-biomarker-related-blood-vessel-damage-all-children-sars-cov-2

[*quote*]
Children's Hospital of Philadelphia
 
CHOP Researchers Find Elevated Biomarker Related to Blood Vessel Damage in All Children with SARS-CoV-2 Regardless of Disease Severity

Published on Dec 08, 2020

Researchers at Children’s Hospital of Philadelphia (CHOP) have found elevated levels of a biomarker related to blood vessel damage in children with SARS-CoV-2 infection, even if the children had minimal or no symptoms of COVID-19. They also found that a high proportion of children with SARS-CoV-2 infection met clinical and diagnostic criteria for thrombotic microangiopathy (TMA). TMA is a syndrome that involves clotting in the small blood vessels and has been identified as a potential cause for severe manifestations of COVID-19 in adults.

Drs. Behrens and Teachey talking Co-senior authors of the study, Dr. David Teachey (R) and Dr. Edward Behrens (L) The findings were published today in Blood Advances.

“We do not yet know the clinical implications of this elevated biomarker in children with COVID-19 and no symptoms or minimal symptoms,” said co-senior author David T. Teachey, MD, an attending physician, Co-Leader of the Immune Dysregulation Frontier Program, and Director of Clinical Research at the Center for Childhood Cancer Research at CHOP. “We should continue testing for and monitoring children with SARS-CoV-2 so that we can better understand how the virus affects them in both the short and long term.”

Most children infected with SARS-CoV-2 have mild or minimal symptoms, although a small proportion develop severe disease or Multisystem Inflammatory Syndrome in Children (MIS-C), a post-viral inflammatory response to COVID-19. Researchers have identified TMA mediated by the complement cascade as a potential cause for severe manifestations of COVID-19 in adults. The complement cascade is part of the immune system that enhances the immune response but also promotes inflammation. However, the role of complement-mediated TMA has not been studied in children.

To assess the role of complement activation in children with SARS-CoV-2, the Immune Dysregulation Frontier Program, including co-senior authors Edward Behrens, MD and Hamid Bassiri, MD, PhD and co-first authors Caroline Diorio, MD and Kevin McNerney, MD, analyzed 50 pediatric patients hospitalized at CHOP with acute SARS-CoV-2 infection between April and July 2020. Of those 50 patients, 21 had minimal COVID-19, 11 had severe COVID-19, and 18 were diagnosed with MIS-C. The researchers used soluble C5b9 (sC5b9) as a biomarker for complement activation and TMA. sC5b9 has been implicated as an indicator of severity in TMA after hematopoietic stem cell transplant; transplant patients with markedly elevated sC5b9 have increased mortality.

The researchers found elevations of C5b9 in patients with severe COVID-19 and MIS-C, but to their surprise, they also found that C5b9 was elevated in patients with minimal or asymptomatic disease. Although the study was prospective, meaning patients were enrolled and data collected from the time of hospitalization, the researchers obtained some of the laboratory data retrospectively when it came to evaluating whether they met the clinical criteria for TMA. Of the 22 patients for whom complete data were available, 19 (86%) met the criteria for TMA. Additionally, sC5b9 levels were elevated both in patients who did and did not meet criteria for TMA.

“Although most children with COVID-19 do not have severe disease, our study shows that there may be other effects of SARS-CoV-2 that are worthy of investigation,” Dr. Teachey said. “Future studies are needed to determine if hospitalized children with SARS-CoV-2 should be screened for TMA, if TMA-directed management is helpful, and if there are any short- or long-term clinical consequences of complement activation and endothelial damage in children with COVID-19 or MIS-C. The most important takeaway from this study is we have more to learn about SARS-CoV-2. We should not make guesses about the short and long-term impact of infection.”

C. Diorio et al. “Evidence of Thrombotic Microangiopathy in Children with SARS-CoV-2 across the Spectrum of Clinical Presentations,” Blood Advances, online December 8, 2020, DOI: 10.1182/bloodadvances.2020003471

Contact: Dana Bate, The Children’s Hospital of Philadelphia, 267-426-6055 or bated@email.chop.edu
[*/quote*]
« Last Edit: July 11, 2024, 08:29:43 PM by Pangwall »
Logged
REVOLUTION!

Krik

  • Jr. Member
  • *
  • Posts: 1724
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #8 on: April 01, 2024, 12:24:47 PM »

https://twitter.com/DaniBeckman/status/1774722377009795525

[*quote*]
Danielle Beckman @DaniBeckman

More evidence of direct #SARSCoV2 brain invasion points out that the neurological, cognitive, and psychiatric symptoms associated with COVID-19 might not only be driven by circulating inflammatory cytokines and indirect neuroinflammation.

@Gaudinlab
 just published a study examining human brain samples from individuals with COVID-19, cerebral organoids, and organotypic culture of human brain explants.

Their results are similar to what I also observed in the monkey brain: 
The primary neural target of SARS-CoV-2 is mostly found to be neuronal, although other neural cell types have been reported to show some degree of permissivenes."

This is why SARS-CoV-2 will never be like the Flu. Show me an influenza strain that directly infects neurons in the primate brain.


Image


https://pbs.twimg.com/media/GKEUKLFaEAAfUKz?format=jpg&name=900x900

Quote
----------------------------
https://twitter.com/Gaudinlab/status/1773666956605849944
[***quote***]
Gaudin lab @Gaudinlab
Mar 29
Want some mechanistic insights on #NeuroCOVID? Have a look at our latest article by @EmmaPartiot et al just released @NatureMicrobiol
"Brain exposure to SARS-CoV-2 virions perturbs synaptic homeostasis"
Here -> https://rdcu.be/dCNLx
https://www.nature.com/articles/s41564-024-01657-2.epdf?sharing_token=wd0A4LcCjb3AqqkEWbOPS9RgN0jAjWel9jnR3ZoTv0MjOBytDsOhlETRzRVyQmZJQpPNpQAatJFHB9Vp0H0c0UcPRRy7DaoSHjvGxZFcwTholybJY8C72HqlMKsltSubuaoKt1Rl9TNWSh0Vdf12d8fOCthdlJG1rEyVan2cbx0%3D
@IRIM_life @CNRSbiologie @umontpellier
Image



https://pbs.twimg.com/media/GJ1QuySWMAA68l1?format=jpg&name=900x900

[***/quote***]
10:56 AM · Apr 1, 2024
17.4K Views
[*/quote*]


https://www.nature.com/articles/s41564-024-01657-2.epdf?sharing_token=wd0A4LcCjb3AqqkEWbOPS9RgN0jAjWel9jnR3ZoTv0MjOBytDsOhlETRzRVyQmZJQpPNpQAatJFHB9Vp0H0c0UcPRRy7DaoSHjvGxZFcwTholybJY8C72HqlMKsltSubuaoKt1Rl9TNWSh0Vdf12d8fOCthdlJG1rEyVan2cbx0%3D
« Last Edit: July 11, 2024, 08:28:52 PM by Pangwall »
Logged
REVOLUTION!

Vultratelly

  • Jr. Member
  • *
  • Posts: 96
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #9 on: May 11, 2024, 06:23:48 PM »

Schweden ist (fast) mitten in Europa. Aber wir verstehen sie nicht. die verdammte Sprachbarriere muß weg!



https://www.gp.se/nyheter/sverige/risk-for-flera-ar-av-hjarndimma-efter-mild-covid.f60cbaf7-0ec9-432f-8626-4311a9e2bddd?access=unknown&utm_source=twitter_organic&utm_medium=social&utm_content=organic_red

[*quote*]
Även de som inte blir så sjuka i covid riskerar långvariga kognitiva problem.

Risk för flera år av ”hjärndimma” efter mild covid

SverigeAtt smittas av covid kan orsaka flera år av hjärndimma, koncentrationssvårigheter och trötthet även om man bara fått förkylningssymptom, det visar ny forskning från Danderyds sjukhus.
– Våra patienter som var med i den här studien har haft milda eller måttliga infektioner, många har haft en vanlig hosta eller som en förkylning, säger överläkaren Kristian Borg.
ANNONS
Ebba Bergström
Publicerad 2024-01-27

Några dagar av feber, hosta och ont i halsen. En känsla av att vara lite ”skruttig”. Numera ser många covid-19 mer som en förkylning och inte som något man behöver oroar sig så mycket för. Men ny forskning från Danderyds sjukhus att även milda infektioner, utan något behov av att söka upp sjukvården, kan orsaka långvariga nedsättningar i minne, uppmärksamhet och förmåga att lära sig ny information.
Direkt kopplat till viruset

Redan 2020 gjordes forskning på virusets påverkan på kognitiva funktioner. Då kollade man på patienter som vårdats på sjukhus och inom intensivvården.

– Vi trodde från början att de här kognitiva symptomen skulle försvinna lika snabbt som problem med flås, nedsatt lukt och smak, men nu står det klart de inte gör inte det, säger Kristian Borg, överläkare och professor vid Karolinska Institutet, som var med och genomförde studien på Danderyds sjukhus.
ANNONS

Då den här senaste studien visat samma resultat slår man fast att det är en direkt konsekvens av viruset.

– Vid första studien spekulerade vi lite i om de kognitiva problemen kom från att personerna legat på intensiven under en lång tid, men nu ser vi att det inte är därför. Istället handlar det om en direkt effekt av själva viruset, säger Kristian Borg.
Oklart om alla tillfrisknar

Exakt hur länge dessa kognitiva problem kan kvarstå vet man fortfarande inte. I studien ingår patienter som insjuknade i Covid-19 i början av 2020 och som fortfarande har samma problem idag.

– Vi har ingen aning om hur länge de här problemen kan bestå, säger Kristian Borg.

Det är även oklart exakt hur man ska göra för att rehabilitera de som är drabbade.

– Jag hoppas ju på att de här problemen lägger sig med tiden, men som det ser ut nu så är det snarare att de förbättringar man ser hos patienterna handlar om att de kompenserar på andra sätt.
Kristian Borg överläkare och professor vid Karolinska Institutet. Han har även varit med och forskat på kognitiva nedsättningar efter covid.
Kristian Borg överläkare och professor vid Karolinska Institutet. Han har även varit med och forskat på kognitiva nedsättningar efter covid. Bild: Marianne Lagerbielke, Danderyds sjukhus
Glömmer hur mejl fungerar

Av de som smittas av covid säger cirka 20 procent att de fortfarande har symptom efter åtta veckor. Runt 10 procent säger att besvären är kvar efter 12 veckor.

På Kognitiva postcovidmottagningen på Danderyds sjukhus har man tagit emot cirka 1 000 patienter över ett och ett halv år. Då är det personer som först försökt rehabiliteras via primärvården.
ANNONS

– Nuförtiden får vi in runt fem eller sex remisser i veckan. Vi trodde att antalet skulle minska vid det här laget, men de har fortsatt att trilla in, säger Kristian Borg.

Bland de patienterna ser man stor variation i vilka problem de har. Det finns de som inte klarar inte av att använda sin dator och de som märker att deras sociala förmågor blivit sämre.

Många av de som var med i studien har blivit tvungna att sjukskriva sig på grund av sin postcovid.

– Det blir väldigt påtagligt om man har ett arbete där man plötsligt inte förstår vad som står i ett mejl, säger Kristian Borg.

LÄS MER:Matteläraren om Pisa-resultatet: Inte förvånad

LÄS MER:Studie: Nya covidvaccin överraskande bra

LÄS MER:Rehab efter covid viktigare än verkningslösa läkemedel
Ebba Bergström
TEXT
Ebba Bergström
ebba.bergstrom@gp.se
Dela
Dela
Dela
Dela
Du kanske också vill läsa
Arkitektens frustration över nya NK – ritade eget förslag
Arkitekt Albert Svensson sågar nya NK i Göteborg.
Polis misstänks för flera fall av sexköp
En polis i Västsverige misstänks för fem fall av sexköp i flera olika städer
”Jag kommer aldrig glömma hur Frölunda behandlat mig”
Berättar om beslutet att lämna SHL och Frölunda HC för spel i Schweiz och Rapperswil-Jona
Chattarna avslöjade grova mutbrott mellan skoljätten och privat byggföretag
Kopplas till renoveringar av flera skolor i Göteborg, Halmstad och Karlstad, därbland NTI-gymnasiet och LBS-kreativa gymnasiet.
ANNONS
ANNONS
Björn Lund, seismolog vid Uppsala universitet. Arkivbild.
Björn Lund, seismolog vid Uppsala universitet. Arkivbild. Bild: Pontus Lundahl/TT
Jordskalv skakade Västerbotten

Sverige
ANNONS
TT
Publicerad igår 12:37

Ett jordskalv har inträffat söder om Skellefteå, rapporterar lokala medier. Skalvet inträffade 10.51 på lördagen och magnituden var 2,9.

– Det är rätt kraftigt. Med svenska mått mätt är det här ett sådant som vi bara har en gång om året, säger Björn Lund, seismolog vid Uppsala universitet, till TT.

– Trots att det inte är ett stort skalv internationellt sett så fortplantar vågorna sig ganska bra i svensk berggrund så det har känts över stora områden.

Björn Lund säger att det finns uppgifter om att skalvet har känts ända ner till Umeå.

Grundades 1810 som Göteborgs-Posten.
Chefredaktör och ansvarig utgivare: Christofer Ahlqvist
Adress: Göteborgs-Posten, Polhemsplatsen 5
405 02 Göteborg Sverige
Telefon: 031-62 40 00
[*/quote*]
« Last Edit: July 11, 2024, 08:29:18 PM by Pangwall »
Logged
Clikron_Pilote hat Recht:

"Wir sind die Schulsoldaten. Wir sind die letzte Generation."
http://www.allaxys.com/~kanzlerzwo/index.php?topic=11591.msg37835#msg37835

Pangwall

  • Jr. Member
  • *
  • Posts: 1675
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #10 on: May 11, 2024, 07:25:30 PM »

Translated with http://www.deepl.com


https://www.gp.se/nyheter/sverige/risk-for-flera-ar-av-hjarndimma-efter-mild-covid.f60cbaf7-0ec9-432f-8626-4311a9e2bddd?access=unknown&utm_source=twitter_organic&utm_medium=social&utm_content=organic_red

[*quote*]
Even those who don't get very sick with COVID are at risk of long-term cognitive problems.

Risk of years of 'brain fog' after mild covid

Sweden

Becoming infected by covid can cause years of brain fog, concentration difficulties and fatigue even if you only have
cold symptoms, according to new research from Danderyd Hospital.
 
"Our patients in this study have had mild or moderate moderate infections, many have had a common cough or like a cold," says chief physician Kristian Borg.

Ebba Bergström
Published 2024-01-27

A few days of fever, cough and sore throat. A feeling of being a bit "cranky". Nowadays, many people see COVID-19 more as a cold and not as something you need to worry about so much. But new research from Danderyd Hospital that even mild infections, without any need to seek medical attention, can cause long-term memory impairment, attention and ability to learn new information.

Directly linked to the virus

As early as 2020, research was done on the impact of the virus on cognitive functions. At the time looked at patients in hospitals and intensive care units. intensive care.

We initially thought that these cognitive symptoms would disappear as quickly as problems with breathing, smell smell and taste, but now it is clear that they do not," says Kristian Borg, senior physician and professor at Karolinska Institutet, who who helped conduct the study at Danderyd Hospital.

As this latest study showed the same results, it is concluded that this is a direct consequence of the virus.

"In the first study, we speculated a bit about whether the cognitive problems from being in intensive care for a long time, but now we see that that this is not the case. Instead, it is a direct effect of the the virus itself," says Kristian Borg.

Unclear if everyone will recover

Exactly how long these cognitive problems may persist is still unknown. The study includes patients who fell ill with Covid-19 in early 2020 and who still have the same problems today.

- "We have no idea how long these problems might persist," says Borg.

It is also unclear exactly how to rehabilitate those affected.

"I hope that these problems will go away with time, but as it now, it's more likely that the improvements you see in patients is that they are compensating in other ways.

Kristian Borg

Borg is a consultant and professor at Karolinska Institutet. He has also been involved in research on cognitive impairment after COVID.

Kristian Borg is a senior consultant and professor at Karolinska Institutet. He has also been involved in research on cognitive impairment after COVID.
Photo: Marianne Lagerbielke, Danderyd Hospital

Forgetting how email works

Of those infected with COVID-19, around 20% say they still have symptoms symptoms after eight weeks. Around 10% say that the symptoms are still after 12 weeks.

At the Cognitive Postcovid Clinic at Danderyds hospital has seen around 1,000 patients over one and a half years. These are people who first tried to be rehabilitated via primary care.

"Nowadays we get around five or six referrals a week. We thought that that the number would decrease by now, but they have continued to in," says Kristian Borg.

Among these patients, there is great variation in the problems they have. There are those who cannot cope with using their computer and those who notice that their social skills have deteriorated.

Many of those involved in the study have had to take sick leave because of their post-covid.

"It becomes very noticeable if you have a job where you suddenly don't understand what's in an email," says Kristian Borg.


READ MORE:Rehab after covid more important than ineffective drugs
Ebba Bergström

Ebba Bergström
ebba.bergstrom@gp.se
[*/quote*]
« Last Edit: July 11, 2024, 08:30:18 PM by Pangwall »
Logged
Stoppt die deutschen Massenmörder!
Stoppt die österreichischen Massenmörder!
Stoppt die schweizer Massenmörder!

Revolution jetzt. Sonst ist es zu spät.

VanLaraklios

  • Jr. Member
  • *
  • Posts: 308
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #11 on: June 27, 2024, 10:02:18 PM »

https://x.com/DaniBeckman/status/1806483203924041882

[*quote*]
---------------------------------------------
Danielle Beckman @DaniBeckman

Not 👏Brain 👏Fog👏
This is a photo of a neuron exploding with #SARSCoV2.
This is Brain Damage.

Image

groß:
https://pbs.twimg.com/media/GRHpwLtbgAAPi6a?format=jpg&name=4096x4096

2:22 AM · Jun 28, 2024
13.8K Views

---------------------------------------------
Danielle Beckman @DaniBeckman

How many groups have to show that SARS-Cov-2 infects the brain, replicates inside neurons, and disrupts synapses? How long will scientists and patients continue to be ignored?
#neuroCovid

Image

groß:
https://pbs.twimg.com/media/GRHreCQbUAA0JZR?format=jpg&name=4096x4096

---------------------------------------------
Sharky @Mr_Landshark

So it’s brain damage that doesn’t heal ?

---------------------------------------------
Danielle Beckman @DaniBeckman

Exactly. Neurons are nonrenewable cells, but the system can compensate (to a certain degree) depending on several factors. The brain is usually very resilient, but with viruses, we don't really know how much.

---------------------------------------------
Phillip J. Buckhaults, Ph.D. @P_J_Buckhaults

pretty sure i lost about 8 iq points each covid infection.
---------------------------------------------
[*/quote*]
« Last Edit: July 11, 2024, 08:30:54 PM by Pangwall »
Logged

Pangwall

  • Jr. Member
  • *
  • Posts: 1675
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #12 on: July 11, 2024, 08:24:29 PM »

https://x.com/DaniBeckman/status/1811232889755042260

[*quote*]
------------------------------------------
Danielle Beckman @DaniBeckman

I will keep repeating that: Olfactory and cognitive systems overlap in the brain.
The virus goes directly into specific brain regions --> brain scan shows volume abnormalities in the same regions ---> patients show cognitive decline and other behavioral alterations
#neuroCovid
Image



https://pbs.twimg.com/media/GSLIR_aa0AAu6iY?format=jpg&name=4096x4096

Quote
https://x.com/DaniBeckman/status/1811210692667822230
------------------------------------------
Danielle Beckman @DaniBeckman
22h
"In our cohort, all survivors experienced one episode of the original #COVID strain infection."

The occurrence of cognitive impairment among older COVID-19 survivors was:
10.2% at 6 months
12.5% at 1 year
19.1% at 2.5 years post-infection.

Still don't believe in #LongCovid?

Quote
https://x.com/EricTopol/status/1811040884038959213
------------------------------------------
Eric Topol @EricTopol

Jul 10
Cognitive decline in older adults (age 60+) after Covid, 2.5 years follow-up
https://nature.com/articles/s43587-024-00667-3

#LongCovid @NatureAging
Image

https://pbs.twimg.com/media/GSIbGtpaUAIrU4J?format=jpg&name=4096x4096

3:27 AM · Jul 11, 2024
94K Views
[*/quote*]
Logged
Stoppt die deutschen Massenmörder!
Stoppt die österreichischen Massenmörder!
Stoppt die schweizer Massenmörder!

Revolution jetzt. Sonst ist es zu spät.

Wrastrolentiks

  • Jr. Member
  • *
  • Posts: 128
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #13 on: July 24, 2024, 02:16:39 PM »

https://x.com/EricTopol/status/1816136576319250568

[*quote*]
Eric Topol
@EricTopol
From paired MRI imaging in >1,300 people:  the pandemic accelerated brain aging.
"Accelerated brain ageing correlated with reduced cognitive performance only in COVID-infected participants."
https://doi.org/10.1101/2024.07.22.24310790
Image

https://pbs.twimg.com/media/GTQ2dO2bEAAFREh?format=jpg&name=4096x4096
5:41 PM · Jul 24, 2024
35K Views
[*/quote*]
Logged

Rhokia

  • Jr. Member
  • *
  • Posts: 1027
Covid19 hinterlässt Narben im Gehirn. IMMER !!! BEI JEDEM !!!
« Reply #14 on: July 30, 2024, 09:38:59 AM »

Nadja Podbregar ist super. Hier hat sie einen ganz frischen Artikel aus Freiburg mitgebracht:


https://www.scinexx.de/news/medizin/corona-hinterlaesst-immunnarbe-im-gehirn/

[*quote*]
Scinexx.de - das wissensmagazin
Medizin

Corona hinterlässt „Immunnarbe“ im Gehirn
Selbst ohne Long-Covid und andere Symptome bleiben Immun-Knötchen im Gehirn erhalten

30. Juli 2024

Mikroglia
Mikroglia-Zellen (rot) sind die Immunwächter des Gehirns. Doch die Corona-Infektion hinterlässt bei ihnen dauerhafte Spuren – selbst wenn wir symptomlos sind und genesen erscheinen. © Artur Plawgo/ iStock
Vorlesen

Verborgene Spätfolge: Eine Corona-Infektion hinterlässt anhaltende Veränderungen im Gehirn – selbst wenn wir nichts davon spüren. Ablesbar ist dies an winzigen Knötchen aus den für die Immunabwehr zuständigen Mikroglia-Zellen des Gehirns, wie Mediziner entdeckt haben. Diese „Immunnarbe“ spricht dafür, dass das angeborene Immunsystem in unserem Denkorgan selbst nach scheinbar völliger Ausheilung der SARS-CoV-2-Infektion aktiviert bleibt.

Auch nach Ende der Corona-Pandemie sind die akuten und chronischen Folgen einer SARS-CoV-2-Infektion noch lange nicht vollständig aufgeklärt.
[...]
Ein besseres Verständnis dieser Prozesse könnte zu neuen diagnostischen und therapeutischen Ansätzen in der Behandlung Long-Covid, aber auch den Spätfolgen anderer Infektionskrankheiten führen. (Acta Neuropathologica, 2024; doi: 10.1007/s00401-024-02770-6)

Quelle: Universitätsklinikum Freiburg
30. Juli 2024 - Nadja Podbregar
[*/quote*]


Daß die Pandemie vorbei ist, ist aber gelogen!


Marius Schwabenland, einer der Autoren, ist übrigens bei Twitter:

https://x.com/M_Schwabenland/status/1817235214139085233

[*quote*]
Marius Schwabenland @M_Schwabenland

What are the long-term consequences of COVID-19 in the brain?
Check out our latest publication on "High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains"!
https://doi.org/10.1007/s00401-024-02770-6
 Photo: DFG
Image
6:26 PM · Jul 27, 2024
284 Views
[*/quote*]


Die Bilder und Links gibt es nur in den Originalen! Also Abmarsch und dort lesen!


Die Uniklinik hat eine Pressemitteilung zu der Studie veröffentlicht:

https://www.uniklinik-freiburg.de/presse/pressemitteilungen/detailansicht/4258-immun-narbe-im-gehirn-von-covid-19-genesenen-nachgewiesen.html

[*quote*]
Home › Presse › Pressemitteilungen › „Immun-Narbe“ im Gehirn von COVID-19-Genesenen nachgewiesen
Freiburg, 29.07.2024
„Immun-Narbe“ im Gehirn von COVID-19-Genesenen nachgewiesen

Neue Studie identifiziert anhaltende Aktivierung des angeborenen Immunsystems im Gehirn von COVID-19-Genesenen / Potentielle Bedeutung für langfristige neurologische Symptome von COVID-19 / Publikation in Acta Neuropathologica

Freiburger Forscher*innen haben wichtige Fortschritte im Verständnis der immunologischen Veränderungen im Gehirn von COVID-19-Genesenen gemacht. Im Gehirn von Personen, die eine SARS-CoV-2-Infektion überstanden haben, fanden sie Anzeichen einer anhaltenden Aktivierung des angeborenen Immunsystems, wie das Forschungsteam unter der Leitung von Prof. Dr. Marco Prinz, Ärztlicher Direktor am Institut für Neuropathologie des Universitätsklinikums Freiburg jetzt zeigt. Diese Erkenntnisse, die am 25. Juli 2024 in Acta Neuropathologica veröffentlicht wurde, könnten entscheidend für die Entwicklung neuer Therapien für Patient*innen mit langfristigen neurologischen Symptomen nach COVID-19 sein.

Hirneigenes Immunsystem nach SARS-CoV-2-Infektion längerfristig gestört

Die Forscher*innen untersuchten die Gehirne von Personen, die an COVID-19 erkrankt, vollständig genesen und zu einem späteren Zeitpunkt an einer anderen Ursache verstorben waren. Bei diesen ermittelten sie immunologische Veränderungen im zentralen Nervensystem. Die Forscher*innen setzten dafür hochmoderne Methoden des maschinellen Lernens und eine räumliche Auflösung auf Einzelzell-Ebene ein. Das erlaubt ein deutlich besseres Verständnis der Funktion einzelner Zellen.

Im Vergleich zu ebenfalls untersuchten Personen ohne vorherige SARS-CoV-2-Infektion fanden die Forscher*innen in den Gehirnen von Genesenen zahlreiche sogenannte Mikrogliaknötchen. Diese charakteristischen Immun-Zellansammlungen weisen auf eine chronische Immunaktivierung hin, ähnlich einer Narbe, die nicht vollständig ausheilt. „Die Mikrogliaknötchen könnten eine zentrale Rolle bei den neurologischen Veränderungen spielen, die bei einigen Genesenen beobachtet werden“, erklärt Dr. Marius Schwabenland, Erstautor der Studie, Assistenzarzt am Institut für Neuropathologie des Universitätsklinikums Freiburg und Clinician-Scientist im IMM-PACT- sowie im Berta-Ottenstein-Programm der Medizinischen Fakultät der Universität Freiburg.

Relevanz für langfristige neurologische Symptome

„Es ist gut möglich, dass die anhaltende Aktivierung des angeborenen Immunsystems im Gehirn zu den langfristigen neurologischen Beschwerden nach einer SARS-CoV-2-Infektion beiträgt. In einer früheren Studie hatten wir bereits Proben nach akuter SARS-CoV-2-Infektion untersucht und ähnliche, deutlich stärkere Veränderungen festgestellt“, erklärt Schwabenland.

Studienleiter Prinz betont: „Unsere Studie ist ein wichtiger Schritt, um zu verstehen, wie COVID-19 das Gehirn langfristig beeinflusst. Dies könnte uns helfen, gezielte Therapien zu entwickeln, die diese Immunreaktionen modulieren und die Lebensqualität der Betroffenen verbessern.“

Zukunftsperspektiven und weitere Forschung

„Unsere Ergebnisse unterstreichen die zentrale Rolle, die fehlregulierte Immunreaktionen bei COVID-19 spielen können – nicht nur bei der akuten Infektion, sondern auch bei Langzeitfolgen wie Long-Covid“, betont Prof. Dr. Dr. Bertram Bengsch, Sektionsleiter an der Klinik für Innere Medizin II und Mitautor der Studie.

Die Untersuchung verschiedener Zelltypen des angeborenen und erworbenen Immunsystems und das Zusammenspiel dieser Zellen stellt einen vielversprechenden Ansatz für künftige Forschungsprojekte dar, die über COVID-19 hinausgehen. Ein besseres Verständnis dieser Prozesse könnte zu neuen diagnostischen und therapeutischen Ansätzen in der Behandlung von Patient*innen mit Infektions- oder Krebserkrankungen führen.

Originaltitel der Studie: High throughput spatial immune mapping reveals an innate immune scar in post‑COVID‑19 brains
DOI: doi.org/10.1007/s00401-024-02770-6
Link zur Studie:  https://link.springer.com/article/10.1007/s00401-024-02770-6

Bildunterschrift: Prof. Dr. Marco Prinz (links) und Dr. Marius Schwabenland (rechts) bei der Hirn-Obduktion von COVID-19 Genesenen.
Bildquelle: Deutsche Forschungsgemeinschaft
Downloads:
Prof._Prinz_GWL_2020-61.jpg
(4.4 MB, jpg)

Universitätsklinikum Freiburg

Zentrale Information
Telefon: 0761 270-0
info@uniklinik-freiburg.de

 
Für Presseanfragen:
Unternehmenskommunikation

Breisacher Straße 153
79110 Freiburg
Telefon: 0761 270-84830
kommunikation@uniklinik-freiburg.de
[*/quote*]



https://link.springer.com/article/10.1007/s00401-024-02770-6

[*quote*]
SpringerLink
Acta Neuropathologica
Article

High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains

    Original Paper
    Open access
    Published: 25 July 2024

    Volume 148, article number 11, (2024)
    Cite this article

Download PDF
https://link.springer.com/content/pdf/10.1007/s00401-024-02770-6.pdf

You have full access to this
open access
article
Acta Neuropathologica
Aims and scope
Submit manuscript
High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains
Download PDF

    Marius Schwabenland, Dilara Hasavci, Sibylle Frase, Katharina Wolf, Nikolaus Deigendesch, Joerg M. Buescher, Kirsten D. Mertz, Benjamin Ondruschka, Hermann Altmeppen, Jakob Matschke, Markus Glatzel, Stephan Frank, Robert Thimme, Juergen Beck, Jonas A. Hosp, Thomas Blank, Bertram Bengsch & Marco Prinz

    154 Accesses
    160 Altmetric
    4 Mentions

    Explore all metrics

Abstract

The underlying pathogenesis of neurological sequelae in post-COVID-19 patients remains unclear. Here, we used multidimensional spatial immune phenotyping and machine learning methods on brains from initial COVID-19 survivors to identify the biological correlate associated with previous SARS-CoV-2 challenge. Compared to healthy controls, individuals with post-COVID-19 revealed a high percentage of TMEM119+P2RY12+CD68+Iba1+HLA-DR+CD11c+SCAMP2+ microglia assembled in prototypical cellular nodules. In contrast to acute SARS-CoV-2 cases, the frequency of CD8+ parenchymal T cells was reduced, suggesting an immune shift toward innate immune activation that may contribute to neurological alterations in post-COVID-19 patients.

Similar content being viewed by others

Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review
Article Open access 12 December 2017
High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses
Article Open access 17 August 2022
Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation
Article Open access 12 January 2022

Introduction

Acute COVID-19 is frequently accompanied by neurological symptoms, and a subset of individuals experiences persistent neurological post-COVID-19 manifestations, referred to as Post-COVID condition (PCC), Post-Acute COVID Syndrome (PACS) or Neuro-Long-COVID-19 [4]. However, the underlying pathogenesis for this phenomenon is largely unclear. Recent studies looking into the blood composition of patients with Long-COVID detected altered composition of immune cells [10, 17, 29], increased peripheral complement activation [3], dysregulation of markers related to blood clotting and coagulation [26], or exaggerated humoral response directed against SARS-CoV-2 [10] with unclear relevance for the central nervous system (CNS). Regarding the central nervous system, some studies encompassed large clinical datasets [2, 13, 24, 30] or advanced imaging techniques. For example, repeated magnetic resonance brain imaging revealed significant longitudinal effects in individuals previously infected with SARS-CoV-2, including a greater reduction in gray matter thickness and global brain size [5] that may be a consequence of T-cell-mediated neuroinflammation previously described in acutely affected COVID-19 brains [12, 22, 28]. Studies involving patients or patient samples of subacute, late-stage COVID-19 indicate an altered glucose metabolism [9] and type I interferon response [18]. Despite these proposed mechanisms, the cellular and molecular processes that are affected in the brains of long-term post-COVID-19 patients are largely missing.

Methods

Specimen collection

Formaldehyde-fixed paraffin-embedded (FFPE) central nervous system samples were obtained from autopsies at the University Medical Center in Freiburg, the Institute of Pathology, University of Basel, Institute of Legal Medicine at the University Medical Center Hamburg-Eppendorf and the Institute of Neuropathology at the University Medical Center Hamburg-Eppendorf. Post-COVID-19 patients had a COVID-19 unrelated cause of death, which was assessed by thorough assessment of the medical records, interviews with relatives, and meticulous autopsy findings. Patients had reported full recovery from COVID-19 and showed no signs of COVID-related symptoms before their passing. In particular, no long-term neurological deficits after exposure to SARS-CoV-2 have been reported. Patients were typically tested negative for SARS-CoV-2 after their COVID-19 infection during their lifetime. Additional testing for SARS-CoV-2 was performed for six patients during autopsy, and the test results were all negative. Patient characteristics are provided in Supplementary Table 1. Lumbar punctures of Neuro-Long-COVID-19 patients were performed at the Department of Neurology and Neuroscience at the University Medical Center Freiburg (Supplementary Table 2). Cerebrospinal fluid from patients with idiopathic intracranial hypertension served as controls. The analyses were performed with the approval of the institutional review boards (Ethics Committee of the University of Freiburg: 211/20, 10008/09; Ethics Committee of the Hamburg Chamber of Physicians: 2020-10353-BO-ff, PV7311; Ethics Committee of Northwestern and Central Switzerland: 2020-00629). The study was performed in agreement with the principles expressed in the Declaration of Helsinki and its amendments.

Immunohistochemistry

The immunohistochemical reactions (chromogenic immunohistochemistry) for CD8a, CD4, CD20, SARS-CoV spike glycoprotein, APP, and Alpha-Syn on 3 µm-thick FFPE sections were performed using the EnVision Flex Kit (DAKO, Agilent, cat. # K8000) and a DAKO Autostainer Link 48 system. EnVision low pH tissue pre-treatment was used for CD8a (Dako, cat. # IR623, RTU), APP (Millipore, cat. # MAB348, 1:2000), SARS-CoV spike glycoprotein (abcam, cat. # ab272420, 1:100), and Alpha-Syn (BioSB, cat. # BSB3291, RTU). EnVision high pH tissue pre-treatment was used for CD20 (DAKO, cat. # IR604, RTU) and CD4 (DAKO, cat. # IR649, RTU). EnVision Flex Mouse Linker (DAKO, cat. # K800221-2) was applied for CD4 immunohistochemistry.

Chromogenic Iba1 immunohistochemistry of 3 µm-thick FFPE sections was performed using the labeled streptavidin–biotin (LSAB) method as previously described [20, 21]. Slides were deparaffinized in Xylene and cooked in EnVision low pH antigen retrieval buffer for 40 min. Endogenous tissue peroxidase was quenched in 3% hydrogen peroxidase (Carl Roth, cat. # 8070.1) for 10 min. Samples were then blocked with 10% normal goat serum (SouthernBiotech, cat. # 0060-01), 1% Triton X-100 (Sigma, cat. # T8787-100ML) in TRIS buffer (EnVision Flex Wash Buffer, DAKO, cat. # K8000) for 1 h. The incubation with Iba1 primary antibody (abcam, cat. # 178846, 1:1000 in the blocking solution) was performed at room temperature overnight. After three washes with TRIS buffer, the slides were incubated with goat anti-rabbit secondary antibody (SouthernBiotech, cat. # 4050-08, 1:300 in the blocking solution) for 45 min. Slides were then washed three times. Streptavidin-HRP (SouthernBiotech, cat. # 7105-05) was diluted 1:1000 in TRIS buffer and added for 45 min. Specimens were then rinsed in TRIS buffer three times and incubated with DAB solution (1 drop EnVision Flex DAB Chromogen per 1 ml EnVision Flex Substrate Buffer).

All sections were counterstained with Gill’s Hematoxylin solution (Sigma, cat. 1051750500) and Vitro-Clud (R. Langenbrinck GmbH, cat. # 04-0001) was used as mounting medium. Imaging was performed on a Zeiss Axioscan 7 system equipped with a 20× objective.

Imaging mass cytometry

Imaging Mass Cytometry was conducted as reported previously [1, 22]. In short, antibodies were conjugated to lanthanide metals using the Maxpar X8 antibody labeling kit. 4 µm thick formaldehyde-fixed paraffin-embedded (FFPE) sections were deparaffinized and cooked in EnVision FLEX Target Retrieval Solution High pH (DAKO, cat. # K8000) for 40 min. Sections were blocked using SuperBlock Blocking Buffer (ThermoFisher, cat. # 37581). The slides were then incubated with the antibody mix (Supplementary Table 3) in 0.5% BSA, 1% Triton-X-100 in TRIS at room temperature overnight. Iridium Cell-ID intercalator (Fluidigm, cat. # 201192A) was used to visualize DNA and applied for 30 min. The measurement was conducted using the Hyperion Imaging Mass Cytometry system (Fluidigm). For the IMC measurements, regions of interest (ROIs) were determined by Iba1 immunohistochemistry on a consecutive section. Areas with most prominent microglia nodules (if present) were selected.

Image segmentation was performed based on the IMCSegmentationPipeline [27]. Image visualization was performed using MCD Viewer v1.0.560.6. An expression threshold of > = 2 and area > = 20 was used for the gating of Iba1 myeloid cells (Fig. 1D). For PhenoGraph clustering, the expression values of CD11c, CD162, CD163, CD204, CD206, CD64, CD68, FCERI, HLA-DR, HLA-DRA, HLA-DRB1, Iba1, INPP5D, Ki67, MX1, P2RY12, S100A9, SCAMP2, SLC2A5, TMEM119, and TYROBP were used. For Fig. 1F, a min–max scaling was performed for normalization. In Fig. 1H, expression values were normalized to Iba1 signal intensity. Compartments (parenchyma vs. nodule) were based on the microglia nodule index [22] (defined as the coverage of Iba1 signal in a 15 µm radius) and a threshold >  = 0.5.

Fig. 1
figure 1

Innate rather than adaptive immune activation in defined compartments of post-COVID-19 brains. a Experimental workflow. Autopsy tissue slices from the upper medulla of 15 initial COVID-19 survivors with SARS-CoV-2-unrelated causes of death (post-COVID-19), 11 acute COVID-19 and 4 SARS-CoV-2 naïve control patients were analyzed by comprehensive neuropathological analyses. CyTOF cytometry by time of flight. b Left: representative immunohistochemistry for CD8a (brown) in the upper medulla oblongata of controls, acute COVID-19 patients (cells are highlighted by arrow heads) and post-COVID-19 patients. Counterstaining with haematoxylin. Scale bar: 100 µm. Middle: quantification thereof. Each symbol represents one patient. Bars represent means ± SEM. P values were determined using Brown-Forsythe and Welsh ANOVA test with Dunnett’s T3 multiple comparisons test. Right: T-cell numbers over different time points post-infection. Acute COVID-19 patients and controls are shown at 0 months post-infection. Each symbol represents one patient. Green line indicates the mean of controls. c Representative images depicting imaging mass cytometry of the medulla oblongata of three post-COVID-19 patients and one age-matched control. Scale bar: 100 µm. d UMAP visualization shows Phenograph clustering of myeloid cells in post-COVID-19 brains. Myeloid cells from both the frontal cortex and the upper medulla oblongata were analyzed. e Mosaic plot representing the contribution of identified myeloid cell clusters to each control, acute COVID-19, and post-COVID-19 brain samples. Myeloid cells from the frontal cortex and the upper medulla oblongata were analyzed. f Heatmaps visualizing the protein expression profiles of the different myeloid clusters. One column represents the normalized expression of one cell in the upper panel. In the lower panel, the mean expression per cluster is shown. g Representative visualization of the microglia nodule index calculated based on Iba1 signal across a 15 µm radius. A threshold of 0.5 was applied for the compartmentalization into parenchymal and nodule-associated myeloid cells. h Violin plots depicting the normalized expression of the indicated markers on Iba1+ myeloid cells in the parenchymal (blue) and subtissular nodule compartment (red) in the medulla of post-COVID-19 individuals. Student’s t test was applied. P values are indicated. Each symbol represents one cell

Full size image
Cerebrospinal fluid pre-treatment

Cerebrospinal fluid samples were centrifuged at 2000g for 10 min at + 4 °C. The cell-free supernatant was snap-frozen and kept at − 80 °C.
Enzyme-linked immunosorbent assays (ELISA)

After thawing CSF samples on ice, enzyme-linked immunosorbent assays (YKL-40: Invitrogen, cat. # EHCHI3L1; TREM2: Invitrogen, cat. # EH464RB; CD14: Invitrogen, cat. # EHCD14; NF-light: Tecan, cat. # UD51001) were performed according to the manufacturer’s instructions. A Spark multimode microplate reader (Tecan) was used for measurements.

Metabolomics

Targeted metabolomics analysis was conducted following established procedures outlined in the previous studies [15] and involved the extraction of samples using a precooled extraction solution (80:20 methanol LC–MS grade: Milli-Q water). Quantification of targeted metabolites through LC–MS was performed on an Agilent 1290 Infinity II UHPLC coupled with an Agilent 6495 QQQ-MS operating in MRM mode. MRM settings were optimized individually for all compounds using pure standards. Isotopically labeled yeast extract (ISOtopic Solutions, Vienna, Austria) was spiked into all samples as internal standard for identification of correct peaks and compensation of matrix effects. LC separation was performed as published previously [19]. Briefly, a Waters Atlantis Premier BEH ZHILIC column (100 × 2.1 mm, 1.7 µm particles) was used, buffer A was 20 mM ammonium carbonate and 5 µM medronic acid in milliQ H2O and buffer B was 90:10 acetonitrile:buffer A and the solvent gradient was from 95 to 55% buffer B over 18 min. Flow rate was 150 µL/min, column temperature was 40 °C, autosampler temperature was 5 °C, and injection volume was 2 µL. Data processing was performed using the R package automRm [6]. Spearman correlations were performed as reported previously [22].
Statistical analyses

Statistical analyses and visualizations were performed using GraphPad Prism 9.5.1. The statistical tests are mentioned in the figure legends. P values are stated in the figures.

Results

Innate rather than adaptive immune activation in defined compartments of post-COVID-19 brains

In a multicenter study, we collected brains from 15 individuals that experienced a previously confirmed SARS-CoV-2 infection, recovered fully but died due to reasons unrelated to COVID-19 up to 27 months after viral infection (Supplementary Table 1). Brains from four healthy controls and 11 acute COVID-19 cases were included for comparison. First, all samples underwent a comprehensive COVID-19 centered neuropathological analysis by board-certified neuropathologists as previously described [12]. Some samples (patients # 10, 11, and 12) were subsequently analyzed by single-cell-based immune phenotyping by cytometry-by-time-of-flight-(CyTOF)-based imaging mass cytometry (IMC) that allows detailed spatial profiling of single immune cells in the diseased CNS (Fig. 1a) [22]. Surprisingly, and in contrast to CNS specimens from acute cases, post-COVID-19 brain revealed only very few parenchymal CD8a+ T cells that were numerically almost compatible to controls (Fig. 1b). Additionally, we have also examined CD4+ T cells and CD20+ B cells (Supplementary Fig. 1) and found no significant differences in parenchymal cell counts between controls and post-COVID-19 cases. In contrast, using high-dimensional, 40 marker-based IMC analyses of samples from the frontal cortex and the medulla, we could identify microglia cells with positive signal in the channels for the microglial markers P2RY12 and TMEM119, accompanied by signals in the channels for myeloid cell molecules CD11c, CD68, CD204, and SCAMP2, along with the induction of the MHC class II-related proteins HLA-DR, HLA-DRA, and HLA-DRB1 (Fig. 1c). We next employed a supervised machine learning approach to segment the images and to extract single-cell expression data based on the intensity of each marker in the respective channel. After gating for the pan-myeloid marker ionized calcium-binding adaptor molecule 1 (Iba1), cells were clustered using the PhenoGraph algorithm (Fig. 1d). This approach identified a total of 18 clusters, as shown in a uniform manifold approximation and projection (UMAP) representing diverse myeloid cells, such as microglia (e.g., P2RY12+, TMEM119+ clusters 1, 2, 7, 8, and 11), perivascular macrophages (CD163+, CD204+, and CD206+ cluster 14), and monocytes (S100A9+ cluster 15). As depicted in mosaic plots, we identified clusters enriched for specific stages following SARS-CoV-2 infection, such as cluster 11 that was enhanced in post-COVID-19, and cluster 7 that was prominent in acute COVID-19 patients (Fig. 1e). Marker expression heat maps depict the varying marker expression profiles leading to distinct clusters (Fig. 1f). For example, microglia cells in cluster 1 exhibited strong positivity for the lysosomal activation marker CD68 and were mostly observed in samples from acute and post-COVID-19 patients, with minimal representation in control samples. Cluster 11, characterized by elevated integrin alpha x (CD11c) expression indicative of an activated microglial cell state, was mostly found in post-COVID-19 patients. Cluster 9 was also found in post-COVID-19 patients and was characterized by a moderate CD11c expression. Cluster 16 cells were primarily seen in acute cases, expressed the lysosomal activation marker CD68, and the MHC class-II-related molecules CD74, HLA-DRA, and HLA-DRB1. Myeloid cluster 14 that was shared across all patient groups expressed the markers CD206 and scavenger receptor cysteine-rich type 1 protein M130 (CD163) indicative of perivascular macrophages. Notably, Iba1+P2RY12+TMEM119+ microglia were found to be assembled in characteristic clusters, known as microglia nodules, that we defined as ≥ 50% coverage of the Iba1 signal in a 15 µm radius. Microglia nodules are usually considered morphological hallmarks of chronic neuropathological processes, such as viral encephalopathies, axonal damages, or neurodegenerative changes [22].

We next explored the spatial distribution of marker expression within single brain sections. To achieve this, we compartmentalized the dataset into regions containing microglia nodules and non-microglia-nodule areas, utilizing our previously developed microglia nodule index (Fig. 1g) [22]. We then compared the normalized marker expression of cells within nodules to those outside nodules in the medulla of post-COVID-19 patients (Fig. 1h). No statistically significant differences were observed for expression of P2RY12 or TMEM119 on microglia localized inside or outside the nodules allowing to unequivocally determine their cellular identity. Importantly, spatial analysis revealed a higher expression of CD11c, CD68, CD204, HLA-DR, HLA-DRA, HLA-DRB1, and SCAMP2 on P2RY12+TMEM119+ microglia within nodules. No differences were observed for CD74 and CD206. Collectively, these data identify the innate rather than the adaptive immune system as main functional player in post-COVID-19 brains and highlight the microglia nodule compartment as the key site of local tissue immune responses.
Persistent activation of microglia characterizes the CNS of post-COVID-19 patients

After having identified microglia nodules as the main immune feature of post-COVID-19 brains, we next asked for the chronicity and the functional relevance of this phenomenon, as these structures are usually absent in healthy brain tissue. Importantly, we found microglia nodules widespread present among post-COVID-19 brains compared to controls (Fig. 2a). Upon quantification, the number of microglia nodules was significantly higher in post-COVID-19 patients when compared to controls, but less frequent compared to acute COVID-19 brains (Fig. 2b). SARS spike glycoprotein immunohistochemistry did not reveal positive signal in the brain parenchyma, indicating the absence of viral presence (Supplementary Fig. 2). To evaluate the consequences of chronic microgliosis, we then assessed the extent of neuronal damage using immunohistochemistry for the amyloid precursor protein (APP), a surrogate marker for axonal damage (Fig. 2c). Although a significant increase in APP deposits was evident in acute COVID-19 cases, only individual patients in the post-COVID cohort exhibited deposits without reaching statistical significance for this group. Because COVID-19 may predispose individuals to develop Parkinson’s disease later in life [25], we investigated the cohort for the presence of alpha-synuclein deposits. In post-COVID-19 brains, we did not observe a significant increase of alpha-synuclein aggregates, a hallmark of several neuropathological conditions that show microglia nodules such as Parkinson’s disease (PD), dementia with Lewy Bodies (DLB), multiple system atrophy (MSA), and others [11] (Fig. 2d). In sum, obvious neuropathological correlates of neurodegeneration were absent from the investigated post-COVID-19 brains even at later stages.

Fig. 2
figure 2

Persistent activation of microglia characterizes the CNS of post-COVID-19 patients. a Representative immunohistochemistry for Iba1 (brown) depicting typical microglial nodules (asterisks) in various medulla oblongata samples from post-COVID-19 and control brain samples. Counterstaining with haematoxylin (blue). Scale bars: 100 µm. b Left: quantification of microglia nodules in the medulla of controls, acute COVID-19 and post-COVID-19 patients. P values were determined using Brown–Forsythe and Welsh ANOVA test with Dunnett’s T3 multiple comparisons test. Bars represent means ± SEM. Each symbol represents one patient. Right: quantification thereof. Acute COVID-19 patients and controls are plotted at the 0 month time point. Green line indicates the mean of controls. c Left: illustrative picture of amyloid precursor protein (APP, brown) immunohistochemistry for axonal damage in the upper medulla. Counterstaining with haematoxylin. Scale bar: 100 µm. Arrows indicate APP+ deposits. Right: quantification of APP deposition. Each symbol represents one patient. Bars represent means ± SEM. Brown–Forsythe and Welsh ANOVA test with Dunnett’s T3 multiple comparisons test were performed. P values are shown. d Left: typical immunohistochemistry for alpha-synuclein (brown) in the brain stems of controls, Parkinson’s disease patients (used as control), and post-COVID-19 patients. Scale bar: 100 µm. Arrows indicate alpha-synuclein deposits. Right: quantification thereof. Each symbol represents one patient. Bars represent means ± SEM. Ordinary one-way ANOVA with Tukey’s multiple comparisons test was applied. P values are shown. e Protein levels of soluble YKL-40, TREM2, CD14, and neurofilament light chain (NF-light) measures by enzyme-linked immunosorbent assay (ELISA) in cerebrospinal fluid samples of Neuro-Long-COVID-19 patients and Post-COVID controls are shown. Each symbol represents one patient. Linear regression lines for each group are depicted. f Heatmap depicting CSF metabolites measured by targeted metabolomics. Colors indicate Spearman correlations of cerebrospinal fluid metabolites. Significance levels are indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001). Boxes show an adjusted FDR < 0.05

Full size image

To determine whether the histologically detectable persistent innate immune activation in post-COVID-19 brains is mirrored by any alterations in the cerebrospinal fluid (CSF), we analyzed this fluid compartment from 31 living individuals with clinically confirmed Neuro-Long-COVID-19 and respective controls (Supplementary Table 2). Neuro-Long-COVID-19 patients fulfilled the Post-COVID condition (PCC) criteria according to the WHO [23]. A few proteins have emerged as robust markers to monitor neuroinflammation in Alzheimer’s disease (AD) or multiple sclerosis due to their reproducible relation to pathological features of the disease: soluble TREM2 (sTREM2) as a marker of microglial activation [14], YKL-40 as an astroglia stimulation molecule [8], CD14 as myeloid cell activation protein [16] and neurofilament light chain (NF-light) as a correlate of neuronal damage. Notably, apart from the expected age-dependent increase, we did not observe higher levels of these markers in the clinically affected cohort compared to controls (Fig. 2e). Given the fact that microglia are metabolically active cells [7] that are extremely sensitive and versatile responders to minute changes of their microenvironment, we performed high-dimensional targeted metabolomics of the CSF and analyzed 67 metabolites in Neuro-Long-COVID-19 patients (Fig. 2f). Although typical metabolites associated with microglial activation, such as tryptophan, kynurenine, or glutamine, were clearly detectable, no major differences in the analyzed metabolite-levels between Neuro-Long-COVID-19 samples and controls were found using this highly sensitive method.

Discussion

Taken together, by combining high-dimensional histological CyTOF analyses with machine learning methods, we studied the complexity of the brain immune landscape after systemic COVID-19 infections at the single-cell level. In this study, we examined autopsy cases from COVID-19 survivors at different time points after SARS-CoV-2 challenge. Long-term neurological symptoms had not been reported in this cohort. Since an autopsy cohort of Neuro-Long-COVID-19 patients was not available to us at this time, we have analyzed cerebrospinal fluid from living individuals with clinically confirmed Neuro-Long-COVID-19 as the closest approximation. Patients in the autopsy cohort had reported full recovery from COVID-19. They were typically tested negative for SARS-CoV-2 after their COVID-19 infection during their lifetime. Based on neuropathological analyses of the autopsy tissue, typical neuropathological hallmarks of neuronal degeneration were not detectable in this patient cohort. Nevertheless, we observed a clear shift from the T-cell linked adaptive immune activation during acute COVID-19 expositions toward a pronounced local innate immune stimulation in the CNS following virus resolution in this cohort. Our data further suggest a pervasive local pro-inflammatory milieu upon transient SARS-CoV-2 challenge mirrored by the presence and perseverance of microglia nodules.

In a parallel approach, we analyzed a cohort of living patients with clinically confirmed Neuro-Long-COVID-19 according to the WHO's Post-COVID Condition (PCC) criteria. Using cerebrospinal fluid (CSF) samples from these patients, we employed ELISA and targeted metabolomics to investigate potential disease-specific patterns. However, we could not detect a distinct disease-specific pattern in these analyses.

Taken together, we observed a dysregulation of the innate immune system in the autopsy cohort of COVID-19 survivors who did not present with neurological symptoms during their lifetime. This dysregulation might also be apparent in COVID-19 survivor with long-term neurological symptoms (Neuro-Long-COVID-19), potentially playing a role in the disease pathogenesis. However, establishing a definitive link remains challenging due to the absence of a dedicated autopsy cohort of patients with confirmed Neuro-Long-COVID-19 at this time. Further studies are required to explore this aspect in the future.

References

    Boettler T, Csernalabics B, Salie H, Luxenburger H, Wischer L, Salimi Alizei E et al (2022) SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol 77:653–659. https://doi.org/10.1016/j.jhep.2022.03.040

    Bowe B, Xie Y, Al-Aly Z (2023) Postacute sequelae of COVID-19 at 2 years. Nat Med 29:2347–2357. https://doi.org/10.1038/s41591-023-02521-2

    Cervia-Hasler C, Bruningk SC, Hoch T, Fan B, Muzio G, Thompson RC et al (2024) Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science 383:eadg7942. https://doi.org/10.1126/science.adg7942

    Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y et al (2021) Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38:101019. https://doi.org/10.1016/j.eclinm.2021.101019

    Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P et al (2022) SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604:697–707. https://doi.org/10.1038/s41586-022-04569-5

    Eilertz D, Mitterer M, Buescher JM (2022) automRm: an R package for fully automatic LC-QQQ-MS data preprocessing powered by machine learning. Anal Chem 94:6163–6171. https://doi.org/10.1021/acs.analchem.1c05224

    Erny D, Dokalis N, Mezo C, Castoldi A, Mossad O, Staszewski O et al (2021) Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Cell Metab 33(2260–2276):e2267. https://doi.org/10.1016/j.cmet.2021.10.010

    Floro S, Carandini T, Pietroboni AM, De Riz MA, Scarpini E, Galimberti D (2022) Role of chitinase 3-like 1 as a biomarker in multiple sclerosis: a systematic review and meta-analysis. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000001164

    Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M et al (2021) Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain 144:1263–1276. https://doi.org/10.1093/brain/awab009

    Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR et al (2023) Distinguishing features of long COVID identified through immune profiling. Nature 623:139–148. https://doi.org/10.1038/s41586-023-06651-y

    Love S, Perry A, Ironside J, Budka H (2018) Greenfield’s neuropathology—two volume set. CRC Press, Boca Raton

    Matschke J, Lutgehetmann M, Hagel C, Sperhake JP, Schroder AS, Edler C et al (2020) Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 19:919–929. https://doi.org/10.1016/S1474-4422(20)30308-2

    Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P et al (2023) Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 380:e072529. https://doi.org/10.1136/bmj-2022-072529

    Morenas-Rodriguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suarez-Calvet M et al (2022) Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer’s disease: a longitudinal observational study. Lancet Neurol 21:329–341. https://doi.org/10.1016/S1474-4422(22)00027-8

    Mossad O, Nent E, Woltemate S, Folschweiller S, Buescher JM, Schnepf D et al (2021) Microbiota-dependent increase in delta-valerobetaine alters neuronal function and is responsible for age-related cognitive decline. Nat Aging 1:1127–1136. https://doi.org/10.1038/s43587-021-00141-4

    Nockher WA, Wick M, Pfister HW (1999) Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis. J Neuroimmunol 101:161–169. https://doi.org/10.1016/s0165-5728(99)00141-1

    Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK et al (2022) Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23:210–216. https://doi.org/10.1038/s41590-021-01113-x

    Radke J, Meinhardt J, Aschman T, Chua RL, Farztdinov V, Lukassen S et al (2024) Proteomic and transcriptomic profiling of brainstem, cerebellum and olfactory tissues in early- and late-phase COVID-19. Nat Neurosci. https://doi.org/10.1038/s41593-024-01573-y

    Schonberger K, Mitterer M, Glaser K, Stecher M, Hobitz S, Schain-Zota D et al (2023) LC-MS-based targeted metabolomics for FACS-purified rare cells. Anal Chem 95:4325–4334. https://doi.org/10.1021/acs.analchem.2c04396

    Schwabenland M, Bruck W, Priller J, Stadelmann C, Lassmann H, Prinz M (2021) Analyzing microglial phenotypes across neuropathologies: a practical guide. Acta Neuropathol 142:923–936. https://doi.org/10.1007/s00401-021-02370-8

    Schwabenland M, Mossad O, Sievert A, Peres AG, Ringel E, Baasch S et al (2023) Neonatal immune challenge poses a sex-specific risk for epigenetic microglial reprogramming and behavioral impairment. Nat Commun 14:2721. https://doi.org/10.1038/s41467-023-38373-0

    Schwabenland M, Salie H, Tanevski J, Killmer S, Lago MS, Schlaak AE et al (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity 54(1594–1610):e1511. https://doi.org/10.1016/j.immuni.2021.06.002

    Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WHOCCDWGoP-C- (2022) A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22:e102–e107. https://doi.org/10.1016/S1473-3099(21)00703-9

    Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC et al (2021) Attributes and predictors of long COVID. Nat Med 27:626–631. https://doi.org/10.1038/s41591-021-01292-y

    Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ (2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8:416–427. https://doi.org/10.1016/S2215-0366(21)00084-5

    Taquet M, Skorniewska Z, Hampshire A, Chalmers JD, Ho LP, Horsley A et al (2023) Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat Med 29:2498–2508. https://doi.org/10.1038/s41591-023-02525-y

    Windhager J, Zanotelli VRT, Schulz D, Meyer L, Daniel M, Bodenmiller B et al (2023) An end-to-end workflow for multiplexed image processing and analysis. Nat Protoc 18:3565–3613. https://doi.org/10.1038/s41596-023-00881-0

    Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP et al (2021) Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature 595:565–571. https://doi.org/10.1038/s41586-021-03710-0

    Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J et al (2024) Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. https://doi.org/10.1038/s41590-023-01724-6

    Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J et al (2023) Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 29:226–235. https://doi.org/10.1038/s41591-022-02116-3

Download references

Acknowledgements

The authors thank Klara Gerber and Dicle Dag for excellent technical assistance, and Alexandar Tzankov for his support of our work. M.S. is supported by the Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, and the IMM-PACT-Programme for Clinician Scientists, Department of Medicine II, Medical Center—University of Freiburg and Faculty of Medicine, University of Freiburg, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—413517907. J. H. is supported by the Berta-Ottenstein-Programme for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. K. W. is supported by the Margarete-von-Wrangell-Fellowship funded by the Ministry of Science, Research and the Arts of Baden-Württemberg. MP, JH, and MS were supported by the Ministry of Science, Research, and the Arts of Baden-Württemberg: Funding Initiative for the Study of Long-COVID (MWK33-7532-56/12/23). Light microscopy imaging was performed at the Lighthouse Core Facility that is funded in part by the Medical Faculty, University of Freiburg (Project Numbers 2023/A2-Fol; 2021/B3-Fol), the DKTK, and the DFG (Project Number 450392965). N.D. and S.F. acknowledge the support by the Botnar Research Centre for Child Health. B.O. and M.G. were supported by NATON as part of the Network University Medicine funded by the BMBF (Project No. 01KX2121). Graphical abstractions were created using BioRender.com.
Funding

Open Access funding enabled and organized by Projekt DEAL.

Author information

Authors and Affiliations

    Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany
    Marius Schwabenland, Dilara Hasavci, Thomas Blank & Marco Prinz

    Department of Neurology and Neuroscience, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
    Sibylle Frase, Katharina Wolf & Jonas A. Hosp

    Department of Neurosurgery, University Medical Center Freiburg, Freiburg, Germany
    Katharina Wolf & Juergen Beck

    Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
    Nikolaus Deigendesch

    Max Planck Institute for Immunobiology and Epigenetics, 79108, Freiburg, Germany
    Joerg M. Buescher

    Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
    Kirsten D. Mertz

    University of Basel, Basel, Switzerland
    Kirsten D. Mertz

    Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Benjamin Ondruschka

    Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    Hermann Altmeppen, Jakob Matschke & Markus Glatzel

    Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
    Stephan Frank

    Clinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Disease, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany
    Robert Thimme & Bertram Bengsch

    Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany
    Bertram Bengsch & Marco Prinz

Contributions

MS, DH, and JB performed experiments and analyzed the results. SiF, KW, JB, and JH examined and diagnosed patients and performed lumbar punctures. Brain autopsies were performed by MS, ND, KM, BO, HA, JM, MG, and StF. MP supervised the project. MP and MS wrote the manuscript. RT, JB, JH, TB, and BB were involved in designing parts of the project and contributed to the writing of the manuscript.
Corresponding author

Correspondence to Marco Prinz.
Ethics declarations
Conflict of interest

The authors declare no competing interests.
Additional information
Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information

Below is the link to the electronic supplementary material.
Supplementary file1 (PDF 5966 kb)
Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article

Schwabenland, M., Hasavci, D., Frase, S. et al. High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains. Acta Neuropathol 148, 11 (2024). https://doi.org/10.1007/s00401-024-02770-6

Download citation

    Received24 April 2024
    Revised15 July 2024
    Accepted15 July 2024
    Published25 July 2024
    DOIhttps://doi.org/10.1007/s00401-024-02770-6

Share this article
[...]

© 2024 Springer Nature
[*/quote*]
Logged

Krik

  • Jr. Member
  • *
  • Posts: 1724
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #15 on: August 22, 2024, 03:27:01 PM »

https://x.com/LadyChuan/status/1826629637780148363

[*quote*]
Lady Chuan @LadyChuan

My 7 year old niece, who contracted Covid 4x during the last school year,  no longer knows her cousin (my daughter) nor her Granddad.

A few days before her last infection she told my Mom how much she misses Granddad and how he would give her everything!

The week before her last infection she Facetime my daughter and I to recite her Bible verse for the week.

Then she got Covid, started losing things, has problems with word finding, and obvious memory loss.

This happened in May.

My SIL can’t get her in to see a Neurologist until November because all appointments are taken.

Is this the government AND the citizens of this country have decided is ok?

No one is protecting the kids…and in most instances, not even their parents.

Does my niece wear a Mask? Yes, when she is with her parents.

Does she wear it consistently at school?
Probably not…not one teacher is Mask and my SIL hasn’t seen another kid Masked since October.

If Masks are mandated in the school setting, they won’t be worn…and it seems that budgeting for clean air is off the table since school starts again next week.
4:36 PM · Aug 22, 2024
72.4K Views
[*/quote*]


https://x.com/LauraMiers/status/1826633630736687568

[*quote*]
Laura Miers @LauraMiers

I’m so sorry. This all sounds extremely familiar since the same thing is occurring in my household. We never got a choice since we were infected in early 2020, so that helps, but I still feel immense guilt. My kids all have new diagnoses & medical problems. Two of my kids are returning to in person— but they will be attending a school for kids who are disabled/chronically ill/neurodivergent/etc. Public school won’t take them because we all pretend the last 4 years never happened, so the school concluded there is no reason they shouldn’t have been in person for the last 3 years, & we shall be punished for it. My other kid will be in public. We are going to have ALL the exposures, & there is nothing I can do about it because the state of NY is cracking down so hard. It feels futile. I’ve resorted to counting down the days/months/years until all my kids will be out of school (if we survive that long.)
4:52 PM · Aug 22, 2024
9,802 Views
['/quote*]
Logged
REVOLUTION!

VanLaraklios

  • Jr. Member
  • *
  • Posts: 308

Virtually all children infected with COVID-19 show signs of blood vessel damage, study shows

Blood vessel damage means one damned thing for damned sure: BRAIN DAMAGE!

The study was done end of 2020. That is FOUR YEARS AGO!. For 4 years now it is known (based on this study)  that Covid destroys the brain. But instead of being careful and avoid exposition to the virus, people force their children into mass infection barracks, and even outlaw it to wear masks.

That is genocide to the whole population on earth.

We told you this since spring 2020. Get your asses moving.

Or die.


https://studyfinds.org/children-with-covid-blood-vessel-damage/

[*/quote*]
Home › Covid-19 News

Virtually all children infected with COVID-19 show signs of blood vessel damage, study shows
By John Anderer
Dec 09, 2020

PHILADELPHIA, Pa. — The news about coronavirus and children just got a lot worse. A troubling study by researchers at the Children’s Hospital of Philadelphia reports a “high proportion” of children infected with SARS-CoV-2 show elevated levels of a biomarker tied to blood vessel damage. Making matters worse, this sign of cardiovascular damage is being seen in asymptomatic children as well as kids experiencing COVID-19 symptoms.

Additionally, many examined children testing positive for SARS-CoV-2 are being diagnosed with thrombotic microangiopathy (TMA). TMA leads to clots in small blood vessels and has been linked to severe COVID symptoms among adult patients.

“We do not yet know the clinical implications of this elevated biomarker in children with COVID-19 and no symptoms or minimal symptoms,” says co-senior author David T. Teachey, MD, Director of Clinical Research at the Center for Childhood Cancer Research at CHOP, in a media release. “We should continue testing for and monitoring children with SARS-CoV-2 so that we can better understand how the virus affects them in both the short and long term.”
The complex connection between kids and COVID

It’s fairly well established at this point that most children who contract coronavirus experience little to no symptoms. However, a small portion of young patients develop major symptoms or a post-viral inflammatory response to COVID-19 called Multisystem Inflammatory Syndrome in Children (MIS-C).

TMA in adults has a connection to more severe cases of COVID-19. Scientists believe the component of the immune system called “complement cascade” helps to mediate TMA in adults. The complement cascade is supposed to enhance and strengthen immune responses when a threat is present, but it can also backfire and lead to more inflammation. Up until now, the role of complement cascade during childhood TMA hadn’t been investigated.

To research the topic of “complement activation” in kids with SARS-CoV-2, researchers analyzed a group of 50 pediatric COVID-19 patients between April and July 2020. Among the group, 21 showed minimal to no symptoms, 11 experienced severe symptoms, and 18 developed MIS-C.

To search for complement activation and TMA among each patient, researchers used soluble C5b9 (sC5b9) as a biomarker. Scientists have used this substance for quite some time to assess the severity of TMA after stem cell procedures. In brief terms, the higher the level of sC5b9 in a transplant patient, the greater their mortality risk.
No symptoms doesn’t mean there’s no problem

Study authors discovered elevated levels of C5b9 in both patients with severe COVID-19 and MIS-C. While this didn’t surprise researchers, they did get a shock from seeing high levels of C5b9 among even asymptomatic youngsters.

Some of the lab data regarding TMA had to be obtained after the fact. This meant researchers didn’t have a complete dataset to work with for all 50 studied patients. Among 22 patients researchers did have complete data for, 86 percent (19 children) were diagnosed with TMA. Every child had elevated levels of sC5b9, even those without TMA.

“Although most children with COVID-19 do not have severe disease, our study shows that there may be other effects of SARS-CoV-2 that are worthy of investigation,” Dr. Teachey concludes. “Future studies are needed to determine if hospitalized children with SARS-CoV-2 should be screened for TMA, if TMA-directed management is helpful, and if there are any short- or long-term clinical consequences of complement activation and endothelial damage in children with COVID-19 or MIS-C. The most important takeaway from this study is we have more to learn about SARS-CoV-2. We should not make guesses about the short and long-term impact of infection.”

The study is published in Blood Advances.
https://ashpublications.org/bloodadvances/article/4/23/6051/474421/Evidence-of-thrombotic-microangiopathy-in-children
[*/quote*]





https://ashpublications.org/bloodadvances/article/4/23/6051/474421/Evidence-of-thrombotic-microangiopathy-in-children

[*quote*]
VASCULAR BIOLOGY| December 8, 2020

Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations

Clinical Trials & Observations
Caroline Diorio,
Kevin O. McNerney,
Michele Lambert,
Michele Paessler,
Elizabeth M. Anderson,
Sarah E. Henrickson,
Julie Chase,
Emily J. Liebling,
Chakkapong Burudpakdee,
Jessica H. Lee,
Frances B. Balamuth,
Allison M. Blatz,
Kathleen Chiotos,
Julie C. Fitzgerald,
Therese M. Giglia,
Kandace Gollomp,
Audrey R. Odom John,
Cristina Jasen,
Tomas Leng,
Whitney Petrosa,
Laura A. Vella,
Char Witmer,
Kathleen E. Sullivan,
Benjamin L. Laskin,
Scott E. Hensley,
Hamid Bassiri,
Edward M. Behrens,
David T. Teachey
Crossmark: Check for Updates
Blood Adv (2020) 4 (23): 6051–6063.
https://doi.org/10.1182/bloodadvances.2020003471
Article history

    Split-Screen
    Share Icon
    Share
    Tools Icon
    Tools
    Open the
    PDF for in another window

Key Points

    sC5b9 plasma levels are elevated in children with SARS-CoV-2 infection, even if they have minimal symptoms of COVID-19.

    A high proportion of children with SARS-CoV-2 infection met clinical criteria for TMA.

Visual Abstract
graphic
View largeDownload slide
Abstract

Most children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have mild or minimal disease, with a small proportion developing severe disease or multisystem inflammatory syndrome in children (MIS-C). Complement-mediated thrombotic microangiopathy (TMA) has been associated with SARS-CoV-2 infection in adults but has not been studied in the pediatric population. We hypothesized that complement activation plays an important role in SARS-CoV-2 infection in children and sought to understand if TMA was present in these patients. We enrolled 50 hospitalized pediatric patients with acute SARS-CoV-2 infection (n = 21, minimal coronavirus disease 2019 [COVID-19]; n = 11, severe COVID-19) or MIS-C (n = 18). As a biomarker of complement activation and TMA, soluble C5b9 (sC5b9, normal 247 ng/mL) was measured in plasma, and elevations were found in patients with minimal disease (median, 392 ng/mL; interquartile range [IQR], 244-622 ng/mL), severe disease (median, 646 ng/mL; IQR, 203-728 ng/mL), and MIS-C (median, 630 ng/mL; IQR, 359-932 ng/mL) compared with 26 healthy control subjects (median, 57 ng/mL; IQR, 9-163 ng/mL; P < .001). Higher sC5b9 levels were associated with higher serum creatinine (P = .01) but not age. Of the 19 patients for whom complete clinical criteria were available, 17 (89%) met criteria for TMA. A high proportion of tested children with SARS-CoV-2 infection had evidence of complement activation and met clinical and diagnostic criteria for TMA. Future studies are needed to determine if hospitalized children with SARS-CoV-2 should be screened for TMA, if TMA-directed management is helpful, and if there are any short- or long-term clinical consequences of complement activation and endothelial damage in children with COVID-19 or MIS-C.
Subjects:
Clinical Trials and Observations, Thrombosis and Hemostasis, Vascular Biology
Introduction

During the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), three distinct clinical phenotypes have emerged in children. Most children with acute SARS-CoV-2 infection are asymptomatic or develop mild symptoms.1-3  A small proportion of acutely infected children, typically adolescents with significant comorbidities, develop severe respiratory symptoms requiring hospitalization or admission to the pediatric intensive care unit.1,2,4  In addition, some children develop multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory syndrome characterized by fever, inflammation, and organ dysfunction in the setting of recent SARS-CoV-2 infection. With few exceptions, MIS-C seems to uniquely affect children.5-8  Severe cases of MIS-C present with shock and cardiovascular collapse, with 60% to 80% of children requiring pediatric intensive care unit care in recent large studies.5,6,9  MIS-C seems to be a postinfectious immune-mediated phenomenon distinct from other manifestations of SARS-CoV-2.10,11  The pathophysiology of these presentations is currently unknown.

High rates of thrombosis and thrombotic-related complications have been reported in adult patients with severe COVID-19.12,13  These complications have been reported in healthy young people, without prior comorbidities, raising the concern that thrombotic complications could be directly caused or exacerbated by SARS-CoV-2 infection.12  Studies in adults have invoked thrombotic microangiopathy (TMA) as a potential cause for severe manifestations of COVID-19.14-16  TMA results from endothelial cell damage to small blood vessels, leading to hemolytic anemia, thrombocytopenia, and, in some cases, organ damage.17-21  TMA has been reported in postmortem studies of adult patients with COVID-19.22

One proposed mechanism for SARS-CoV-2–mediated TMA is via complement activation.15-18  Complement dysregulation results in unregulated formation of the C5b9 membrane attack complex, leading to the clinical manifestations of TMA. Soluble C5b9 (sC5b9) is a clinically available biomarker and has been implicated as an indicator of severity in hematopoietic stem cell transplant–associated TMA (HSCT-TMA), as patients with markedly elevated sC5b9 have increased mortality.23  In mouse models of the related coronaviruses (SARS-CoV and Middle East respiratory syndrome coronavirus), knockout or blockade of components of the alternative complement pathway led to amelioration of severe respiratory syndromes and a decrease in cytokine production.24,25

In an initial small cohort of children, we previously showed that sC5b9 levels may be elevated across the spectrum of manifestations of SARS-CoV-2 infections.11  We did not, however, evaluate whether these children met the clinical criteria for diagnosis of TMA nor did we compare these values vs those of healthy control subjects. We hypothesized that sC5b9 was a marker of TMA in patients with evidence of SARS-CoV-2 infection. Here, we present serum levels of sC5b9 in healthy control subjects and in children with acute SARS-CoV-2 or MIS-C, and evaluate these cohorts for the clinical and laboratory findings of TMA.
Methods
Study design and population

We prospectively enrolled patients admitted to the Children’s Hospital of Philadelphia (CHOP) during the COVID-19 pandemic who had a positive SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) from upper respiratory tract mucosa, or who met clinical criteria for MIS-C. The enrollment criteria have been previously described.11  Patients were classified into 3 groups: minimal COVID-19, severe COVID-19, or MIS-C. Minimal COVID-19 was defined as patients with an incidental finding of COVID-19 during routine testing before admission or a procedure, or those with mild COVID-19 symptoms that did not require noninvasive mechanical ventilation (including high-flow nasal cannula, continuous positive airway pressure, or bilevel positive airway pressure). Severe COVID-19 was defined as patients requiring new noninvasive or invasive mechanical ventilation, or escalation above their baseline invasive or noninvasive mechanical ventilation. MIS-C was defined per the Centers for Disease Control and Prevention criteria as patients who had fever, laboratory evidence of inflammation, illness with at least 2 organ systems involved (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurologic), no alternative plausible diagnosis and positive SARS-CoV-2 infection by RT-PCR, serology (performed in a Clinical Laboratory Improvement Amendments/College of American Pathologists [CLIA/CAP] laboratory), or proven COVID-19 exposure to a close contact within 4 weeks before onset of symptoms.26  Patients were prospectively classified into one of these groups by physicians with expertise in pediatric hematology/oncology (C.D. and D.T.T.), pediatric infectious diseases (H.B.), and pediatric rheumatology (E.M.B.). Adjudicators were blinded to sC5b9 levels and TMA clinical criteria at the time of classification into these groups. All patients who consented were enrolled in a consecutive manner. If patients were subsequently found to not meet criteria (ie, false-positive SARS-CoV-2 infection or different infectious etiology determined as cause of MIS-C symptoms), they remained enrolled but were excluded from analyses.

Subject samples were compared with those of normal control samples obtained from the coagulation laboratory at CHOP. Discarded plasma collected from otherwise healthy children who had been evaluated for symptoms of a bleeding disorder (eg, epistaxis, menorrhagia) was used for the control groups. A limited chart review was performed to confirm that these patients had no comorbid medical illness or medical problems. Children who were found to have comorbid medical issues, other than underlying bleeding disorders, were excluded.

Patients were categorized as having TMA based on the following 7 criteria, adapted from Gloude et al27 : elevated lactate dehydrogenase (LDH) levels greater than the upper limit of normal for age, schistocytes on blood smear, new thrombocytopenia below the normal range for age, new anemia below the normal range for age, evidence of proteinuria (≥1+ proteinuria [30 mg/dL] on random urinalysis or random urine protein/creatinine ratio ≥2 mg/mg), hypertension (blood pressure >99th percentile for age, sex, and height if aged <18 years, ≥140 mm Hg systolic or 90 mm Hg diastolic if aged ≥18 years, at least twice during the admission, or if receiving antihypertensive therapy for new hypertension), and elevated sC5b9. To meet criteria for TMA, patients had to meet at least 5 of the 7 criteria during their hospital admission for COVID-19 or MIS-C. Hematoxylin and eosin–stained peripheral blood smears were independently examined for schistocytes by a hematologist and hematopathologist, who were blinded to the categorization and clinical histories of patients, as well as to the other examiners’ findings. In a subsequent analysis, a simple set of clinical criteria was proposed to define TMA in settings in which sC5b9 and other diagnostics may be unavailable. These criteria included the presence of thrombocytopenia, microangiopathic hemolytic anemia (anemia for age and schistocytes on a peripheral blood smear), and organ dysfunction. Organ dysfunction was defined as renal dysfunction, liver dysfunction (bilirubin levels >2 times the upper limit of normal for age, alanine aminotransferase or aspartate aminotransferase levels >3 times the upper limit of normal), or cardiac dysfunction (troponin levels greater than the upper limit of normal or requirement for inotropic support). The glomerular filtration rate (GFR) was calculated by using the original Schwartz formula.28  Patients were classified as having renal dysfunction according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria.29  Baseline creatinine was defined as the lowest creatinine level in the 3 months before admission or, if unavailable, was calculated per KDIGO definitions. Acute kidney injury (AKI) was defined as KDIGO stage 2 or higher (at least a twofold increase from baseline).

Two different sensitivity analyses with highly stringent criteria were performed. First, we evaluated all patients included in the clinical cohort for TMA based on the aforementioned criteria. In this analysis, we imputed all missing data as negative. In the second sensitivity analysis, sC5b9 was excluded in the criteria for TMA. We used the remaining 6 clinical criteria to classify all patients as having clinical TMA (met 5 or 6 criteria), being indeterminate (4 criteria), or not meeting criteria for TMA (≤3 criteria). In patients who were deemed indeterminate, we looked at whether sC5b9 elevation would lead them to meet criteria for TMA.
Data collection

Data were abstracted from the patient chart on to a standardized case report form using a Research Electronic Data Capture database (Vanderbilt University, Nashville, TN) hosted at CHOP.30  Data were abstracted by a physician or a research assistant. All data elements extracted were validated by a physician. Data collected included demographic information, comorbid conditions, and most extreme laboratory values for laboratory studies of interest. Clinical criteria for TMA were abstracted as outlined earlier.
Blood collection and assays

Blood draws were obtained in conjunction with the first clinical blood draw after consent was obtained, within the first 2 weeks of the positive SARS-CoV-2 test or admission for MIS-C. For most patients, blood samples were obtained within 48 hours of admission. Blood was collected in a lithium heparin tube and processed into plasma and cell pellets. Separated components were frozen for batched analysis.
Proinflammatory cytokine profiling

Ten proinflammatory cytokines were measured (interferon-γ, interleukin IL-1β [IL-1β], IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor necrosis factor-α) using V-Plex Pro-inflammatory Panel 1 Human Kits (catalog #K15049D; Meso Scale Diagnostics, Rockville, MD). All assays were performed in duplicate, according to the manufacturer’s protocol. Assays were read and analyzed on a QuickPlex SQ120 (Meso Scale Diagnostics). Of particular interest to TMA is the neutrophil chemotactic factor IL-8, due to its role as a marker of endothelial damage.31
sC5b9 assay

Plasma samples were assayed for sC5b9 at 2 dilutions by using a human C5b9 enzyme-linked immunosorbent assay (ELISA) set (#558315; BD Biosciences, San Jose, CA) according to the manufacturer’s protocols. All samples were assayed in triplicate. Standard curves were used to derive sC5b9 levels from best fit curves.

The upper limit of normal for the sC5b9 assay was set as 247 ng/mL, based on the upper limit of normal defined by two CLIA/CAP clinical assays (250 ng/mL, Machaon Diagnostics, Oakland, CA; 244 ng/mL, Cincinnati Children’s Hospital, Cincinnati, OH). We validated this upper limit of normal on our research-based ELISA by running samples from 26 healthy control subjects; the mean value from these controls was 84.5 ng/mL, and two standard deviations above this mean was 247 ng/mL.
SARS-CoV-2–specific antibodies

Complement is believed to be activated by coronaviruses in large part via the alternative pathway.24,25  Furthermore, in the complement-mediated TMA syndromes, complement is activated by the loss of negative regulation of the alternative pathway.30  We previously showed that most patients, and specifically patients with MIS-C, had elevations in anti–SARS-CoV-2 antibody titers.31  We considered whether sC5b9 elevations may be related to classical pathway activation from antiviral antibody–antigen complexes rather than the alternative complement activation of TMA. SARS-CoV-2–specific antibodies were measured by using ELISA as previously described.32  Serum IgG, IgA, and IgM antibodies against the receptor-binding domain (RBD) of the spike protein were measured.32,33  Optical densities at the 450 nm wavelength were obtained on a SpectraMax 190 Microplate Reader (Molecular Devices, San Jose, CA). Serum antibody titers are expressed as the reciprocal serum dilution at a set optical density based on a standard from the monoclonal antibody CR3022 starting at 0.5 μg/mL.
Statistical analyses

Analysis and visualizations were performed by using Prism 8 (GraphPad, San Diego, CA) and Stata/IC (StataCorp, College Station, TX). Descriptive statistics were used to summarize characteristics in each group. Pairwise comparisons were performed by using Kruskal-Wallis testing. The Mann-Whitney U test was used to compute P values between 2 groups, and post hoc Dunn’s test for multiple comparisons was used to compute P values. Pearson’s r was used to calculate correlations between sC5b9 and clinical variables and to examine the relationship between sC5b9 and log-transformed viral titers. The χ2 test was used to compare count data.
Study approval

This study was conducted according to the guidelines of the Declaration of Helsinki. Due to the COVID-19 pandemic, verbal consent was obtained from a legally authorized representative, with consent forms signed by the consenting physician or research assistant and a physical copy provided to the consenting party. Assent was obtained from children aged >7 years, if appropriate. The study protocol was approved by the Institutional Review Board (IRB) at CHOP. For healthy control subjects, protected health information was not recorded. The CHOP IRB determined that the limited chart review of this control cohort met the IRB exemption criteria per 45 CFR 46.104(d) 4(ii) and waiver of Health Insurance Portability and Accountability Act of 1996 authorization.
Results

Between 3 April 2020, and 7 July 2020, a total of 112 patients were screened and 58 were enrolled. Fifty patients were included in this analysis for whom complete sC5b9 data were available (supplemental Figure 1). All included patients had either a positive SARS-CoV-2 PCR or a positive SARS-CoV-2 antibody test. Patients were classified into the 3 categories described earlier: minimal COVID-19 (n = 21), severe COVID-19 (n = 11), or MIS-C (n = 18). In addition, remnant plasma on healthy control subjects was collected (n = 26). Demographic characteristics of the patients are presented in Table 1. Clinical characteristics were consistent with previously reported pediatric patients with MIS-C and COVID-19.5,7  Twenty of these patients (n = 5, minimal COVID-19; n = 9, severe COVID-19; and n = 6, MIS-C) were included in a previously published analysis, focused on comparing clinical features and cytokines between groups.11  Study identifiers have been included to allow for comparison across reports.
Table 1.

Demographic data associated with patients included in the sample
Variable   Minimal COVID-19 (n = 21)   Severe COVID-19 (n = 11)   MIS-C (n = 18)
Age, median (IQR), y    13 (5-17)    15 (14-17)    9 (7-13)
Sex, n (%)            
 Female    9 (43)    6 (55)    9 (50)
 Male    12 (57)    5 (45)    9 (50)
Race, n (%)            
 White    8 (38)    5 (45)    8 (44)
 Black    10 (48)    3 (27)    7 (39)
 Other    3 (14)    2 (18)    2 (11)
 Declined or not reported    0    1 (9)    1 (6)
Ethnicity, n (%)            
 Hispanic    4 (19)    3 (27)    3 (17)
 Not Hispanic    17 (81)    7 (64)    14 (78)
 Declined    0    1 (9)    1 (6)
BMI percentile, median (IQR)    65 (19.9-90.23); n = 19    82 (65-95)    93 (80-98)
Pediatric intensive care unit admission, n (%)            
 Yes    2 (10)    11 (100)    13 (72)
 No    19 (90)    0    5 (28)
Extracorporeal membrane oxygenation, n (%)            
 Yes    0    2 (18)    0
 No    21 (100)    9 (82)    18
Inotropic support, n (%)            
 Yes    0    8 (73)    12 (67)
 No    21 (100)    3 (27)    6 (33)
Invasive mechanical ventilation, n (%)            
 Yes    1 (5)*    9 (82)    4 (22)
 No    20 (95)    2 (18)    14 (78)
Liver dysfunction,†n (%)            
 Yes    5 (24)    5 (45)    3 (17)
 No    16 (76)    6 (55)    15 (83)
Renal dysfunction,‡n (%)            
 Yes    2 (10)    4 (36)    5 (28)
 No    16 (76)    7 (64)    13 (72)
 Not available    3 (14)        
Dialysis, n (%)            
 Yes    0    1 (9)    0
 No    21 (100)    10 (91)    18 (100)
Hypertension,§n (%)            
 Yes    11 (52)    9 (82)    10 (56)
 No    10 (48)    2 (18)    8 (44)
Proteinuria, n (%)            
 Yes    7 (33)    8 (72)    12 (66)
 No    7 (33)    3 (27)    4 (22)
 Not available    7 (33)    0    4 (22)
Outcome, n (%)            
 Discharged    21 (100)    7 (64)    18 (100)
 Remains hospitalized    0    2 (18)    0
 Death    0    2 (18)    0
*

One patient with minimal COVID-19 symptoms was admitted during a trauma team activation and was intubated for airway protection.


Defined as bilirubin levels >2 times the upper limit of normal for age, alanine aminotransferase or aspartate aminotransferase levels >3 times the upper limit of normal.


Defined according to KDIGO criteria.
§

Defined as blood pressure >99th percentile for age, height, and sex.

Laboratory data are presented in Table 2. If <50% of the patients in the group had data available for a given laboratory value, these data were excluded from the table. Median D-dimer values tended to be higher in patients with MIS-C than in those with severe COVID-19. Patients with severe COVID-19 and MIS-C had highly elevated inflammatory markers, including ferritin and C-reactive protein. Patients with MIS-C also had evidence of acute cardiac injury with elevated troponin and B-type natriuretic peptide protein levels.
Table 2.

Median, IQR, and number of patients of the most extreme laboratory values during the admission for patients included in the sample
Value (reference range)   Minimal COVID-19   Severe COVID-19   MIS-C
Median (IQR)   n   Median (IQR)   n   Median (IQR)   n
Coagulation
 D-dimer, highest (0.27-0.60 μg/mL FEU)    —        2.53 (0.6-20.5)    11    4.93 (3.42-5.75)    17
 PT, highest (11.6-13.8 s)    —        16 (13.2-31)    11    15.4 (14.4-17.4)    18
 PTT, highest (22-36 s)    —        52.4 (37.5-78.8)    11    31.8 (28.4-36.6)    17
 Fibrinogen (172-471 mg/dL)                    
  Lowest    —        297 (239-332)    10    297 (237-370)    17
  Highest    —        488 (305-890)    10    572 (484-721)    17
Chemistry
 AST, highest (10-30 U/L)    59 (40-72)    17    123 (54-627)    11    88 (63-104)    18
 Creatinine, highest (0.3-0.8 mg/dL)    0.4 (0.3-0.8)    19    0.7 (0.3-2.3)    11    0.6 (0.5-1.3)    18
 GFR, minimum (mL/min)    193 (108-221)    18    111 (40-243)    11    136 (65-182)    18
 BUN, highest (7-18 mg/dL)    12 (7-23)    19    23 (13-34)    11    21.5 (16-39)    18
Hematology
 Platelets (150-400 K/μL)                        
  Lowest    220 (127-295)    21    128 (78-165)    11    141 (121-194)    18
  Highest    414 (165-363)    21    311 (223-347)    11    414 (275-483)    18
 Hemoglobin, lowest (12-16 g/dL)    9.2 (7.4-11.9)    21    8.9 (6.7-11.1)    11    8.9 (7.9-10)    18
Inflammatory and cardiac
 Ferritin, highest (10.0-82.0 ng/ml)    —        419 (164-2747)    10    806 (665-1162)    17
 CRP, highest (0-0.9 mg/dL)    13.9 (3.1-18.3)    11    30.3 (7-34.9)    11    23.7 (19-34.6)    18
 ESR, highest (0-20 mm/h)    —        –        59 (43-82)    17
 BNP, highest (≤100 pg/mL)    —        307 (46-542)    8    997 (510-1242)    17
 Troponin, highest (<0.3 ng/ml)    —        0.13 (0.02-1.79)    9    0.39 (0.07-1.34)    17
 IL-8    10 (5-16.6)    15    32.7 (12.3-124)    11    37.3 (20.4-56.7)    17
 Interferon-γ    14 (4-150)    15    54 (12-100)    11    191 (41-481)    17
 sC5b9 (≤257 ng/mL)    392 (244-622)    21    646 (203-728)    11    630 (359-932)    18

Results were not reported if >50% of data were missing.

AST, aspartate transaminase; BNP, B-type natriuretic peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FEU, fibrinogen equivalent units; PT, prothrombin time; PTT, partial thromboplastin time.

The median sC5b9 level in the healthy control subjects (57 ng/mL; interquartile range [IQR], 9-163 ng/mL) differed significantly from that in patients with minimal disease (392 ng/mL; IQR, 244-622 ng/mL), severe disease (646 ng/mL; IQR, 203-728 ng/mL), and MIS-C (630 ng/mL; IQR, 359-932 ng/mL) (P < .001 in each case) (Figure 1A). There were no statistically significant differences between patients with minimal disease, severe disease, or MIS-C. One patient with minimal symptoms of COVID-19 but a very high sC5b9 (1568 ng/mL) was concomitantly diagnosed with systemic lupus erythematosus. To ensure that comorbidities such as lupus that can be associated with complement dysfunction were not confounding this relationship, we repeated this analysis but excluded all patients with a diagnosis of lupus, cancer, sickle cell disease, renal disease, or inflammatory disease. Levels of sC5b9 in patients with minimal COVID-19, severe COVID-19, and MIS-C remained elevated compared with levels from healthy control subjects (P < .0001) (supplemental Figure 2).
Figure 1.
Elevations in sC5b9 correlate with renal dysfunction. (A) Elevated sC5b9 levels in patients with minimal COVID-19 (n = 21), severe COVID-19 (n = 11), and MIS-C (n = 18) are significantly different relative to those of healthy control subjects (n = 26). (B) sC5b9 levels are significantly higher in those with AKI (n = 9) than without AKI (n = 38). Increases in sC5b9 levels in patients with all 3 manifestations of disease (N = 48) correlate in a statistically significant manner with elevations in creatinine (C) and in elevations of blood urea nitrogen (BUN; D) and GFR (E). Dotted line indicates upper limit of normal cutoff for sC5b9 of 247 ng/mL.
View largeDownload PPT

Elevations in sC5b9 correlate with renal dysfunction. (A) Elevated sC5b9 levels in patients with minimal COVID-19 (n = 21), severe COVID-19 (n = 11), and MIS-C (n = 18) are significantly different relative to those of healthy control subjects (n = 26). (B) sC5b9 levels are significantly higher in those with AKI (n = 9) than without AKI (n = 38). Increases in sC5b9 levels in patients with all 3 manifestations of disease (N = 48) correlate in a statistically significant manner with elevations in creatinine (C) and in elevations of blood urea nitrogen (BUN; D) and GFR (E). Dotted line indicates upper limit of normal cutoff for sC5b9 of 247 ng/mL.

Clinical TMA and sC5b9 elevations are closely associated with renal damage.17  We compared plasma sC5b9 levels between those with AKI (defined as KIDGO stage 2 or above) and those without AKI (KDIGO stage 1 or less), and found significantly higher sC5b9 levels in those with AKI (717 ng/mL; IQR, 404-1232 ng/mL) than in those without AKI (433 ng/mL; IQR, 232-706 ng/mL) (P = .0374) (Figure 1B). We next evaluated correlations between sC5b9, creatinine, GFR, and blood urea nitrogen in the entire combined cohort with SARS-CoV-2 or MIS-C. Because creatinine levels in children increase with age, the correlation between sC5b9 and age was also examined. Elevations in sC5b9 correlated in a statistically significant manner with the maximum creatinine (r = 0.36; P = .01), blood urea nitrogen (r = 0.29; P = .04), and GFR (r = –0.36; P = .01) measured during hospitalization (Figure 1C-E) but not with age (P = .512). In our cohort, 10% of minimal COVID-19, 36% of severe COVID-19, and 28% of MIS-C patients had evidence of AKI (Table 1).

In patients with severe COVID-19 and MIS-C, we examined correlations between sC5b9 and markers of inflammation, hemolysis, and coagulopathy, including ferritin, C-reactive protein, LDH, prothrombin time, partial thromboplastin time, fibrinogen, D-dimer, aspartate transaminase, hemoglobin, and platelets. Peak values were used for all except hemoglobin, in which the lowest value was used, and for fibrinogen and platelets, in which both peak value and lowest value were calculated. This analysis was limited to those with severe COVID-19 and MIS-C, due to a high proportion of missing data in children with minimal disease. Heatmaps of Pearson r correlations and P values are shown in Figure 2. sC5b9 did not correlate significantly with any of these variables. Clinical variables, including markers of coagulopathy and cytopenias, clustered together.
Figure 2.
Heatmaps of Pearson r correlations demonstrate clusertings of laboratory findings. Heatmaps of Pearson r correlations (A) and associated P values (B) for ancillary findings of thrombotic microangiopathy in patients with severe COVID-19 (n = 11) and patients with MIS-C (n = 18).
View largeDownload PPT

Heatmaps of Pearson r correlations demonstrate clusertings of laboratory findings. Heatmaps of Pearson r correlations (A) and associated P values (B) for ancillary findings of thrombotic microangiopathy in patients with severe COVID-19 (n = 11) and patients with MIS-C (n = 18).

Peripheral blood smears were available on 34 patients. Schistocytes were present in 5 (45%) of 11 patients with minimal COVID-19, 7 (87%) of 8 patients with severe COVID-19, and 13 (87%) of 15 patients with MIS-C (χ2 = 6.59; P = .037) (supplemental Figure 3). We retrospectively evaluated if patients met expanded clinical criteria for TMA in the subgroup of patients who had a blood smear, complete blood count, and LDH level available (n = 19). Of those patients, 17 (89%) met clinical criteria for TMA. sC5b9 levels were elevated both in patients who did and did not meet criteria for TMA (supplemental Figure 4). Some patients in the severe COVID-19 and minimal COVID-19 cohorts had comorbidities; these are listed in Table 3. Of note, all patients in the MIS-C group were previously healthy or had minimal comorbidities. Of those who met criteria for AKI in Figure 1B, 7 of 9 patients had all criteria for TMA assessed, and all 7 met criteria for TMA.
Table 3.

Criteria for TMA in patients with MIS-C, minimal COVID-19, and severe COVID-19
ID   Age, y   Other conditions   Elevated LDH   Schistocytes   Low platelets   Anemia   HTN   Protein in urine   Elevated sC5b9   Met criteria for TMA?   No. of criterion
Minimal COVID-19
 13    4    Sickle cell disease    ✓    ✓    ✓    ✓    ✓            Yes    5
 38    17    Obesity, asthma    ✓        ✓        ✓    ✓    ✓    Yes    5
 Summary: fraction (%)    2/2 (100)    1/2 (50)    2/2 (100)    1/2 (50)    2/2 (100)    1/2 (50)    1/2 (50)    2/2 (100)    
Severe COVID-19
 10    10    Panhypopituitarism    ✓    ✓    ✓    ✓        ✓    ✓    Yes    6
 33    15    Obesity, PCOS    ✓    ✓        ✓    ✓        ✓    Yes    5
 37    15    Obesity    ✓    ✓        ✓    ✓    ✓    ✓    Yes    6
 4    18    Obesity, hypertension, diabetes mellitus    ✓    ✓    ✓    ✓    ✓    ✓    ✓    Yes    7
 Summary: fraction (%)    4/4 (100)    4/4 (100)    2/4 (67)    4/4 (100)    3/4 (75)    3/4 (75)    4/4 (100)    4/4 (100)    
MIS-C
 19    5    Previously healthy        ✓    ✓    ✓    ✓    ✓    ✓    Yes    6
 22    6    Previously healthy    ✓    ✓        ✓    ✓    ✓    ✓    Yes    6
 18    6    Previously healthy    ✓    ✓    ✓    ✓    ✓    ✓    ✓    Yes    7
 24    7    Previously healthy    ✓    ✓    ✓    ✓    ✓        ✓    Yes    6
 29    8    Asthma    ✓    ✓            ✓    ✓    ✓    Yes    5
 44    8    Previously healthy    ✓    ✓        ✓    ✓        ✓    Yes    5
 55    8    Precocious puberty    ✓        ✓    ✓    ✓    ✓    ✓    Yes    6
 28    9    Previously healthy        ✓    ✓    ✓    ✓        ✓    Yes    5
 50    9    Previously healthy    ✓    ✓    ✓    ✓    ✓    ✓    ✓    Yes    7
 48    11    Previously healthy    ✓    ✓        ✓        ✓    ✓    Yes    5
 26    13    Previously healthy        ✓    ✓    ✓    ✓    ✓        Yes    5
 27    14    Previously healthy        ✓    ✓    ✓            ✓    No    4
 51    17    Asthma        ✓        ✓        ✓    ✓    No    4
 Summary: fraction (%)    8/13(61)    12/13 (92)    8/13(61)    12/13 (92)    10/13 (76)    9/13 (69)    12/13 (92)    11/13 (85)    

Criteria for TMA as defined by Gloude et al.27  Meeting at least 5 of the 7 criteria are required to meet definition. Protein in urine defined as random urine protein measurement ≥30 mg/dL or urine protein/creatinine ratio ≥2 mg/mg. Hypertension defined as >99th percentile for age, height, and sex. Check marks indicate that the criterion was met; blank spaces indicate that the criterion was not met.

B-ALL, B-cell acute lymphoblastic leukemia; HTN, hypertension; PCOS, polycystic ovarian syndrome.

We found that 13 (38%) of 34 patients met simple clinical criteria for TMA (microangiopathic hemolytic anemia, thrombocytopenia, and evidence of organ damage). In patients who met simple clinical criteria for TMA, the median sC5b9 level was 420 ng/mL, compared with 634 ng/mL in patients who did not meet simple criteria for TMA (P = .60). Urinalyses were available on 28 of these patients, and proteinuria was present in 9 of 13 patients who met criteria for simple TMA and 10 of 15 patients who did not (χ2 = 2.92; P = .09).

Supplemental Table 1 presents similar data on patients in whom full peripheral blood smears, LDH levels, and complete blood count were not available. We performed a sensitivity analysis and evaluated whether all patients, regardless of whether complete criteria were available, met criteria for TMA. For this analysis, sC5b9 elevations were included in the clinical criteria for TMA. All missing data were counted as negative. In total, 24 (48%) of 50 patients met criteria for TMA, including 21% of patients with minimal disease, 82% of patients with severe disease, and 61% of patients with MIS-C (supplemental Table 2). Summary data for patients according to disease category are presented in supplemental Tables 3-5.

We considered that sC5b9 elevations could be caused by an unknown pathophysiological process in SARS-CoV-2 patients other than TMA. We therefore performed a sensitivity analysis in which sC5b9 was not included in the criteria for TMA. To test the most stringent hypothesis, missing data were imputed to be negative. Fifteen (30%) of 50 patients still met criteria for TMA, 9 patients were indeterminate, and 26 patients did not meet criteria for TMA. Of the 9 indeterminate patients, all 9 had elevations in sC5b9 that would have led them to meet criteria for TMA if sC5b9 had been included.

To probe if the complement activation of SARS-CoV-2 infection could be related to immune complex and classical activation, we measured antibody response in the first 33 patients enrolled (12 minimal COVID-19, 11 severe COVID-19, and 10 MIS-C) and tested whether antibody titers correlated with sC5b9 levels. IgG, IgM, and IgA levels against the SARS-CoV-2 spike protein RBD did not significantly correlate with sC5b9 (Figure 3).
Figure 3.
Absence of correlation between sC5b9 elevatons and antibodies against SARS-CoV-2. Correlation between sC5b9 vs the logarithmically transformed value of IgG (A), IgM (B), and IgA (C) against the SARS-CoV-2 RBD protein for a subset of included patients with MIS-C (n = 10), severe disease (n = 11), and minimal disease (n = 12).
View largeDownload PPT

Absence of correlation between sC5b9 elevatons and antibodies against SARS-CoV-2. Correlation between sC5b9 vs the logarithmically transformed value of IgG (A), IgM (B), and IgA (C) against the SARS-CoV-2 RBD protein for a subset of included patients with MIS-C (n = 10), severe disease (n = 11), and minimal disease (n = 12).

Levels of IL-8, measured as a marker of endothelial dysfunction, differed significantly between patients with MIS-C (P = .0166) and patients with severe COVID-19 (P = .0079), when compared with minimal COVID-19 patients, but not between patients with MIS-C and severe disease (P = .99) (supplemental Figure 5). Levels of IL-8 did not correlate with elevations in sC5b9 (P = .184). Levels of interferon-γ differed significantly between patients with minimal disease and MIS-C (P = .01) but not between those with MIS-C and severe disease (P = .13) or between those with minimal disease and severe disease (P > .99).
Discussion

We shows activation of the final common pathway of complement activation in the 3 most commonly described presentations of SARS-CoV-2 in pediatric patients. Strikingly, sC5b9 levels were abnormal even in children with minimal disease or an incidental finding of SARS-CoV-2 infection, suggesting that any exposure to SARS-CoV-2 may be sufficient to induce elevations in this biomarker. In addition, schistocytes were prevalent in blood smears of patients with minimal COVID-19, severe COVID-19, and MIS-C. IL-8, a marker of endothelial damage, was also significantly higher in patients with MIS-C and severe COVID-19 compared with the minimal COVID-19 group.34  These findings together suggest more severe endothelial dysfunction in MIS-C and severe COVID-19. The majority (19 of 22) of children who had all laboratory and clinical criteria for TMA measured met criteria for TMA, as did 8 of 9 patients with AKI. Even in children on whom all criteria were not measured, and when missing values were assumed to be negative, nearly one-half (48%) met criteria for TMA.

Elevations in sC5b9 correlated with evidence of renal dysfunction, implying that higher levels of terminal complement activation were associated with renal injury. Elevations in sC5b9 occurred independently of laboratory features associated with TMA such as elevations in LDH and decreases in platelets and hemoglobin. sC5b9 was also elevated independently of inflammatory markers. The presence of elevated sC5b9 levels in all SARS-CoV-2 groups compared with healthy control subjects suggests that complement activation and thrombotic microangiopathy are prevalent in pediatric patients with SARS-CoV-2 infections.

The presence of elevated sC5b9 even in children with minimal symptoms of COVID-19 disease is particularly striking. This finding implies that SARS-CoV-2 clinical syndromes are associated with robust complement activation, even when symptoms are minimal. We also found higher levels of complement activation in patients with more severe manifestations of COVID-19 than in those with minimal COVID-19, implying that some degree of complement activation may be necessary to combat the virus, but excessive complement activation may lead to an overly robust immune response. Notably, patients with MIS-C, who have generally cleared SARS-CoV-2 infection at the time of presentation, also had high levels of complement activation. We would therefore expect that the particle which incites complement activation is no longer present. This implies that prolonged and excessive activation in the host may be what leads to pathology. sC5b9 elevations did not correlate with SARS-CoV-2 RBD antibody production, which suggests that anti–SARS-CoV-2 immune complex is likely not the driving force of complement activation in these patients. Previous studies have shown that proteins on SARS-CoV-2 contain mannose groups recognized by the mannose-binding lectin complement pathway, and autopsy specimens of lungs from patients who have died of COVID-19 have exhibited immunohistochemistry staining for mannose-binding lectin, C3, C4, and sC5b9.35  Direct viral activation of the complement cascade by the alternative pathway has been previously shown in mouse models of the related coronaviruses SARS-CoV-1 and Middle East respiratory syndrome coronavirus.24,25  SARS-CoV-2 has been shown to infect tissues with angiotensin-converting enzyme 2 receptor expression, including the lungs, heart, kidneys, intestines, and endothelial cells, suggesting a mechanism of viral infection, complement activation, and vascular and organ injury.35,36  MIS-C is hypothesized to be a postinfectious etiology; it is not clear if complement activation in MIS-C occurs by the same mechanism as in acute SARS-CoV-2 infection.10,11  Future work will need to better elucidate the role of the complement cascade in the pathogenesis of MIS-C and COVID-19 in children, particularly given the high rates of TMA seen in this population.

Regardless of the mechanism of complement activation in SARS-CoV-2 infection, the finding of elevated sC5b9 in children across the spectrum of presentations of SARS-CoV-2 is an important area for future inquiry. Elevations in sC5b9 have been shown to be associated with an increased risk of death in pediatric HSCT-TMA.23  The pathophysiology of complement activation in pediatric patients is likely similar to that in adult patients.37  A key treatment of HSCT-TMA in pediatric patients is eculizumab, a monoclonal antibody against the complement protein C5.34,38  Although eculizumab has been shown to improve survival in children with HSCT-TMA, it can cause vulnerability to encapsulated bacteria and lead to serious meningococcal infections even with appropriate vaccinations and prophylaxis.39-41  Thus, in pediatric patients with SARS-CoV-2, the consideration of eculizumab should likely be limited to only those patients with the most severe manifestations of disease with organ-threatening evidence of TMA. Other complement-targeted therapies for treatment of COVID-19 are currently being explored in adult patients, including possible inhibition of the lectin pathway, blockade of C3, and utilization of eculizumab for blockade of C5.42-45  The degree to which complement activation may be necessary for control of SARS-CoV-2 infection and the factors that lead to inappropriate complement overactivation are not yet clear. This represents an important area for future investigations. Future studies are also needed to establish the prognostic implications of elevated sC5b9 in children with SARS-CoV-2 and to define the potential role and appropriateness of complement blockade in this population.

The short- and long-term implications of complement activation in children with SARS-CoV-2 are unclear, especially in children with minimal or no symptoms. HSCT recipients who develop TMA can develop life-long clinical issues, including hypertension, pulmonary hypertension, stroke, and chronic kidney disease.41  It is therefore possible that there could be unrecognized long-term consequences of TMA due to SARS-CoV-2 infection. Future work is needed to better understand the long-term sequelae of SARS-CoV-2 infection and SARS-CoV-2–related TMA. Children with elevated sC5b9 and evidence of TMA should arguably be monitored for resolution of findings and for potential long-term sequelae. It is unclear whether children with elevated sC5b9 but no other evidence of TMA require monitoring. These are important areas for future study.

Our study is limited by several important factors. First, we enrolled patients prospectively in the described biospecimen repository; however, some clinical data were collected retrospectively. The high incidence of TMA seen in patients with complete laboratory evaluation for TMA (19 of 22 patients) is confounded by ascertainment bias, as LDH was more frequently obtained in sicker children. Markers of hemolysis, including LDH, unfortunately cannot be measured accurately on banked specimens. Future work should prospectively examine children with SARS-CoV-2 infection for clinical signs of TMA, particularly hypertension and proteinuria. Second, we compared hospitalized patients with severe COVID-19 and MIS-C vs hospitalized patients with either mild symptoms or who were asymptomatic. By definition, these hospitalized children had other comorbidities leading to their admission, which could have caused elevations in sC5b9. However, even when excluding patients with potentially confounding comorbidities, there were still significant elevations in sC5b9 relative to healthy control subjects. Future studies should seek to characterize the role of terminal complement activation and TMA in pediatric patients who have asymptomatic SARS-CoV-2 infection and who are without comorbidities. Our healthy control subjects were also patients who were being evaluated for a bleeding disorder. Although we do not believe that this affected complement activation, future studies should seek to include children without any clinical comorbidities as healthy control subjects. Of note, the normal range of sC5b9 in our assay was in concordance with that of sC5b9 measured in CLIA/CAP clinical laboratories. Practical considerations associated with the ethical conduct of research during a pandemic precluded inclusion of these comparator groups and limited our study to a relatively small sample size. Finally, although measures of renal function included in this study were all based on creatinine, future investigations should use cystatin C as a potentially more precise measure of renal function in children.39

We have shown that terminal complement activation is present in children across the spectrum of SARS-CoV-2 infection and that a high proportion of these children met clinical criteria for TMA. Elevations in sC5b9 occur independently of other laboratory markers associated with COVID-19 and MIS-C, and are associated with evidence of renal dysfunction. Although additional studies are clearly needed, evaluation for clinical TMA and complications of TMA should be considered in hospitalized children with SARS-CoV-2. The long-term implications of complement activation and TMA in these children need to be studied.

Presented in abstract form at the 62nd annual meeting of the American Society of Hematology, 5-8 December 2020.

Requests for data sharing may be submitted to the corresponding author (Hamid Bassiri; e-mail: bassiri@email.chop.edu).
Acknowledgments

Financial support for this project was provided by CHOP Frontiers Program Immune Dysregulation Team (D.T.T., E.M.B., and H.B.), National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (R01AI121250 [E.M.B.]; R01AI103280, R01AI123433, and R21AI144472 [A.R.O.J.]; K08 AI136660 [L.A.V.]; and K08AI135091 [S. E. Henrickson]), NIH/National Cancer Institute (R01CA193776, X01HD100702-01, 5UG1CA233249, and R01A1123538) (D.T.T.), the Leukemia and Lymphoma Society (D.T.T.), Cookies for Kids Cancer (D.T.T.), Alex’s Lemonade Stand Foundation for Childhood Cancer (D.T.T.), Children’s Oncology Group (D.T.T.), Stand UP 2 Cancer (D.T.T.), Team Connor Childhood Cancer Foundation (H.B.), Burroughs Wellcome Fund CAMS (S. E. Henrickson and A.R.O.J.), Clinical Immunology Society (S. E. Henrickson), the American Academy of Allergy, Asthma, and Immunology (S. E. Henrickson), and the Agency for Healthcare Research and Quality (K12HS026393) (K.C.). C.D. is supported by an Institute for Translation Medicine and Therapheutics (ITMAT) scholarship and by the CHOP Gail Slap Fellowship Award. A.M.B. is supported by NIH/National Institute of General Medical Sciences (T32-GM075766). J.C.F. is supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases (K23DK119463). E.M.A. was supported by the NIH Training in Virology T32 Program (T32-AI-007324).
Authorship

Contribution: H.B., E.M.B., and D.T.T. contributed equally to the manuscript and are joint last authors; C.D., K.O.M., M.L., M.P., E.M.A., F.B.B., K.G., C.W., K.E.S., B.L.L., S. E. Henrickson, H.B., E.M.B., and D.T.T. designed the research; C.D., K.O.M., J.C., J.H.L., T.L., W.P., S. E. Henrickson, K.C., L.A.V., A.R.O.J., and A.M.B. assisted in the consenting and recruitment of patients; C.D., K.O.M., J.H.L., and J.C. enrolled patients; K.O.M., E.M.A., and C.B. performed the assays described; C.D., K.O.M., M.L., M.P., S. E. Henrickson, J.C., E.J.L., J.H.L., L.A.V., C.J., T.L., H.B., E.M.B., and D.T.T. performed data abstraction and validation; C.D., K.O.M., F.B.B., A.M.B., K.C., J.C.F., T.M.G., K.G., A.R.O.J., W.P., L.A.V., C.W., K.E.S., B.L.L., S. E. Hensley, H.B., E.M.B., and D.T.T. contributed to data analysis and helped write the manuscript; and all authors contributed intellectually and reviewed and revised the manuscript.

Conflict-of-interest disclosure: D.T.T. serves on advisory boards for Janssen, Amgen, La Roche, Sobi, and Humanigen. H.B. has stock ownership in CSL Behring and is a consultant for Kriya Therapeutics. S. E. Henrickson served on the advisory board for Horizon Pharma. A.R.O.J. serves on the advisory board of Pluton Biosciences. M.L. is an advisory board member for Octapharma and Shionogi; a consultant for Amgen, Novartis, Shionogi, Dova, Principia, Argenz, and Bayer; and has received research funding from Sysmex, Novartis, and AstraZeneca. K.E.S. received personal fees from Elsevier and the Immune Deficiency Foundation. B.L.L. has a patent application under review (Compositions and Methods for Treatment of HSCT-Associated Thrombotic Microangiopathy. United States Patent Number PCT/US2014/055922, 2014). S.E.H. has received consultancy fees from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. The remaining authors declare no competing financial interests.

Correspondence: Hamid Bassiri, Children’s Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104; e-mail: bassiri@email.chop.edu.
References
1.
Castagnoli
R
, Votto
M
, Licari
A
, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review
. JAMA Pediatr
. 2020
;174
(9
):882
-889
.
Google Scholar
Crossref
PubMed
 
2.
Hoang
A
, Chorath
K
, Moreira
A
, et al. COVID-19 in 7780 pediatric patients: a systematic review
. EClinicalMedicine
. 2020
;24
(100433
):100433
.
Google Scholar
Crossref
PubMed
 
3.
Verdoni
L
, Mazza
A
, Gervasoni
A
, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study
. Lancet
. 2020
;395
(10239
):1771
-1778
.
Google Scholar
Crossref
PubMed
 
4.
Dong
Y
, Mo
X
, Hu
Y
, et al. Epidemiology of COVID-19 among children in China
. Pediatrics
. 2020
;145
(6
):e20200702
.
Google Scholar
Crossref
PubMed
 
5.
Feldstein
LR
, Rose
EB
, Horwitz
SM
, et al; CDC COVID-19 Response Team
. Multisystem inflammatory syndrome in U.S. children and adolescents
. N Engl J Med
. 2020
;383
(4
):334
-346
.
Google Scholar
Crossref
PubMed
 
6.
Riphagen
S
, Gomez
X
, Gonzalez-Martinez
C
, Wilkinson
N
, Theocharis
P
. Hyperinflammatory shock in children during COVID-19 pandemic
. Lancet
. 2020
;395
(10237
):1607
-1608
.
Google Scholar
Crossref
PubMed
 
7.
Dufort
EM
, Koumans
EH
, Chow
EJ
, et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team
. Multisystem inflammatory syndrome in children in New York State
. N Engl J Med
. 2020
;383
(4
):347
-358
.
Google Scholar
Crossref
PubMed
 
8.
Shaigany
S
, Gnirke
M
, Guttmann
A
, et al. An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19
. Lancet
. 2020
;396
(10246
):e8
-e10
.
Google Scholar
Crossref
PubMed
 
9.
Godfred-Cato
S
, Bryant
B
, Leung
J
, et al; California MIS-C Response Team
. COVID-19-associated multisystem inflammatory syndrome in children—United States, March-July 2020
. MMWR Morb Mortal Wkly Rep
. 2020
;69
(32
):1074
-1080
.
Google Scholar
Crossref
PubMed
 
10.
Lee
PY
, Day-Lewis
M
, Henderson
LA
, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children
. J Clin Invest
. 2020
;130
(11
):5942
-5950
.
Google Scholar
Crossref
PubMed
 
11.
Diorio
C
, Henrickson
SE
, Vella
LA
, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2
. J Clin Invest
. 2020
;130
(11
):5967
-5975
.
Google Scholar
Crossref
PubMed
 
12.
Oxley
TJ
, Mocco
J
, Majidi
S
, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young
. N Engl J Med
. 2020
;382
(20
):e60
.
Google Scholar
Crossref
PubMed
 
13.
Klok
FA
, Kruip
MJHA
, van der Meer
NJM
, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis
. Thromb Res
. 2020
;191
:148
-150
.
Google Scholar
Crossref
PubMed
 
14.
Ackermann
M
, Verleden
SE
, Kuehnel
M
, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19
. N Engl J Med
. 2020
;383
(2
):120
-128
.
Google Scholar
Crossref
PubMed
 
15.
Campbell
CM
, Kahwash
R
. Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis?
Circulation
. 2020
;141
(22
):1739
-1741
.
Google Scholar
Crossref
PubMed
 
16.
Merrill
JT
, Erkan
D
, Winakur
J
, James
JA
. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications
. Nat Rev Rheumatol
. 2020
;16
(10
):581
-589
.
Google Scholar
Crossref
PubMed
 
17.
Skendros
P
, Mitsios
A
, Chrysanthopoulou
A
, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
. J Clin Invest
. 2020
;130
(11
):6151
-6157
.
Google Scholar
Crossref
PubMed
 
18.
Yu
J
, Yuan
X
, Chen
H
, Chaturvedi
S
, Braunstein
EM
, Brodsky
RA
. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition
. Blood
. 2020
;136
(18
):2080
-2089
.
Article
Google Scholar
Crossref
PubMed
 
19.
George
JN
, Nester
CM
. Syndromes of thrombotic microangiopathy
. N Engl J Med
. 2014
;371
(7
):654
-666
.
Google Scholar
Crossref
PubMed
 
20.
Brocklebank
V
, Wood
KM
, Kavanagh
D
. Thrombotic microangiopathy and the kidney
. Clin J Am Soc Nephrol
. 2018
;13
(2
):300
-317
.
Google Scholar
Crossref
PubMed
 
21.
Arnold
DM
, Patriquin
CJ
, Nazy
I
. Thrombotic microangiopathies: a general approach to diagnosis and management
. CMAJ
. 2017
;189
(4
):E153
-E159
.
Google Scholar
Crossref
PubMed
 
22.
Menter
T
, Haslbauer
JD
, Nienhold
R
, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction
. Histopathology
. 2020
;77
(2
):198
-209
.
Google Scholar
Crossref
PubMed
 
23.
Jodele
S
, Davies
SM
, Lane
A
, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
. Blood
. 2014
;124
(4
):645
-653
.
Article
Google Scholar
Crossref
PubMed
 
24.
Jiang
Y
, Zhao
G
, Song
N
, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV
. Emerg Microbes Infect
. 2018
;7
(1
):77
.
Google Scholar
PubMed
 
25.
Gralinski
LE
, Sheahan
TP
, Morrison
TE
, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis
. MBio
. 2018
;9
(5
):9
.
Google Scholar
Crossref
 
26.
Centers for Disease Control
. Emergency preparedness and response: multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019
(COVID-19). Health advisory. https://emergency.cdc.gov/han/2020/han00432.asp. Accessed 1 September 2020.
27.
Gloude
NJ
, Dandoy
CE
, Davies
SM
, et al. Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy
. J Clin Immunol
. 2020
;40
(5
):699
-707
.
Google Scholar
Crossref
PubMed
 
28.
Schwartz
GJ
, Gauthier
B
. A simple estimate of glomerular filtration rate in adolescent boys
. J Pediatr
. 1985
;106
(3
):522
-526
.
Google Scholar
Crossref
PubMed
 
29.
Kaddourah
A
, Basu
RK
, Bagshaw
SM
, Goldstein
SL
; AWARE Investigators
. Epidemiology of acute kidney injury in critically ill children and young adults
. N Engl J Med
. 2017
;376
(1
):11
-20
.
Google Scholar
Crossref
PubMed
 
30.
Harris
PA
, Taylor
R
, Minor
BL
, et al; REDCap Consortium
. The REDCap consortium: building an international community of software platform partners
. J Biomed Inform
. 2019
;95
:103208
.
Google Scholar
Crossref
PubMed
 
31.
Anderson
EM
, Diorio
C
, Goodwin
EC
, et al SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19.
medRxiv
. doi: https://doi.org/10.1101/2020.08.17.20176552
.
32.
Flannery
DD
, Gouma
S
, Dhudasia
MB
, et al. SARS-CoV-2 seroprevalence among parturient women in Philadelphia
. Sci Immunol
. 2020
;5
(49
):eabd5709
.
Google Scholar
Crossref
PubMed
 
33.
Amanat
F
, Stadlbauer
D
, Strohmeier
S
, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans
. Nat Med
. 2020
;26
(7
):1033
-1036
.
Google Scholar
Crossref
PubMed
 
34.
Dvorak
CC
, Higham
C
, Shimano
KA
. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management
. Front Pediatr
. 2019
;7
:133
.
Google Scholar
Crossref
PubMed
 
35.
Noris
M
, Benigni
A
, Remuzzi
G
. The case of complement activation in COVID-19 multiorgan impact
. Kidney Int
. 2020
;98
(2
):314
-322
.
Google Scholar
Crossref
PubMed
 
36.
Varga
Z
, Flammer
AJ
, Steiger
P
, et al. Endothelial cell infection and endotheliitis in COVID-19
. Lancet
. 2020
;395
(10234
):1417
-1418
.
Google Scholar
Crossref
PubMed
 
37.
Gavriilaki
E
, Brodsky
RA
. Complementopathies and precision medicine
. J Clin Invest
. 2020
;130
(5
):2152
-2163
.
Google Scholar
Crossref
PubMed
 
38.
Jodele
S
, Fukuda
T
, Vinks
A
, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy
. Biol Blood Marrow Transplant
. 2014
;20
(4
):518
-525
.
Google Scholar
Crossref
PubMed
 
39.
Benamu
E
, Montoya
JG
. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis
. Curr Opin Infect Dis
. 2016
;29
(4
):319
-329
.
Google Scholar
Crossref
PubMed
 
40.
Bouts
A
, Monnens
L
, Davin
JC
, Struijk
G
, Spanjaard
L
. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy
. Pediatr Nephrol
. 2011
;26
(10
):1919
-1920
.
Google Scholar
Crossref
PubMed
 
41.
Jodele
S
, Laskin
BL
, Dandoy
CE
, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury
. Blood Rev
. 2015
;29
(3
):191
-204
.
Google Scholar
Crossref
PubMed
 
42.
Rambaldi
A
, Gritti
G
, Micò
MC
, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. [published online ahead of print 9 August 2020]
. Immunobiology
.
43.
Gavriilaki
E
, Brodsky
RA
. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily
. Br J Haematol
. 2020
;189
(6
):e227
-e230
.
Google Scholar
Crossref
PubMed
 
44.
Risitano
AM
, Mastellos
DC
, Huber-Lang
M
, et al. Complement as a target in COVID-19?
Nat Rev Immunol
. 2020
;20
(6
):343
-344
.
Google Scholar
Crossref
PubMed
 
45.
Mastellos
DC
, Pires da Silva
BGP
, Fonseca
BAL
, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy
. Clin Immunol
. 2020
;220
:108598
.
Google Scholar
Crossref
PubMed
 
Author notes
*

C.D. and K.O.M. contributed equally to this work.


H.B., E.M.B., and D.T.T. contributed equally to this work.

The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
Supplemental data
Supplement File 1- pdf file
Volume 4, Issue 23
December 8 2020

    Previous Article
     

Potential Articles of Interest

    Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation
    Caroline Diorio, Blood
    Sars-Cov-2 Induced Endotheliopathy and the Impact on Clinical Outcomes in Critically Ill Pediatric Patients
    Shreya Agarwal, Blood
    The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections
    Meady Chiem, Blood

    EGb 761: Safe, Effective for Mild Cognitive Impairment Patients

Treatment of mild neurocognitive impairment Jun-Dec 2024
Ginkgo for Neurocognitive Impairment: A Systematic Review
Treatment of mild neurocognitive impairment Jun-Dec 2024
EGb 761 Enhances Cognitive Function in Mild Neurocognitive Disorder

    Treatment of mild neurocognitive impairment Jun-Dec 2024

[...]
    American Society of Hematology
    2021 L Street NW, Suite 900
    Washington, DC 20036
    TEL +1 202-776-0544
    FAX +1 202-776-0545
[*/quote*]
« Last Edit: October 25, 2024, 10:07:42 PM by VanLaraklios »
Logged

Pangwall

  • Jr. Member
  • *
  • Posts: 1675
Re: Der Beweis ist erbracht: SarsCoV2 verursacht Hirnschäden!
« Reply #17 on: November 17, 2024, 05:08:16 PM »

Für die Akten:


This is only an anchor for the original site. DO GO THERE AND DO READ THERE! No embedded urls copied, so do read the original!

https://theconversation.com/mounting-research-shows-that-covid-19-leaves-its-mark-on-the-brain-including-significant-drops-in-iq-scores-224216

[*quote*]
The Conversation
Academic rigour, journalistic flair

Research shows that even mild COVID-19 can lead to the equivalent of seven years of brain aging.
 Victor Habbick Visions/Science Photo Library via Getty Images
Mounting research shows that COVID-19 leaves its mark on the brain, including significant drops in IQ scores
Published: February 28, 2024 11.42pm CET

Author Ziyad Al-Aly
Chief of Research and Development, VA St. Louis Health Care System. Clinical Epidemiologist, Washington University in St. Louis

Disclosure statement

Ziyad Al-Aly receives funding from the U.S. Department of Veterans Affairs.
Partners

View all partners
Languages

    Français
    English

CC BY ND
We believe in the free flow of information
Republish our articles for free, online or in print, under Creative Commons licence.
Email
X (Twitter)
Facebook4.9k
LinkedIn
Print

From the very early days of the pandemic, brain fog emerged as a significant health condition that many experience after COVID-19.

Brain fog is a colloquial term that describes a state of mental sluggishness or lack of clarity and haziness that makes it difficult to concentrate, remember things and think clearly.

Fast-forward four years and there is now abundant evidence that being infected with SARS-CoV-2 – the virus that causes COVID-19 – can affect brain health in many ways.

In addition to brain fog, COVID-19 can lead to an array of problems, including headaches, seizure disorders, strokes, sleep problems, and tingling and paralysis of the nerves, as well as several mental health disorders.
Europeans, get our weekly newsletter with analysis from European scholars

A large and growing body of evidence amassed throughout the pandemic details the many ways that COVID-19 leaves an indelible mark on the brain. But the specific pathways by which the virus does so are still being elucidated, and curative treatments are nonexistent.

Now, two 2024 studies published in the New England Journal of Medicine shed further light on the profound toll of COVID-19 on cognitive health.

I am a physician scientist, and I have been devoted to studying long COVID since early patient reports about this condition – even before the term “long COVID” was coined. I have testified before the U.S. Senate as an expert witness on long COVID and have published extensively on this topic.
How COVID-19 leaves its mark on the brain

Here are some of the most important studies to date documenting how COVID-19 affects brain health:

    Large epidemiological analyses showed that people who had COVID-19 were at an increased risk of cognitive deficits, such as memory problems.

    Imaging studies done in people before and after their COVID-19 infections show shrinkage of brain volume and altered brain structure after infection.

    A study of people with mild to moderate COVID-19 showed significant prolonged inflammation of the brain and changes that are commensurate with seven years of brain aging.

    Severe COVID-19 that requires hospitalization or intensive care may result in cognitive deficits and other brain damage that are equivalent to 20 years of aging.

    Laboratory experiments in human and mouse brain organoids designed to emulate changes in the human brain showed that SARS-CoV-2 infection triggers the fusion of brain cells. This effectively short-circuits brain electrical activity and compromises function.

    Autopsy studies of people who had severe COVID-19 but died months later from other causes showed that the virus was still present in brain tissue. This provides evidence that contrary to its name, SARS-CoV-2 is not only a respiratory virus, but it can also enter the brain in some individuals. But whether the persistence of the virus in brain tissue is driving some of the brain problems seen in people who have had COVID-19 is not yet clear.

    Studies show that even when the virus is mild and exclusively confined to the lungs, it can still provoke inflammation in the brain and impair brain cells’ ability to regenerate.

    COVID-19 can also disrupt the blood brain barrier, the shield that protects the nervous system – which is the control and command center of our bodies – making it “leaky.” Studies using imaging to assess the brains of people hospitalized with COVID-19 showed disrupted or leaky blood brain barriers in those who experienced brain fog.

    A large preliminary analysis pooling together data from 11 studies encompassing almost 1 million people with COVID-19 and more than 6 million uninfected individuals showed that COVID-19 increased the risk of development of new-onset dementia in people older than 60 years of age.

Autopsies have revealed devastating damage in the brains of people who died with COVID-19.
Drops in IQ

Most recently, a new study published in the New England Journal of Medicine assessed cognitive abilities such as memory, planning and spatial reasoning in nearly 113,000 people who had previously had COVID-19. The researchers found that those who had been infected had significant deficits in memory and executive task performance.

This decline was evident among those infected in the early phase of the pandemic and those infected when the delta and omicron variants were dominant. These findings show that the risk of cognitive decline did not abate as the pandemic virus evolved from the ancestral strain to omicron.

In the same study, those who had mild and resolved COVID-19 showed cognitive decline equivalent to a three-point loss of IQ. In comparison, those with unresolved persistent symptoms, such as people with persistent shortness of breath or fatigue, had a six-point loss in IQ. Those who had been admitted to the intensive care unit for COVID-19 had a nine-point loss in IQ. Reinfection with the virus contributed an additional two-point loss in IQ, as compared with no reinfection.

Generally the average IQ is about 100. An IQ above 130 indicates a highly gifted individual, while an IQ below 70 generally indicates a level of intellectual disability that may require significant societal support.

To put the finding of the New England Journal of Medicine study into perspective, I estimate that a three-point downward shift in IQ would increase the number of U.S. adults with an IQ less than 70 from 4.7 million to 7.5 million – an increase of 2.8 million adults with a level of cognitive impairment that requires significant societal support.

Another study in the same issue of the New England Journal of Medicine involved more than 100,000 Norwegians between March 2020 and April 2023. It documented worse memory function at several time points up to 36 months following a positive SARS-CoV-2 test.
Parsing the implications

Taken together, these studies show that COVID-19 poses a serious risk to brain health, even in mild cases, and the effects are now being revealed at the population level.

A recent analysis of the U.S. Current Population Survey showed that after the start of the COVID-19 pandemic, an additional 1 million working-age Americans reported having “serious difficulty” remembering, concentrating or making decisions than at any time in the preceding 15 years. Most disconcertingly, this was mostly driven by younger adults between the ages of 18 to 44.

Data from the European Union shows a similar trend – in 2022, 15% of people in the EU reported memory and concentration issues.

Looking ahead, it will be critical to identify who is most at risk. A better understanding is also needed of how these trends might affect the educational attainment of children and young adults and the economic productivity of working-age adults. And the extent to which these shifts will influence the epidemiology of dementia and Alzheimer’s disease is also not clear.

The growing body of research now confirms that COVID-19 should be considered a virus with a significant impact on the brain. The implications are far-reaching, from individuals experiencing cognitive struggles to the potential impact on populations and the economy.

Lifting the fog on the true causes behind these cognitive impairments, including brain fog, will require years if not decades of concerted efforts by researchers across the globe. And unfortunately, nearly everyone is a test case in this unprecedented global undertaking.

    Intelligence
    Brain
    IQ
    COVID-19
    SARS-CoV-2
    Long COVID
    Brain fog
    Long COVID-19
    SARS-CoV-2 virus
    Cognitive health

Keep up with the global economy …

Interest rate decisions, the cost of living and the global scam economay all have impacts on business we need to be aware of.



This is why I co-write a weekly business and economy email newsletter. It brings a curated summary of the week's briefings from academic researchers around the world straight to your inbox. And it's free.

Tracy Walsh
Editor, Economy + Business, The Conversation U.S.
You might also like
Early COVID-19 research is riddled with poor methods and low-quality results − a problem for science the pandemic worsened but didn’t create
Long COVID stemmed from mild cases of COVID-19 in most people, according to a new multicountry study
Long COVID leaves newly disabled people facing old barriers – a sociologist explains
Long COVID: How researchers are zeroing in on the self-targeted immune attacks that may lurk behind it
0 Comments

Comments are open on selected articles and must comply with our community standards.

Events

Copyright © 2010–2024, The Conversation Media Group Ltd
[*/quote*]
Logged
Stoppt die deutschen Massenmörder!
Stoppt die österreichischen Massenmörder!
Stoppt die schweizer Massenmörder!

Revolution jetzt. Sonst ist es zu spät.
Pages: [1]